CA2642737A1 - Oxazole ketones as modulators of fatty acid amide hydrolase - Google Patents
Oxazole ketones as modulators of fatty acid amide hydrolase Download PDFInfo
- Publication number
- CA2642737A1 CA2642737A1 CA002642737A CA2642737A CA2642737A1 CA 2642737 A1 CA2642737 A1 CA 2642737A1 CA 002642737 A CA002642737 A CA 002642737A CA 2642737 A CA2642737 A CA 2642737A CA 2642737 A1 CA2642737 A1 CA 2642737A1
- Authority
- CA
- Canada
- Prior art keywords
- oxazol
- phenylheptanoyl
- nmr
- phenylheptan
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 Oxazole ketones Chemical class 0.000 title claims abstract description 22
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 title abstract description 41
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 title abstract description 37
- 150000001875 compounds Chemical class 0.000 claims abstract description 296
- 238000000034 method Methods 0.000 claims abstract description 150
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 49
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 208000035475 disorder Diseases 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 22
- 208000002193 Pain Diseases 0.000 claims abstract description 16
- 230000036407 pain Effects 0.000 claims abstract description 16
- 230000001404 mediated effect Effects 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 8
- 208000030814 Eating disease Diseases 0.000 claims abstract description 8
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract description 8
- 206010061218 Inflammation Diseases 0.000 claims abstract description 8
- 208000016285 Movement disease Diseases 0.000 claims abstract description 8
- 230000036506 anxiety Effects 0.000 claims abstract description 8
- 235000014632 disordered eating Nutrition 0.000 claims abstract description 8
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- 208000019116 sleep disease Diseases 0.000 claims abstract description 8
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 34
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 239000000651 prodrug Substances 0.000 claims description 27
- 229940002612 prodrug Drugs 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 239000002207 metabolite Substances 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 206010028813 Nausea Diseases 0.000 claims description 8
- 230000000202 analgesic effect Effects 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 230000008693 nausea Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 206010047700 Vomiting Diseases 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- OXLLSWJNKVTREA-UHFFFAOYSA-N 1-[5-(4-nitropyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound [O-][N+](=O)C1=CC=NC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 OXLLSWJNKVTREA-UHFFFAOYSA-N 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 4
- 208000003577 HIV wasting syndrome Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 4
- HSRNGWUJIIATGJ-UHFFFAOYSA-N 1-[5-(4-nitrophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 HSRNGWUJIIATGJ-UHFFFAOYSA-N 0.000 claims description 3
- VUJNAFDBKSPYIU-UHFFFAOYSA-N 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 VUJNAFDBKSPYIU-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000018652 Closed Head injury Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010062016 Immunosuppression Diseases 0.000 claims description 3
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 3
- 208000003435 Optic Neuritis Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 201000004982 autoimmune uveitis Diseases 0.000 claims description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims description 3
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 3
- BVYCAKRFEFPFPH-UHFFFAOYSA-N methyl 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 BVYCAKRFEFPFPH-UHFFFAOYSA-N 0.000 claims description 3
- WETRYXNVVPWMEG-UHFFFAOYSA-N methyl 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 WETRYXNVVPWMEG-UHFFFAOYSA-N 0.000 claims description 3
- NKJKMKLILUICDP-UHFFFAOYSA-N methyl 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 NKJKMKLILUICDP-UHFFFAOYSA-N 0.000 claims description 3
- NLMLYHBPAHKJHY-UHFFFAOYSA-N methyl 3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoate Chemical compound COC(=O)C1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 NLMLYHBPAHKJHY-UHFFFAOYSA-N 0.000 claims description 3
- SEBDMKMIOLJEIA-UHFFFAOYSA-N methyl 4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 SEBDMKMIOLJEIA-UHFFFAOYSA-N 0.000 claims description 3
- OSRNMMMQPVBPDU-UHFFFAOYSA-N methyl 5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]furan-2-carboxylate Chemical compound O1C(C(=O)OC)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 OSRNMMMQPVBPDU-UHFFFAOYSA-N 0.000 claims description 3
- FAAKZLWBDFYQAH-UHFFFAOYSA-N methyl 5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 FAAKZLWBDFYQAH-UHFFFAOYSA-N 0.000 claims description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 2
- WEVVZHLIKWCAAK-UHFFFAOYSA-N 1-[5-(1-methylimidazol-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound CN1C=CN=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 WEVVZHLIKWCAAK-UHFFFAOYSA-N 0.000 claims description 2
- IIIXOTPVEWBIMZ-UHFFFAOYSA-N 1-[5-(1-methyltetrazol-5-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound CN1N=NN=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 IIIXOTPVEWBIMZ-UHFFFAOYSA-N 0.000 claims description 2
- SJMDEKOYAAGHHD-UHFFFAOYSA-N 1-[5-(2,4-dimethoxypyrimidin-5-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound COC1=NC(OC)=NC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 SJMDEKOYAAGHHD-UHFFFAOYSA-N 0.000 claims description 2
- GZXPZNRGZSEVND-UHFFFAOYSA-N 1-[5-(2,6-dimethoxypyrimidin-4-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound COC1=NC(OC)=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=N1 GZXPZNRGZSEVND-UHFFFAOYSA-N 0.000 claims description 2
- VHWRVXJXQJGKCG-UHFFFAOYSA-N 1-[5-(2-aminophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound NC1=CC=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 VHWRVXJXQJGKCG-UHFFFAOYSA-N 0.000 claims description 2
- VNIXKUPUOKDAMU-UHFFFAOYSA-N 1-[5-(2-fluorophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound FC1=CC=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 VNIXKUPUOKDAMU-UHFFFAOYSA-N 0.000 claims description 2
- OJSBYACDUHKDQN-UHFFFAOYSA-N 1-[5-(2-methoxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound COC1=CC=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 OJSBYACDUHKDQN-UHFFFAOYSA-N 0.000 claims description 2
- RTBHOZQWSHSKQV-UHFFFAOYSA-N 1-[5-(3-hydroxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound OC1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 RTBHOZQWSHSKQV-UHFFFAOYSA-N 0.000 claims description 2
- JEYHVMNCHCSLCT-UHFFFAOYSA-N 1-[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound COC1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 JEYHVMNCHCSLCT-UHFFFAOYSA-N 0.000 claims description 2
- HEPNJQHVFLSRJH-UHFFFAOYSA-N 1-[5-(3-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound CC1=CC=CN=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 HEPNJQHVFLSRJH-UHFFFAOYSA-N 0.000 claims description 2
- ZRLZJOGIGHXUEI-UHFFFAOYSA-N 1-[5-(3-nitrophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 ZRLZJOGIGHXUEI-UHFFFAOYSA-N 0.000 claims description 2
- LYWGIAKTUZDFAK-UHFFFAOYSA-N 1-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound C1=CC(O)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 LYWGIAKTUZDFAK-UHFFFAOYSA-N 0.000 claims description 2
- UDHKCBXBANIODD-UHFFFAOYSA-N 1-[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound C1=CC(OC)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 UDHKCBXBANIODD-UHFFFAOYSA-N 0.000 claims description 2
- APJNZPUSSLCYBE-UHFFFAOYSA-N 1-[5-(4-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound COC1=CC=NC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 APJNZPUSSLCYBE-UHFFFAOYSA-N 0.000 claims description 2
- ZZFYSIWCDNANCX-UHFFFAOYSA-N 1-[5-(4-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound CC1=CC=NC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 ZZFYSIWCDNANCX-UHFFFAOYSA-N 0.000 claims description 2
- DEUJPRBSWMXMKH-UHFFFAOYSA-N 1-[5-(6-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound CC1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=N1 DEUJPRBSWMXMKH-UHFFFAOYSA-N 0.000 claims description 2
- MSPDKDPNQMFJKX-UHFFFAOYSA-N 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzonitrile Chemical compound N=1C=C(C=2C(=CC=CC=2)C#N)OC=1C(=O)CCCCCCC1=CC=CC=C1 MSPDKDPNQMFJKX-UHFFFAOYSA-N 0.000 claims description 2
- FDKSOWGEQNEDFL-UHFFFAOYSA-N 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 FDKSOWGEQNEDFL-UHFFFAOYSA-N 0.000 claims description 2
- BLWLXRQXFINMOD-UHFFFAOYSA-N 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-4-carbonitrile Chemical compound N=1C=C(C=2N=CC=C(C=2)C#N)OC=1C(=O)CCCCCCC1=CC=CC=C1 BLWLXRQXFINMOD-UHFFFAOYSA-N 0.000 claims description 2
- NTUVMOFSGKYQFZ-UHFFFAOYSA-N 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 NTUVMOFSGKYQFZ-UHFFFAOYSA-N 0.000 claims description 2
- UDCOFTGPNZNXSW-UHFFFAOYSA-N 3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 UDCOFTGPNZNXSW-UHFFFAOYSA-N 0.000 claims description 2
- NBRGHYDUKUTOFG-UHFFFAOYSA-N 3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 NBRGHYDUKUTOFG-UHFFFAOYSA-N 0.000 claims description 2
- UCAHPLLNYOIPBO-UHFFFAOYSA-N 3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzonitrile Chemical compound N=1C=C(C=2C=C(C=CC=2)C#N)OC=1C(=O)CCCCCCC1=CC=CC=C1 UCAHPLLNYOIPBO-UHFFFAOYSA-N 0.000 claims description 2
- HJWOQYUOVBMTHU-UHFFFAOYSA-N 4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 HJWOQYUOVBMTHU-UHFFFAOYSA-N 0.000 claims description 2
- YERKRUARNQUCLI-UHFFFAOYSA-N 4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 YERKRUARNQUCLI-UHFFFAOYSA-N 0.000 claims description 2
- NWKAGRFQZYTCQZ-UHFFFAOYSA-N 4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzonitrile Chemical compound N=1C=C(C=2C=CC(=CC=2)C#N)OC=1C(=O)CCCCCCC1=CC=CC=C1 NWKAGRFQZYTCQZ-UHFFFAOYSA-N 0.000 claims description 2
- IISRXOQGPNUEFV-UHFFFAOYSA-N 5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]-1h-pyrimidine-2,4-dione Chemical compound N=1C=C(C=2C(NC(=O)NC=2)=O)OC=1C(=O)CCCCCCC1=CC=CC=C1 IISRXOQGPNUEFV-UHFFFAOYSA-N 0.000 claims description 2
- KMDBSYSLINSAAZ-UHFFFAOYSA-N 5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 KMDBSYSLINSAAZ-UHFFFAOYSA-N 0.000 claims description 2
- ORFONPQCVWDLCV-UHFFFAOYSA-N 5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 ORFONPQCVWDLCV-UHFFFAOYSA-N 0.000 claims description 2
- BIKJVTXNEUTMOY-UHFFFAOYSA-N 5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]thiophene-2-sulfonamide Chemical compound S1C(S(=O)(=O)N)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 BIKJVTXNEUTMOY-UHFFFAOYSA-N 0.000 claims description 2
- MCKAMZSBTSLCAF-UHFFFAOYSA-N 6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]-1h-pyrimidine-2,4-dione Chemical compound N=1C=C(C=2NC(=O)NC(=O)C=2)OC=1C(=O)CCCCCCC1=CC=CC=C1 MCKAMZSBTSLCAF-UHFFFAOYSA-N 0.000 claims description 2
- DZMRAEAGLIEJDZ-UHFFFAOYSA-N 6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=N1 DZMRAEAGLIEJDZ-UHFFFAOYSA-N 0.000 claims description 2
- SHWZOKMNLUJQPA-UHFFFAOYSA-N 6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxylic acid Chemical compound N1=CC(C(=O)O)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 SHWZOKMNLUJQPA-UHFFFAOYSA-N 0.000 claims description 2
- SNZSJZIWVONPEX-UHFFFAOYSA-N 7-phenyl-1-[5-[3-(2,2,2-trifluoroacetyl)phenyl]-1,3-oxazol-2-yl]heptan-1-one Chemical compound FC(F)(F)C(=O)C1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 SNZSJZIWVONPEX-UHFFFAOYSA-N 0.000 claims description 2
- PXPNASDGWRDRRC-UHFFFAOYSA-N 7-phenyl-1-[5-[4-(2,2,2-trifluoroacetyl)phenyl]-1,3-oxazol-2-yl]heptan-1-one Chemical compound C1=CC(C(=O)C(F)(F)F)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 PXPNASDGWRDRRC-UHFFFAOYSA-N 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- 206010021333 Ileus paralytic Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 208000031271 Unwanted pregnancy Diseases 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 208000028004 allergic respiratory disease Diseases 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 229960002870 gabapentin Drugs 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- IMTYQPIAPDYUAT-UHFFFAOYSA-N methyl 6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=N1 IMTYQPIAPDYUAT-UHFFFAOYSA-N 0.000 claims description 2
- QXAMYZXRQXXJJA-UHFFFAOYSA-N methyl 6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 QXAMYZXRQXXJJA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 230000003959 neuroinflammation Effects 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 229940005483 opioid analgesics Drugs 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 201000007620 paralytic ileus Diseases 0.000 claims description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 2
- 229960001233 pregabalin Drugs 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000009881 secretory diarrhea Diseases 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 229960004380 tramadol Drugs 0.000 claims description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 claims 2
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 claims 2
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 2
- GTXPWUDHFBBHPF-UHFFFAOYSA-N 1-[5-(2-hydroxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound OC1=CC=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 GTXPWUDHFBBHPF-UHFFFAOYSA-N 0.000 claims 1
- VUVQZGRXZQQJSL-UHFFFAOYSA-N 1-[5-(2-nitrophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound [O-][N+](=O)C1=CC=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 VUVQZGRXZQQJSL-UHFFFAOYSA-N 0.000 claims 1
- FFYPIAWDEMJSQC-UHFFFAOYSA-N 1-[5-(3-aminophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound NC1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 FFYPIAWDEMJSQC-UHFFFAOYSA-N 0.000 claims 1
- WQCULMFTJFIQCX-UHFFFAOYSA-N 1-[5-(3-fluorophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound FC1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 WQCULMFTJFIQCX-UHFFFAOYSA-N 0.000 claims 1
- MXLYRBIVTQTDKC-UHFFFAOYSA-N 1-[5-(4-aminophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound C1=CC(N)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 MXLYRBIVTQTDKC-UHFFFAOYSA-N 0.000 claims 1
- BJJKIYZDDJWPTF-UHFFFAOYSA-N 1-[5-(4-aminopyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound NC1=CC=NC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 BJJKIYZDDJWPTF-UHFFFAOYSA-N 0.000 claims 1
- TYWVRNPNBJLNRH-UHFFFAOYSA-N 1-[5-(4-fluorophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound C1=CC(F)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 TYWVRNPNBJLNRH-UHFFFAOYSA-N 0.000 claims 1
- VWPPMWZJHIIAFS-UHFFFAOYSA-N 1-[5-(5-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound N1=CC(C)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 VWPPMWZJHIIAFS-UHFFFAOYSA-N 0.000 claims 1
- IZJRXEBLZDQURD-UHFFFAOYSA-N 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 IZJRXEBLZDQURD-UHFFFAOYSA-N 0.000 claims 1
- HRIZEWKXUSOTQT-UHFFFAOYSA-N 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 HRIZEWKXUSOTQT-UHFFFAOYSA-N 0.000 claims 1
- ARGRFJQYTPIDDM-UHFFFAOYSA-N 4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 ARGRFJQYTPIDDM-UHFFFAOYSA-N 0.000 claims 1
- YZUZJEBJPIUSPA-UHFFFAOYSA-N 7-phenyl-1-[5-[2-(2,2,2-trifluoroacetyl)phenyl]-1,3-oxazol-2-yl]heptan-1-one Chemical compound FC(F)(F)C(=O)C1=CC=CC=C1C1=CN=C(C(=O)CCCCCCC=2C=CC=CC=2)O1 YZUZJEBJPIUSPA-UHFFFAOYSA-N 0.000 claims 1
- WSTXCZKZJBJXQK-UHFFFAOYSA-N 7-phenyl-1-[5-[4-(trifluoromethyl)pyridin-2-yl]-1,3-oxazol-2-yl]heptan-1-one Chemical compound FC(F)(F)C1=CC=NC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 WSTXCZKZJBJXQK-UHFFFAOYSA-N 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 26
- 239000003940 fatty acid amidase inhibitor Substances 0.000 abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 233
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 186
- 238000005481 NMR spectroscopy Methods 0.000 description 122
- 235000019439 ethyl acetate Nutrition 0.000 description 116
- 238000003818 flash chromatography Methods 0.000 description 99
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 86
- 239000007787 solid Substances 0.000 description 69
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 60
- 239000003921 oil Substances 0.000 description 42
- 235000019198 oils Nutrition 0.000 description 42
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 37
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 34
- 101150041968 CDC13 gene Proteins 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 33
- 239000000203 mixture Substances 0.000 description 26
- XUUBEONIIXLAOP-UHFFFAOYSA-N tert-butyl-dimethyl-[7-phenyl-1-(5-tributylstannyl-1,3-oxazol-2-yl)heptoxy]silane Chemical compound O1C([Sn](CCCC)(CCCC)CCCC)=CN=C1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 XUUBEONIIXLAOP-UHFFFAOYSA-N 0.000 description 26
- 150000001412 amines Chemical class 0.000 description 18
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- 238000012746 preparative thin layer chromatography Methods 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- WYURNTSHIVDZCO-SVYQBANQSA-N oxolane-d8 Chemical compound [2H]C1([2H])OC([2H])([2H])C([2H])([2H])C1([2H])[2H] WYURNTSHIVDZCO-SVYQBANQSA-N 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 150000001408 amides Chemical class 0.000 description 10
- 229930003827 cannabinoid Natural products 0.000 description 10
- 239000003557 cannabinoid Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 201000006417 multiple sclerosis Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 229960004242 dronabinol Drugs 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 229940065144 cannabinoids Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 229910052740 iodine Chemical group 0.000 description 6
- 239000008177 pharmaceutical agent Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 208000008238 Muscle Spasticity Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 208000018198 spasticity Diseases 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000218236 Cannabis Species 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 239000002621 endocannabinoid Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000020341 sensory perception of pain Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000004410 intraocular pressure Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 3
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 3
- 229950007031 palmidrol Drugs 0.000 description 3
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- ZBOYJODMIAUJHH-SANMLTNESA-N (2s)-1-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound C=1C(OC)=C(CN2[C@@H](CCCC2)C(O)=O)C(OC)=CC=1OCC(C=1C)=CC=CC=1C1=CC=CC=C1 ZBOYJODMIAUJHH-SANMLTNESA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FQWXWLOWHZQJGA-UHFFFAOYSA-N 1-[3-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]phenyl]-2,2,2-trifluoroethanone Chemical compound N=1C=C(C=2C=C(C=CC=2)C(=O)C(F)(F)F)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 FQWXWLOWHZQJGA-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NCIWQHRKDUIXTK-UHFFFAOYSA-N 2-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]benzonitrile Chemical compound N=1C=C(C=2C(=CC=CC=2)C#N)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 NCIWQHRKDUIXTK-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- WNFSKUZIZDMIEB-UHFFFAOYSA-N 3-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]benzenesulfonamide Chemical compound N=1C=C(C=2C=C(C=CC=2)S(N)(=O)=O)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 WNFSKUZIZDMIEB-UHFFFAOYSA-N 0.000 description 2
- XYVMOLOUBJBNBF-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical class OC1=NC=CO1 XYVMOLOUBJBNBF-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000009132 Catalepsy Diseases 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101100189356 Mus musculus Papolb gene Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- ROFVXGGUISEHAM-UHFFFAOYSA-N URB597 Chemical compound NC(=O)C1=CC=CC(C=2C=C(OC(=O)NC3CCCCC3)C=CC=2)=C1 ROFVXGGUISEHAM-UHFFFAOYSA-N 0.000 description 2
- 206010047853 Waxy flexibility Diseases 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 2
- 229950011318 cannabidiol Drugs 0.000 description 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical group O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004634 feeding behavior Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Chemical group 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- FZCFGTYSKJLRRR-UHFFFAOYSA-N heptan-1-one Chemical compound CCCCCC[C]=O FZCFGTYSKJLRRR-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- ZVLWSWKADRMTFX-UHFFFAOYSA-N methyl 4-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CN=C(C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)O1 ZVLWSWKADRMTFX-UHFFFAOYSA-N 0.000 description 2
- GSMOPRLFHYCKRO-UHFFFAOYSA-N methyl 6-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1C1=CN=C(C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)O1 GSMOPRLFHYCKRO-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229960002969 oleic acid Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 229910052701 rubidium Inorganic materials 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ZGVHQYTXKINIJN-UHFFFAOYSA-N tert-butyl-[1-[5-(3-fluorophenyl)-1,3-oxazol-2-yl]-7-phenylheptoxy]-dimethylsilane Chemical compound N=1C=C(C=2C=C(F)C=CC=2)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 ZGVHQYTXKINIJN-UHFFFAOYSA-N 0.000 description 2
- ZQDPYBCFCBBRAE-UHFFFAOYSA-N tert-butyl-[1-[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptoxy]-dimethylsilane Chemical compound C1=CC(OC)=CC=C1C1=CN=C(C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)O1 ZQDPYBCFCBBRAE-UHFFFAOYSA-N 0.000 description 2
- ACKSDYYLZQEGBK-UHFFFAOYSA-N tert-butyl-[1-[5-(4-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptoxy]-dimethylsilane Chemical compound COC1=CC=NC(C=2OC(=NC=2)C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)=C1 ACKSDYYLZQEGBK-UHFFFAOYSA-N 0.000 description 2
- JEQULBHHKQDPHE-UHFFFAOYSA-N tert-butyl-dimethyl-[1-[5-(3-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptoxy]silane Chemical compound CC1=CC=CN=C1C1=CN=C(C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)O1 JEQULBHHKQDPHE-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MXHYFISNECFQHA-UHFFFAOYSA-N (4-iodophenyl) acetate Chemical compound CC(=O)OC1=CC=C(I)C=C1 MXHYFISNECFQHA-UHFFFAOYSA-N 0.000 description 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RAOQEOLDFDHACL-UHFFFAOYSA-N 1-(2-chlorophenyl)-2,2,2-trifluoroethanone Chemical compound FC(F)(F)C(=O)C1=CC=CC=C1Cl RAOQEOLDFDHACL-UHFFFAOYSA-N 0.000 description 1
- KYFMLRJTDPGABF-UHFFFAOYSA-N 1-(3-chlorophenyl)-2,2,2-trifluoroethanone Chemical compound FC(F)(F)C(=O)C1=CC=CC(Cl)=C1 KYFMLRJTDPGABF-UHFFFAOYSA-N 0.000 description 1
- IHGSAQHSAGRWNI-UHFFFAOYSA-N 1-(4-bromophenyl)-2,2,2-trifluoroethanone Chemical compound FC(F)(F)C(=O)C1=CC=C(Br)C=C1 IHGSAQHSAGRWNI-UHFFFAOYSA-N 0.000 description 1
- TWQKSZUNMHKBKF-UHFFFAOYSA-N 1-[5-(furan-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one Chemical compound N=1C=C(C=2OC=CC=2)OC=1C(=O)CCCCCCC1=CC=CC=C1 TWQKSZUNMHKBKF-UHFFFAOYSA-N 0.000 description 1
- TYHUGKGZNOULKD-UHFFFAOYSA-N 1-fluoro-2-iodobenzene Chemical compound FC1=CC=CC=C1I TYHUGKGZNOULKD-UHFFFAOYSA-N 0.000 description 1
- VSKSBSORLCDRHS-UHFFFAOYSA-N 1-fluoro-3-iodobenzene Chemical compound FC1=CC=CC(I)=C1 VSKSBSORLCDRHS-UHFFFAOYSA-N 0.000 description 1
- KGNQDBQYEBMPFZ-UHFFFAOYSA-N 1-fluoro-4-iodobenzene Chemical compound FC1=CC=C(I)C=C1 KGNQDBQYEBMPFZ-UHFFFAOYSA-N 0.000 description 1
- DVQWNQBEUKXONL-UHFFFAOYSA-N 1-iodo-2-methoxybenzene Chemical compound COC1=CC=CC=C1I DVQWNQBEUKXONL-UHFFFAOYSA-N 0.000 description 1
- JXMZUNPWVXQADG-UHFFFAOYSA-N 1-iodo-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1I JXMZUNPWVXQADG-UHFFFAOYSA-N 0.000 description 1
- RSHBAGGASAJQCH-UHFFFAOYSA-N 1-iodo-3-methoxybenzene Chemical compound COC1=CC=CC(I)=C1 RSHBAGGASAJQCH-UHFFFAOYSA-N 0.000 description 1
- CBYAZOKPJYBCHE-UHFFFAOYSA-N 1-iodo-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(I)=C1 CBYAZOKPJYBCHE-UHFFFAOYSA-N 0.000 description 1
- SCCCFNJTCDSLCY-UHFFFAOYSA-N 1-iodo-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(I)C=C1 SCCCFNJTCDSLCY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- YYZORCCDLMGZTQ-UHFFFAOYSA-N 2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylic acid Chemical compound O1C(C(=O)O)=CN=C1C(=O)CCCCCCC1=CC=CC=C1 YYZORCCDLMGZTQ-UHFFFAOYSA-N 0.000 description 1
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 description 1
- PKUBXIFGWVFJNV-UHFFFAOYSA-N 2-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]aniline Chemical compound N=1C=C(C=2C(=CC=CC=2)N)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 PKUBXIFGWVFJNV-UHFFFAOYSA-N 0.000 description 1
- YXSQNDYUVZJEAH-UHFFFAOYSA-N 2-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]benzamide Chemical compound N=1C=C(C=2C(=CC=CC=2)C(N)=O)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 YXSQNDYUVZJEAH-UHFFFAOYSA-N 0.000 description 1
- SNCFGPCIWABOSP-UHFFFAOYSA-N 2-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]benzenesulfonamide Chemical compound N=1C=C(C=2C(=CC=CC=2)S(N)(=O)=O)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 SNCFGPCIWABOSP-UHFFFAOYSA-N 0.000 description 1
- RCRCTBLIHCHWDZ-DOFZRALJSA-N 2-arachidonoylglycerol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-DOFZRALJSA-N 0.000 description 1
- PZSISEFPCYMBDL-UHFFFAOYSA-N 2-bromo-3-methylpyridine Chemical compound CC1=CC=CN=C1Br PZSISEFPCYMBDL-UHFFFAOYSA-N 0.000 description 1
- LSZMVESSGLHDJE-UHFFFAOYSA-N 2-bromo-4-methylpyridine Chemical compound CC1=CC=NC(Br)=C1 LSZMVESSGLHDJE-UHFFFAOYSA-N 0.000 description 1
- YWNJQQNBJQUKME-UHFFFAOYSA-N 2-bromo-5-methylpyridine Chemical compound CC1=CC=C(Br)N=C1 YWNJQQNBJQUKME-UHFFFAOYSA-N 0.000 description 1
- NHNAEZDWNCRWRW-UHFFFAOYSA-N 2-bromobenzamide Chemical compound NC(=O)C1=CC=CC=C1Br NHNAEZDWNCRWRW-UHFFFAOYSA-N 0.000 description 1
- AFMPMSCZPVNPEM-UHFFFAOYSA-N 2-bromobenzonitrile Chemical compound BrC1=CC=CC=C1C#N AFMPMSCZPVNPEM-UHFFFAOYSA-N 0.000 description 1
- FGSAQRJRWCZLOB-UHFFFAOYSA-N 2-chloro-4-fluoropyridine Chemical compound FC1=CC=NC(Cl)=C1 FGSAQRJRWCZLOB-UHFFFAOYSA-N 0.000 description 1
- LIEPVGBDUYKPLC-UHFFFAOYSA-N 2-chloro-4-nitropyridine Chemical compound [O-][N+](=O)C1=CC=NC(Cl)=C1 LIEPVGBDUYKPLC-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- QRXBTPFMCTXCRD-UHFFFAOYSA-N 2-chloropyridine-4-carbonitrile Chemical compound ClC1=CC(C#N)=CC=N1 QRXBTPFMCTXCRD-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-M 2-furoate Chemical compound [O-]C(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-M 0.000 description 1
- UBPDKIDWEADHPP-UHFFFAOYSA-N 2-iodoaniline Chemical compound NC1=CC=CC=C1I UBPDKIDWEADHPP-UHFFFAOYSA-N 0.000 description 1
- JKHHRSIUFVAEOY-UHFFFAOYSA-N 2-iodobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1I JKHHRSIUFVAEOY-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- PLRNXYASTRYASJ-UHFFFAOYSA-N 3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2OC(=NC=2)C(=O)CCCCCCC=2C=CC=CC=2)=C1 PLRNXYASTRYASJ-UHFFFAOYSA-N 0.000 description 1
- PVKAKLPASHXLJF-UHFFFAOYSA-N 3-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]benzonitrile Chemical compound N=1C=C(C=2C=C(C=CC=2)C#N)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 PVKAKLPASHXLJF-UHFFFAOYSA-N 0.000 description 1
- XHKNXOUIUKTEIC-UHFFFAOYSA-N 3-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]phenol Chemical compound N=1C=C(C=2C=C(O)C=CC=2)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 XHKNXOUIUKTEIC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ODJFDWIECLJWSR-UHFFFAOYSA-N 3-bromobenzamide Chemical compound NC(=O)C1=CC=CC(Br)=C1 ODJFDWIECLJWSR-UHFFFAOYSA-N 0.000 description 1
- MUBJNMWVQGHHLG-UHFFFAOYSA-N 3-bromobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(Br)=C1 MUBJNMWVQGHHLG-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- FXTKWBZFNQHAAO-UHFFFAOYSA-N 3-iodophenol Chemical compound OC1=CC=CC(I)=C1 FXTKWBZFNQHAAO-UHFFFAOYSA-N 0.000 description 1
- SGDZCJMWEVDNLQ-UHFFFAOYSA-N 4-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]benzenesulfonamide Chemical compound N=1C=C(C=2C=CC(=CC=2)S(N)(=O)=O)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 SGDZCJMWEVDNLQ-UHFFFAOYSA-N 0.000 description 1
- QJPJQTDYNZXKQF-UHFFFAOYSA-N 4-bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 1
- ZRWNRAJCPNLYAK-UHFFFAOYSA-N 4-bromobenzamide Chemical compound NC(=O)C1=CC=C(Br)C=C1 ZRWNRAJCPNLYAK-UHFFFAOYSA-N 0.000 description 1
- STYQHICBPYRHQK-UHFFFAOYSA-N 4-bromobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Br)C=C1 STYQHICBPYRHQK-UHFFFAOYSA-N 0.000 description 1
- HQSCPPCMBMFJJN-UHFFFAOYSA-N 4-bromobenzonitrile Chemical compound BrC1=CC=C(C#N)C=C1 HQSCPPCMBMFJJN-UHFFFAOYSA-N 0.000 description 1
- JHNRTJRDRWKAIW-UHFFFAOYSA-N 4-chloro-2,6-dimethoxypyrimidine Chemical compound COC1=CC(Cl)=NC(OC)=N1 JHNRTJRDRWKAIW-UHFFFAOYSA-N 0.000 description 1
- WXJQQLDICAOBJB-UHFFFAOYSA-N 5-bromothiophene-2-sulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Br)S1 WXJQQLDICAOBJB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical class CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical class COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical class CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229910008066 SnC12 Inorganic materials 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100028651 Tenascin-N Human genes 0.000 description 1
- 101710087911 Tenascin-N Proteins 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000347391 Umbrina cirrosa Species 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 description 1
- DVKHVXKZASLYBY-UHFFFAOYSA-N [4-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]phenyl] acetate Chemical compound C1=CC(OC(=O)C)=CC=C1C1=CN=C(C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)O1 DVKHVXKZASLYBY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000002948 appetite stimulant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003554 cannabinoid 1 receptor agonist Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000005534 decanoate group Chemical class 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- 239000012351 deprotecting agent Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- FXHGMKSSBGDXIY-UHFFFAOYSA-N heptanal Chemical compound CCCCCCC=O FXHGMKSSBGDXIY-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical class OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940099262 marinol Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- UFTUTXWWFGXRST-UHFFFAOYSA-N methyl 2-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1C1=CN=C(C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)O1 UFTUTXWWFGXRST-UHFFFAOYSA-N 0.000 description 1
- MYGAJZBZLONIBZ-UHFFFAOYSA-N methyl 2-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1Cl MYGAJZBZLONIBZ-UHFFFAOYSA-N 0.000 description 1
- KKOUHTMLFUAAGG-UHFFFAOYSA-N methyl 2-chloropyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(Cl)=C1 KKOUHTMLFUAAGG-UHFFFAOYSA-N 0.000 description 1
- BXXLTVBTDZXPTN-UHFFFAOYSA-N methyl 2-iodobenzoate Chemical compound COC(=O)C1=CC=CC=C1I BXXLTVBTDZXPTN-UHFFFAOYSA-N 0.000 description 1
- KMFJVYMFCAIRAN-UHFFFAOYSA-N methyl 3-bromobenzoate Chemical compound COC(=O)C1=CC=CC(Br)=C1 KMFJVYMFCAIRAN-UHFFFAOYSA-N 0.000 description 1
- CZNGTXVOZOWWKM-UHFFFAOYSA-N methyl 4-bromobenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1 CZNGTXVOZOWWKM-UHFFFAOYSA-N 0.000 description 1
- QZNOFANOWONPOF-UHFFFAOYSA-N methyl 5-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]furan-2-carboxylate Chemical compound O1C(C(=O)OC)=CC=C1C1=CN=C(C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)O1 QZNOFANOWONPOF-UHFFFAOYSA-N 0.000 description 1
- PHJCQZAZGFRCQN-UHFFFAOYSA-N methyl 5-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1C1=CN=C(C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)O1 PHJCQZAZGFRCQN-UHFFFAOYSA-N 0.000 description 1
- FBPIDMAELBIRLE-UHFFFAOYSA-N methyl 5-bromofuran-2-carboxylate Chemical compound COC(=O)C1=CC=C(Br)O1 FBPIDMAELBIRLE-UHFFFAOYSA-N 0.000 description 1
- QLWUHAQCKDHUNL-UHFFFAOYSA-N methyl 5-bromothiophene-2-carboxylate Chemical compound COC(=O)C1=CC=C(Br)S1 QLWUHAQCKDHUNL-UHFFFAOYSA-N 0.000 description 1
- UYFAXIBESZLCHR-UHFFFAOYSA-N methyl 6-[2-[1-[tert-butyl(dimethyl)silyl]oxy-7-phenylheptyl]-1,3-oxazol-5-yl]pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(C=2OC(=NC=2)C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)=N1 UYFAXIBESZLCHR-UHFFFAOYSA-N 0.000 description 1
- TWUXBVMXSBEKHA-UHFFFAOYSA-N methyl 6-chloropyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(Cl)=N1 TWUXBVMXSBEKHA-UHFFFAOYSA-N 0.000 description 1
- RMEDXVIWDFLGES-UHFFFAOYSA-N methyl 6-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(Cl)N=C1 RMEDXVIWDFLGES-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008008 oral excipient Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000005541 phosphonamide group Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920001184 polypeptide Chemical group 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical class OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- FYHDBVPPOGESTQ-UHFFFAOYSA-N tert-butyl-[1-[5-(2,6-dimethoxypyrimidin-4-yl)-1,3-oxazol-2-yl]-7-phenylheptoxy]-dimethylsilane Chemical compound COC1=NC(OC)=CC(C=2OC(=NC=2)C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)=N1 FYHDBVPPOGESTQ-UHFFFAOYSA-N 0.000 description 1
- JHEOJDCOAGEDDG-UHFFFAOYSA-N tert-butyl-[1-[5-(2-fluorophenyl)-1,3-oxazol-2-yl]-7-phenylheptoxy]-dimethylsilane Chemical compound N=1C=C(C=2C(=CC=CC=2)F)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 JHEOJDCOAGEDDG-UHFFFAOYSA-N 0.000 description 1
- KMJPBTDCHRRVLX-UHFFFAOYSA-N tert-butyl-[1-[5-(2-methoxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptoxy]-dimethylsilane Chemical compound COC1=CC=CC=C1C1=CN=C(C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)O1 KMJPBTDCHRRVLX-UHFFFAOYSA-N 0.000 description 1
- SPXPEXLRZGLIGE-UHFFFAOYSA-N tert-butyl-[1-[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptoxy]-dimethylsilane Chemical compound COC1=CC=CC(C=2OC(=NC=2)C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)=C1 SPXPEXLRZGLIGE-UHFFFAOYSA-N 0.000 description 1
- MXZSIGLDFFSEIG-UHFFFAOYSA-N tert-butyl-[1-[5-(4-fluorophenyl)-1,3-oxazol-2-yl]-7-phenylheptoxy]-dimethylsilane Chemical compound N=1C=C(C=2C=CC(F)=CC=2)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 MXZSIGLDFFSEIG-UHFFFAOYSA-N 0.000 description 1
- KOFAITKBZLHZJA-UHFFFAOYSA-N tert-butyl-dimethyl-[1-[5-(2-nitrophenyl)-1,3-oxazol-2-yl]-7-phenylheptoxy]silane Chemical compound N=1C=C(C=2C(=CC=CC=2)[N+]([O-])=O)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 KOFAITKBZLHZJA-UHFFFAOYSA-N 0.000 description 1
- HMWKDPJORXZWLF-UHFFFAOYSA-N tert-butyl-dimethyl-[1-[5-(3-nitrophenyl)-1,3-oxazol-2-yl]-7-phenylheptoxy]silane Chemical compound N=1C=C(C=2C=C(C=CC=2)[N+]([O-])=O)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 HMWKDPJORXZWLF-UHFFFAOYSA-N 0.000 description 1
- WGZWQXJPXVHXSF-UHFFFAOYSA-N tert-butyl-dimethyl-[1-[5-(4-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptoxy]silane Chemical compound CC1=CC=NC(C=2OC(=NC=2)C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)=C1 WGZWQXJPXVHXSF-UHFFFAOYSA-N 0.000 description 1
- BEFUKSFGVFXTCV-UHFFFAOYSA-N tert-butyl-dimethyl-[1-[5-(4-nitrophenyl)-1,3-oxazol-2-yl]-7-phenylheptoxy]silane Chemical compound N=1C=C(C=2C=CC(=CC=2)[N+]([O-])=O)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 BEFUKSFGVFXTCV-UHFFFAOYSA-N 0.000 description 1
- WKPGSGOJVLRPRZ-UHFFFAOYSA-N tert-butyl-dimethyl-[1-[5-(5-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptoxy]silane Chemical compound N1=CC(C)=CC=C1C1=CN=C(C(CCCCCCC=2C=CC=CC=2)O[Si](C)(C)C(C)(C)C)O1 WKPGSGOJVLRPRZ-UHFFFAOYSA-N 0.000 description 1
- CEGYEKAUAHZACN-UHFFFAOYSA-N tert-butyl-dimethyl-[7-phenyl-1-[5-[4-(trifluoromethyl)pyridin-2-yl]-1,3-oxazol-2-yl]heptoxy]silane Chemical compound N=1C=C(C=2N=CC=C(C=2)C(F)(F)F)OC=1C(O[Si](C)(C)C(C)(C)C)CCCCCCC1=CC=CC=C1 CEGYEKAUAHZACN-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-M thiophene-2-carboxylate Chemical compound [O-]C(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-M 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- GDJZZWYLFXAGFH-UHFFFAOYSA-M xylenesulfonate group Chemical group C1(C(C=CC=C1)C)(C)S(=O)(=O)[O-] GDJZZWYLFXAGFH-UHFFFAOYSA-M 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Certain oxazole ketone compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as MS).
Description
OXAZOLE KETONES AS MODULATORS OF
FATTY ACID AMIDE HYDROLASE
Description Field of Invention:
The present invention relates to certain 2-keto-oxazole compounds, pharmaceutical compositions containing them, and methods of using them for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity.
Background:
Medicinal benefits have been attributed to the cannabis plant for centuries.
The primary bioactive constituent of cannabis is A9-tetrahydro-cannabinol (THC).
The discovery of THC eventually led to the identification of two endogenous cannabinoid receptors responsible for its pharmacological actions, namely CB1 and CB2 (Goya, Exp. Opin. Ther. Patents 2000, 10, 1529). These discoveries not only established the site of action of THC, but also inspired inquiries into the endogenous agonists of these receptors, or "endocannabinoids". The first endocannabinoid identified was the fatty acid amide anandamide (AEA). AEA
itself elicits many of the pharmacological effects of exogenous cannabinoids (Piomefli, Nat. Rev. Neurosci. 2003, 4(11), 873).
The catabolism of AEA is primarily attributable to the integral membrane bound protein fatty acid amide hydrolase (FAAH), which hydrolyzes AEA to arachidonic acid. FAAH was characterized in 1996 by Cravatt and co-workers (Cravatt, Nature 1996, 384, 83). It was subsequently determined that FAAH is additionally responsible for the catabolism of a large number of important lipid signaling fatty acid amides including: another major endocannabinoid, 2-arachidonoylglycerol (2-AG) (Science 1992, 258, 1946-1949); the sleep-inducing substance, oleamide (OEA) (Science 1995, 268, 1506); the appetite-suppressing agent, N-oleoylethanolamine (Rodriguez de Fonesca, Nature 2001, 414, 209);
and the anti-inflammatory agent, palmitoylethanolamide (PEA) (Lambert, Curr.
Med. Chem. 2002, 9(6), 663).
Small-molecule inhibitors of FAAH should elevate the concentrations of these endogenous signaling lipids and thereby produce their associated beneficial pharmacological effects. There have been some reports of the effects of various FAAH inhibitors in pre-clinical models.
In particular, two carbamate-based inhibitors of FAAH were reported to have analgesic properties in animal models. In rats, BMS-1 (see WO 02/087569), which has the structure shown below, was reported to have an analgesic effect in the Chung spinal nerve ligation model of neuropathic pain, and the Hargraves test of acute thermal nociception. . URB-597 was reported to have efficacy in the zero plus maze model of anxiety in rats, as well as analgesic efficacy in the rat hot plate and formalin tests (Kathuria, Nat. Med. 2003, 9(9), 76). The sulfonylfluoride AM374 was also shown to significantly reduce spasticity in chronic relapsing experimental autoimmune encephalomyelitis (CREAE) mice, an animal model of multiple sclerosis (Baker, FASEB J. 2001, 15(2), 300).
F H
&TN N/ ~
~ O I \ \ OH N'o BMS-1 ~ URB-597 _F
OSO
In addition, the oxazolopyridine ketone OL-135 is reported to be a potent inhibitor of FAAH, and has been reported to have analgesic activity in both the hot plate and tail emersion tests of thermal nociception in rats (WO 04/033652).
FATTY ACID AMIDE HYDROLASE
Description Field of Invention:
The present invention relates to certain 2-keto-oxazole compounds, pharmaceutical compositions containing them, and methods of using them for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity.
Background:
Medicinal benefits have been attributed to the cannabis plant for centuries.
The primary bioactive constituent of cannabis is A9-tetrahydro-cannabinol (THC).
The discovery of THC eventually led to the identification of two endogenous cannabinoid receptors responsible for its pharmacological actions, namely CB1 and CB2 (Goya, Exp. Opin. Ther. Patents 2000, 10, 1529). These discoveries not only established the site of action of THC, but also inspired inquiries into the endogenous agonists of these receptors, or "endocannabinoids". The first endocannabinoid identified was the fatty acid amide anandamide (AEA). AEA
itself elicits many of the pharmacological effects of exogenous cannabinoids (Piomefli, Nat. Rev. Neurosci. 2003, 4(11), 873).
The catabolism of AEA is primarily attributable to the integral membrane bound protein fatty acid amide hydrolase (FAAH), which hydrolyzes AEA to arachidonic acid. FAAH was characterized in 1996 by Cravatt and co-workers (Cravatt, Nature 1996, 384, 83). It was subsequently determined that FAAH is additionally responsible for the catabolism of a large number of important lipid signaling fatty acid amides including: another major endocannabinoid, 2-arachidonoylglycerol (2-AG) (Science 1992, 258, 1946-1949); the sleep-inducing substance, oleamide (OEA) (Science 1995, 268, 1506); the appetite-suppressing agent, N-oleoylethanolamine (Rodriguez de Fonesca, Nature 2001, 414, 209);
and the anti-inflammatory agent, palmitoylethanolamide (PEA) (Lambert, Curr.
Med. Chem. 2002, 9(6), 663).
Small-molecule inhibitors of FAAH should elevate the concentrations of these endogenous signaling lipids and thereby produce their associated beneficial pharmacological effects. There have been some reports of the effects of various FAAH inhibitors in pre-clinical models.
In particular, two carbamate-based inhibitors of FAAH were reported to have analgesic properties in animal models. In rats, BMS-1 (see WO 02/087569), which has the structure shown below, was reported to have an analgesic effect in the Chung spinal nerve ligation model of neuropathic pain, and the Hargraves test of acute thermal nociception. . URB-597 was reported to have efficacy in the zero plus maze model of anxiety in rats, as well as analgesic efficacy in the rat hot plate and formalin tests (Kathuria, Nat. Med. 2003, 9(9), 76). The sulfonylfluoride AM374 was also shown to significantly reduce spasticity in chronic relapsing experimental autoimmune encephalomyelitis (CREAE) mice, an animal model of multiple sclerosis (Baker, FASEB J. 2001, 15(2), 300).
F H
&TN N/ ~
~ O I \ \ OH N'o BMS-1 ~ URB-597 _F
OSO
In addition, the oxazolopyridine ketone OL-135 is reported to be a potent inhibitor of FAAH, and has been reported to have analgesic activity in both the hot plate and tail emersion tests of thermal nociception in rats (WO 04/033652).
O
CN O
I
N
Results of research on the effects of certain exogenous cannabinoids has elucidated that a FAAH inhibitor may be useful for treating various conditions, diseases, disorders, or symptoms. These include pain, nausea/emesis, anorexia, spasticity, movement disorders, epilepsy and glaucoma. To date, approved therapeutic uses for cannabinoids include the relief of chemotherapy-induced nausea and emesis among patients with cancer and appetite enhancement in patients with HIV/AIDS who experience anorexia as a result of wasting syndrome.
Two products are commercially available in some countries for these indications, namely, dronabinol (Marinol ) and nabilone.
Apart from the approved indications, a therapeutic field that has received much attention for cannabinoid use is analgesia, i.e., the treatment of pain.
Five small randomized controlled trials showed that THC is superior to placebo, producing dose-related analgesia (Robson, Br. J. Psychiatry 2001, 178, 107-115).
Atlantic Pharmaceuticals is reported to be developing a synthetic cannabinoid, CT-3, a 1,1-dimethyl heptyl derivative of the carboxylic metabolite of tetrahydrocannabinol, as an orally active analgesic and anti-inflammatory agent.
A pilot phase II trial in chronic neuropathic pain with CT-3 was reported as being initiated in Germany in May 2002.
A number of individuals with multiple sclerosis have claimed a benefit from cannabis for both disease-related pain and spasticity, with support from small controlled trials (Svendsen, Br. Med. J. 2004, 329, 253). Likewise, various victims of spinal cord injuries, such as paraplegia, have reported that their painful spasms are alleviated after smoking marijuana. A report showing that cannabinoids appear to control spasticity and tremor in the CREAE model of multiple sclerosis demonstrated that these effects are mediated by CB1 and CB2 receptors (Baker, Nature 2000, 404, 84-87). Phase 3 clinical trials have been undertaken in multiple sclerosis and spinal cord injury patients with a narrow ratio mixture of tetrahydrocannabinol/cannabidiol (THC/CBD).
Reports of small-scale controlled trials have been conducted to investigate other potential commercial uses of cannabinoids have been made. Trials in volunteers have been reported that confirmed that oral, injected and smoked cannabinoids produced dose-related reductions in intraocular pressure (IOP) and therefore may relieve glaucoma symptoms. Ophthalmologists have prescribed cannabis for patients with glaucoma in whom other drugs have failed to adequately control intraocular pressure (Robson, 2001).
Inhibition of FAAH using a small-molecule inhibitor may be advantageous compared to treatment with a direct-acting CB1 agonist. Administration of exogenous CB1 agonists may produce a range of responses, including reduced nociception, catalepsy, hypothermia, and increased feeding behavior. These four in particular are termed the "cannabinoid tetrad." Experiments with FAAH -/-mice show reduced responses in tests of nociception, but did not show catalepsy, hypothermia, or increased feeding behavior (Cravatt, Proc. Natt. Acad. Sci.
USA
2001, 98(16), 9371). Fasting caused levels of AEA to increase in rat limbic forebrain, but not in other brain areas, providing evidence that stimulation of AEA
biosynthesis may be anatomically regionalized to targeted CNS pathways (Kirkham, Br. J. Pharrnacol. 2002, 136, 550). The finding that AEA increases are localized within the brain, rather than systemic, suggests that FAAH
inhibition with a small molecule could enhance the actions of AEA and other fatty acid amides in tissue regions where synthesis and release of these signaling molecules is occurring in a given pathophysiological condition (Piomelli, 2003).
In addition to the effects of a FAAH inhibitor on AEA and other endocannabinoids, inhibitors of FAAH's catabolism of other lipid mediators may be used in treating other therapeutic indications. For example, PEA has demonstrated biological effects in animal models of inflammation, immunosuppression, analgesia, and neuroprotection (Ueda, J. Bio1. Chem. 2001, 276(38), 35552). Oleamide, another substrate of FAAH, induces sleep (Boger, Proc. Natl. Acad. Sci. USA 2000, 97(10), 5044; Mendelson, Neuropsychopharmacology 2001, 25, S36).
Thus, there is evidence that small-molecule FAAH inhibitors may be useful in treating pain of various etiologies, anxiety, multiple sclerosis and other movement disorders, nausea/emesis, eating disorders, epilepsy, glaucoma, inflammation, imrnunosuppression, neuroprotection, and sleep disorders, and potentially with fewer side effects than treatment with an exogenous cannabinoid.
Various srnall-molecule FAAH modulators have been reported, e.g., in WO
04/033652, U.S. Patent No. 6,462,054, U.S. Patent No. 6,096,784, WO
99/26584, WO 97/49667, and WO 96/09817. However, there is still a need for other potent FAAH modulators with desirable pharmaceutical properties.
Summary Certain 2-keto-oxazole derivatives have now been found to have FAAH-modulating activity. More particularly, in one general aspect the invention relates to compounds of the following Formula (I):
O
R~
O
(Ar)--~
In Formula (I), Ar is a 5- or 6-membered aryl or heteroaryl ring having a carbon as its point of attachment to the oxazole; R' is independently -Cl_salkyl, -C3_6cycloalkyl, -CF3, -CN, -C(O)C,-4alkyl optionally substituted with one, two, or three fluoro substituents, -CO2C,.~alkyl, -CO2H, -C(O)N(Ra)Rb; -OH, -OC~_salkyl, halo, -NO2i -NRaRb, -N(Ra)CORb, -N(Ra)SO2Rb, SO2N(Ra)Rb, or S(O)o_2Ra; where Ra and Rb are each independently -H, -C,.6alkyl, or -C3_6cycloalkyl; and R2 is independently -H, -C1_6alkyl, -C3.6cycloalkyl, -CF3, -CN, -C(O)C,.4alkyl optionally substituted with one, two, or three fluoro substituents, -CO2CI-4alkyl, -CO2H, -C(O)N(Rc)Rd, -OH, -OC,_6alkyl, halo, -NO2, -NRORd, -N(R )CORd, -N(R )SO2Rd, SO2N(R~)Rd, or S(O)o_2R ; where Rc and Rd are each independently -H, -C1~alkyi, or -C3_6cycloalkyl; or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite of said compound.
CN O
I
N
Results of research on the effects of certain exogenous cannabinoids has elucidated that a FAAH inhibitor may be useful for treating various conditions, diseases, disorders, or symptoms. These include pain, nausea/emesis, anorexia, spasticity, movement disorders, epilepsy and glaucoma. To date, approved therapeutic uses for cannabinoids include the relief of chemotherapy-induced nausea and emesis among patients with cancer and appetite enhancement in patients with HIV/AIDS who experience anorexia as a result of wasting syndrome.
Two products are commercially available in some countries for these indications, namely, dronabinol (Marinol ) and nabilone.
Apart from the approved indications, a therapeutic field that has received much attention for cannabinoid use is analgesia, i.e., the treatment of pain.
Five small randomized controlled trials showed that THC is superior to placebo, producing dose-related analgesia (Robson, Br. J. Psychiatry 2001, 178, 107-115).
Atlantic Pharmaceuticals is reported to be developing a synthetic cannabinoid, CT-3, a 1,1-dimethyl heptyl derivative of the carboxylic metabolite of tetrahydrocannabinol, as an orally active analgesic and anti-inflammatory agent.
A pilot phase II trial in chronic neuropathic pain with CT-3 was reported as being initiated in Germany in May 2002.
A number of individuals with multiple sclerosis have claimed a benefit from cannabis for both disease-related pain and spasticity, with support from small controlled trials (Svendsen, Br. Med. J. 2004, 329, 253). Likewise, various victims of spinal cord injuries, such as paraplegia, have reported that their painful spasms are alleviated after smoking marijuana. A report showing that cannabinoids appear to control spasticity and tremor in the CREAE model of multiple sclerosis demonstrated that these effects are mediated by CB1 and CB2 receptors (Baker, Nature 2000, 404, 84-87). Phase 3 clinical trials have been undertaken in multiple sclerosis and spinal cord injury patients with a narrow ratio mixture of tetrahydrocannabinol/cannabidiol (THC/CBD).
Reports of small-scale controlled trials have been conducted to investigate other potential commercial uses of cannabinoids have been made. Trials in volunteers have been reported that confirmed that oral, injected and smoked cannabinoids produced dose-related reductions in intraocular pressure (IOP) and therefore may relieve glaucoma symptoms. Ophthalmologists have prescribed cannabis for patients with glaucoma in whom other drugs have failed to adequately control intraocular pressure (Robson, 2001).
Inhibition of FAAH using a small-molecule inhibitor may be advantageous compared to treatment with a direct-acting CB1 agonist. Administration of exogenous CB1 agonists may produce a range of responses, including reduced nociception, catalepsy, hypothermia, and increased feeding behavior. These four in particular are termed the "cannabinoid tetrad." Experiments with FAAH -/-mice show reduced responses in tests of nociception, but did not show catalepsy, hypothermia, or increased feeding behavior (Cravatt, Proc. Natt. Acad. Sci.
USA
2001, 98(16), 9371). Fasting caused levels of AEA to increase in rat limbic forebrain, but not in other brain areas, providing evidence that stimulation of AEA
biosynthesis may be anatomically regionalized to targeted CNS pathways (Kirkham, Br. J. Pharrnacol. 2002, 136, 550). The finding that AEA increases are localized within the brain, rather than systemic, suggests that FAAH
inhibition with a small molecule could enhance the actions of AEA and other fatty acid amides in tissue regions where synthesis and release of these signaling molecules is occurring in a given pathophysiological condition (Piomelli, 2003).
In addition to the effects of a FAAH inhibitor on AEA and other endocannabinoids, inhibitors of FAAH's catabolism of other lipid mediators may be used in treating other therapeutic indications. For example, PEA has demonstrated biological effects in animal models of inflammation, immunosuppression, analgesia, and neuroprotection (Ueda, J. Bio1. Chem. 2001, 276(38), 35552). Oleamide, another substrate of FAAH, induces sleep (Boger, Proc. Natl. Acad. Sci. USA 2000, 97(10), 5044; Mendelson, Neuropsychopharmacology 2001, 25, S36).
Thus, there is evidence that small-molecule FAAH inhibitors may be useful in treating pain of various etiologies, anxiety, multiple sclerosis and other movement disorders, nausea/emesis, eating disorders, epilepsy, glaucoma, inflammation, imrnunosuppression, neuroprotection, and sleep disorders, and potentially with fewer side effects than treatment with an exogenous cannabinoid.
Various srnall-molecule FAAH modulators have been reported, e.g., in WO
04/033652, U.S. Patent No. 6,462,054, U.S. Patent No. 6,096,784, WO
99/26584, WO 97/49667, and WO 96/09817. However, there is still a need for other potent FAAH modulators with desirable pharmaceutical properties.
Summary Certain 2-keto-oxazole derivatives have now been found to have FAAH-modulating activity. More particularly, in one general aspect the invention relates to compounds of the following Formula (I):
O
R~
O
(Ar)--~
In Formula (I), Ar is a 5- or 6-membered aryl or heteroaryl ring having a carbon as its point of attachment to the oxazole; R' is independently -Cl_salkyl, -C3_6cycloalkyl, -CF3, -CN, -C(O)C,-4alkyl optionally substituted with one, two, or three fluoro substituents, -CO2C,.~alkyl, -CO2H, -C(O)N(Ra)Rb; -OH, -OC~_salkyl, halo, -NO2i -NRaRb, -N(Ra)CORb, -N(Ra)SO2Rb, SO2N(Ra)Rb, or S(O)o_2Ra; where Ra and Rb are each independently -H, -C,.6alkyl, or -C3_6cycloalkyl; and R2 is independently -H, -C1_6alkyl, -C3.6cycloalkyl, -CF3, -CN, -C(O)C,.4alkyl optionally substituted with one, two, or three fluoro substituents, -CO2CI-4alkyl, -CO2H, -C(O)N(Rc)Rd, -OH, -OC,_6alkyl, halo, -NO2, -NRORd, -N(R )CORd, -N(R )SO2Rd, SO2N(R~)Rd, or S(O)o_2R ; where Rc and Rd are each independently -H, -C1~alkyi, or -C3_6cycloalkyl; or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite of said compound.
In preferred embodiments, the compound of Formula (I) is a compound specifically described or exemplified in the detailed description below.
In a further general aspect, the invention relates to pharmaceutical compositions each comprising: (a) an effective amount of an agent selected from compounds of Formula (I) and pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites thereof; and (b) a pharmaceutically acceptable excipient.
In another general aspect, the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by FAAH activity, comprising administering to the subject in need of such treatment an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite of such compound.
In certain preferred embodiments of the inventive method, the disease, disorder, or medical condition is selected from: anxiety, pain, sleep disorders, eating disorders, inflammation, multiple sclerosis and other movement disorders, HIV wasting syndrome, closed head injury, stroke, Alzheimer's disease, epilepsy, Tourette's syndrome, Niemann-Pick disease, Parkinson's disease, Huntington's chorea, optic neuritis, autoimmune uveitis, symptoms of drug withdrawal, nausea, emesis, sexual dysfunction, post-traumatic stress disorder, cerebral vasospasm, glaucoma, irritable bowel syndrome, inflammatory bowel disease, immunosuppression, gastroesophageal reflux disease, paralytic ileus, secretory diarrhea, gastric ulcer, rheumatoid arthritis, unwanted pregnancy, hypertension, cancer, hepatitis, allergic airway disease, auto-immune diabetes, intractable pruritis, and neuroinflammation.
In a further general aspect, the invention relates to pharmaceutical compositions each comprising: (a) an effective amount of an agent selected from compounds of Formula (I) and pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites thereof; and (b) a pharmaceutically acceptable excipient.
In another general aspect, the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by FAAH activity, comprising administering to the subject in need of such treatment an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite of such compound.
In certain preferred embodiments of the inventive method, the disease, disorder, or medical condition is selected from: anxiety, pain, sleep disorders, eating disorders, inflammation, multiple sclerosis and other movement disorders, HIV wasting syndrome, closed head injury, stroke, Alzheimer's disease, epilepsy, Tourette's syndrome, Niemann-Pick disease, Parkinson's disease, Huntington's chorea, optic neuritis, autoimmune uveitis, symptoms of drug withdrawal, nausea, emesis, sexual dysfunction, post-traumatic stress disorder, cerebral vasospasm, glaucoma, irritable bowel syndrome, inflammatory bowel disease, immunosuppression, gastroesophageal reflux disease, paralytic ileus, secretory diarrhea, gastric ulcer, rheumatoid arthritis, unwanted pregnancy, hypertension, cancer, hepatitis, allergic airway disease, auto-immune diabetes, intractable pruritis, and neuroinflammation.
Additional embodiments, features, and advantages of the invention will be apparent from the appended claims, which are incorporated into this summary by reference, as well as from the following detailed description.
Detailed Description of Invention and Its Preferred Embodiments:
The invention may be more fully appreciated by reference to the following description, including the following glossary of terms and the concluding examples. For the sake of brevity, the disclosures of the publications cited in this specification are herein incorporated by reference.
As used herein, the terms "including", "containing" and "comprising" are used herein in their open, non-limiting sense.
The term "alkyl" refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain. Exemplary alkyl groups include methyl (Me, which also may be structurally depicted by /), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and the like.
The term "aryl" refers to a monocyclic, fused bicyclic, or fused polycyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) having from 3 to 12 ring atoms per carbocycle. (Carbon atoms in aryl groups are sp2 hybridized.) Illustrative examples of aryl groups include phenyl, naphthyl, anthracenyl, phenanthrenyl, and the like.
The term "heteroaryl" refers to a monocyclic, fused bicyclic, or fused polycyclic aromatic heterocycle (ring structure having ring atoms selected from carbon atoms as well as nitrogen, oxygen, and sulfur heteroatoms) having from to 12 ring atoms per heterocycle. Illustrative examples of heteroaryl groups include the following moieties:
~ O~ ~ N~ ~ QN~UUON) 8- , N~l % CNN NN N~ S O
N Nv IN [\J~, cc,cc,cc>,acQ
N~ S \ \ \ ( \ \ ~ \
N N N ( -' ~ , and the Iike.
N N
The term "cycloalkyl" refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic, carbocycle having from 3 to ring atoms per carbocycle. Illustrative examples of cycloalkyl groups include the following moieties:
oØ0,0. ,0,0. 0.
Co. (DO, cl~>, C---O 0-13 , ~, / ~ , ~, ~/ and the like.
The term "halogen" represents chlorine, fluorine, bromine or iodine. The term "halo" represents chloro, fluoro, bromo or iodo.
The term "substituted" means that the specified group or moiety bears one or more substituents. The term "unsubstituted" means that the specified group bears no substituents. The term "optionally substituted" means that the specified group is unsubstituted or substituted by one or more substituents. Where the term "substituted" is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.
Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms.
In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. AII optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula. Thus, any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof.
Furthermore, certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers. Additionally, any formula given herein is intended to represent hydrates, solvates, and polymorphs of such compounds, and mixtures thereof.
Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, phosphorous, fluorine, and chlorine, such as 2H, 3H 11C, 13C, 14C, 15N
180,17o, 31 P 32P1 35S, 18F, 36Cf, '251, respectively. Various isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H, "C, and'4C are incorporated. Such isotopically labeled compounds are useful in metabolic studies (preferably with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)]
including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or "C labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the moiety for the variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula.
In preferred embodiments of the invention, Ar is selected from the group consisting of phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrimidine-dione, pyrazinyl, thiophenyl, furanyl, imidazolyl, oxazolyl, and tetrazolyl. More preferably, Ar is selected from the group consisting of 3-(R')-phenyl, 3-(R1)-2-pyridyl, 4-(R')-pyridyl, 5-(R1)-2-pyridyl, 6-(R1)-2-pyridyl, 5-(R')-2-furanyl, 5-(R1)-2-thiophenyl, 1-(R')-1 H-2-imidazolyl, and 1-(R1)-1H-5-tetrazolyl. Preferabiy, R' is selected from the group consisting of -CH3, -CFa, -CN, -C(O)CF3, -COZCH3, -COZH, -C(O)NH2, -OH, -OCH3, fluoro, -NO2, -NH2, and -SO2NHa. Preferably, R2 is -H.
The invention includes also pharmaceutically acceptable salts of the compounds represented by Formula (I), such as of those described above.
Pharmaceutically acceptable salts of the specific compounds exemplified are especia(iy preferred.
A "pharmaceutically acceptable salt" is intended to mean a salt of a free acid or base of a compound represented by Formula (I) that is not toxic, bioiogically intolerable, or otherwise biologically undesirable. See, generally, S.M.
Berge, et al., "Pharmaceutical Salts", J. Pharm. Sci., 1977, 66:1-19, and Handbook of Pharmaceutical Salts, Propertions, Selection, and Use; Stahl, P.H., Wermuth, C.G., Eds.; Wiley-VCH and VHCA: Zurich, 2002. Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. A compound of Formula (f) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
Exemplary pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, y-hydroxybutyrates, glycolates, tartrates, methanesulfonates, propanesulfonates, naphthalene-l-sulfonates, naphthalene-2-sulfonates, and mandelates.
If the compound of Formula (I) contains a basic nitrogen, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid, a suffonic acid, such as Iauryisulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, or ethanesulfonic acid, or the like.
Detailed Description of Invention and Its Preferred Embodiments:
The invention may be more fully appreciated by reference to the following description, including the following glossary of terms and the concluding examples. For the sake of brevity, the disclosures of the publications cited in this specification are herein incorporated by reference.
As used herein, the terms "including", "containing" and "comprising" are used herein in their open, non-limiting sense.
The term "alkyl" refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain. Exemplary alkyl groups include methyl (Me, which also may be structurally depicted by /), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and the like.
The term "aryl" refers to a monocyclic, fused bicyclic, or fused polycyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) having from 3 to 12 ring atoms per carbocycle. (Carbon atoms in aryl groups are sp2 hybridized.) Illustrative examples of aryl groups include phenyl, naphthyl, anthracenyl, phenanthrenyl, and the like.
The term "heteroaryl" refers to a monocyclic, fused bicyclic, or fused polycyclic aromatic heterocycle (ring structure having ring atoms selected from carbon atoms as well as nitrogen, oxygen, and sulfur heteroatoms) having from to 12 ring atoms per heterocycle. Illustrative examples of heteroaryl groups include the following moieties:
~ O~ ~ N~ ~ QN~UUON) 8- , N~l % CNN NN N~ S O
N Nv IN [\J~, cc,cc,cc>,acQ
N~ S \ \ \ ( \ \ ~ \
N N N ( -' ~ , and the Iike.
N N
The term "cycloalkyl" refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic, carbocycle having from 3 to ring atoms per carbocycle. Illustrative examples of cycloalkyl groups include the following moieties:
oØ0,0. ,0,0. 0.
Co. (DO, cl~>, C---O 0-13 , ~, / ~ , ~, ~/ and the like.
The term "halogen" represents chlorine, fluorine, bromine or iodine. The term "halo" represents chloro, fluoro, bromo or iodo.
The term "substituted" means that the specified group or moiety bears one or more substituents. The term "unsubstituted" means that the specified group bears no substituents. The term "optionally substituted" means that the specified group is unsubstituted or substituted by one or more substituents. Where the term "substituted" is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.
Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms.
In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. AII optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula. Thus, any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof.
Furthermore, certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers. Additionally, any formula given herein is intended to represent hydrates, solvates, and polymorphs of such compounds, and mixtures thereof.
Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, phosphorous, fluorine, and chlorine, such as 2H, 3H 11C, 13C, 14C, 15N
180,17o, 31 P 32P1 35S, 18F, 36Cf, '251, respectively. Various isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H, "C, and'4C are incorporated. Such isotopically labeled compounds are useful in metabolic studies (preferably with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)]
including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or "C labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the moiety for the variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula.
In preferred embodiments of the invention, Ar is selected from the group consisting of phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrimidine-dione, pyrazinyl, thiophenyl, furanyl, imidazolyl, oxazolyl, and tetrazolyl. More preferably, Ar is selected from the group consisting of 3-(R')-phenyl, 3-(R1)-2-pyridyl, 4-(R')-pyridyl, 5-(R1)-2-pyridyl, 6-(R1)-2-pyridyl, 5-(R')-2-furanyl, 5-(R1)-2-thiophenyl, 1-(R')-1 H-2-imidazolyl, and 1-(R1)-1H-5-tetrazolyl. Preferabiy, R' is selected from the group consisting of -CH3, -CFa, -CN, -C(O)CF3, -COZCH3, -COZH, -C(O)NH2, -OH, -OCH3, fluoro, -NO2, -NH2, and -SO2NHa. Preferably, R2 is -H.
The invention includes also pharmaceutically acceptable salts of the compounds represented by Formula (I), such as of those described above.
Pharmaceutically acceptable salts of the specific compounds exemplified are especia(iy preferred.
A "pharmaceutically acceptable salt" is intended to mean a salt of a free acid or base of a compound represented by Formula (I) that is not toxic, bioiogically intolerable, or otherwise biologically undesirable. See, generally, S.M.
Berge, et al., "Pharmaceutical Salts", J. Pharm. Sci., 1977, 66:1-19, and Handbook of Pharmaceutical Salts, Propertions, Selection, and Use; Stahl, P.H., Wermuth, C.G., Eds.; Wiley-VCH and VHCA: Zurich, 2002. Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. A compound of Formula (f) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
Exemplary pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, y-hydroxybutyrates, glycolates, tartrates, methanesulfonates, propanesulfonates, naphthalene-l-sulfonates, naphthalene-2-sulfonates, and mandelates.
If the compound of Formula (I) contains a basic nitrogen, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid, a suffonic acid, such as Iauryisulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, or ethanesulfonic acid, or the like.
If the compound of Formula (I) is an acid, such as a carboxylic acid or sulfonic acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, or alkaline earth metal hydroxide, or the like. Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as benzylamines, pyrrolidines, piperidine, morpholine, and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
The invention also relates to treatment methods employing pharmaceutically acceptable prodrugs of the compounds of Formula (I). The term "prodrug" means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH
is converted to the compound of Formula (I)). A "pharmaceutically acceptable prodrug" is a prodrug that is not toxic, biologically intolerable, or otherwise biologically unsuitable for administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
Exemplary prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, covalently joined through an amide or ester bond to a free amino, hydroxy, or carboxylic acid group of a compound of Formula (I). Examples of amino acid residues include the twenty naturally occurring amino acids, commonly designated by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.
The invention also relates to treatment methods employing pharmaceutically acceptable prodrugs of the compounds of Formula (I). The term "prodrug" means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH
is converted to the compound of Formula (I)). A "pharmaceutically acceptable prodrug" is a prodrug that is not toxic, biologically intolerable, or otherwise biologically unsuitable for administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
Exemplary prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, covalently joined through an amide or ester bond to a free amino, hydroxy, or carboxylic acid group of a compound of Formula (I). Examples of amino acid residues include the twenty naturally occurring amino acids, commonly designated by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.
Additional types of prodrugs may be produced, for instance, by derivatizing free carboxyl groups of structures of Formula (I) as amides or alkyl esters.
Exemplary amides include those derived from ammonia, primary C1_6alkyl amines and secondary di(Cl_salkyl) amines. Secondary amines include 5- or 6-membered heterocycloalkyl or heteroaryl ring moieties. Preferred amides are derived from ammonia, C1_3alkyl primary amines, and di(C1_2alkyl)amines. Exemplary esters of the invention include C1_7alkyl, C5_7cycloalkyl, phenyl, and phenyl(C1_6alkyl) esters.
Preferred esters include methyl esters. Prodrugs may also be prepared by derivatizing free hydroxy groups using groups including hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, following procedures such as those outlined in Adv. Drug Delivery Rev. 1996, 19, 115. Carbamate derivatives of hydroxy and amino groups may also yield prodrugs. Carbonate derivatives, sulfonate esters, and sulfate esters of hydroxy groups may also provide prodrugs. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester, optionally substituted with one or more ether, amine, or carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also useful to yield prodrugs. Prodrugs of this type may be prepared as described in J. Med. Chem. 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. AII of these prodrug moieties may incorporate groups including ether, amine, and carboxylic acid functionalities.
Pharmaceutically active metabolites may also be used in the methods of the invention. A "pharmaceutically active metabolite" means a pharmacologically active product of metabolism in the body of a compound of Formula (I) or salt thereof. Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini et al., J. Med. Chem. 1997, 40, 2011-2016; Shan et al., J. Pharm. Sci. 1997, 86 (7), 765-767; Bagshawe, Drug Dev. Res. 1995, 34, 220-230; Bodor, Adv. Drug Res.
1984, 13, 224-331; Bundgaard, Design of Prodrugs (Elsevier Press, 1985); and Larsen, Design and Application of Prodrugs, Drug Design and Development (Krogsgaard-Larsen et al., eds., Harwood Academic Publishers, 1991).
Exemplary amides include those derived from ammonia, primary C1_6alkyl amines and secondary di(Cl_salkyl) amines. Secondary amines include 5- or 6-membered heterocycloalkyl or heteroaryl ring moieties. Preferred amides are derived from ammonia, C1_3alkyl primary amines, and di(C1_2alkyl)amines. Exemplary esters of the invention include C1_7alkyl, C5_7cycloalkyl, phenyl, and phenyl(C1_6alkyl) esters.
Preferred esters include methyl esters. Prodrugs may also be prepared by derivatizing free hydroxy groups using groups including hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, following procedures such as those outlined in Adv. Drug Delivery Rev. 1996, 19, 115. Carbamate derivatives of hydroxy and amino groups may also yield prodrugs. Carbonate derivatives, sulfonate esters, and sulfate esters of hydroxy groups may also provide prodrugs. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester, optionally substituted with one or more ether, amine, or carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also useful to yield prodrugs. Prodrugs of this type may be prepared as described in J. Med. Chem. 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. AII of these prodrug moieties may incorporate groups including ether, amine, and carboxylic acid functionalities.
Pharmaceutically active metabolites may also be used in the methods of the invention. A "pharmaceutically active metabolite" means a pharmacologically active product of metabolism in the body of a compound of Formula (I) or salt thereof. Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini et al., J. Med. Chem. 1997, 40, 2011-2016; Shan et al., J. Pharm. Sci. 1997, 86 (7), 765-767; Bagshawe, Drug Dev. Res. 1995, 34, 220-230; Bodor, Adv. Drug Res.
1984, 13, 224-331; Bundgaard, Design of Prodrugs (Elsevier Press, 1985); and Larsen, Design and Application of Prodrugs, Drug Design and Development (Krogsgaard-Larsen et al., eds., Harwood Academic Publishers, 1991).
The compounds of Formula (I) and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites (collectively, "agents") of the present invention are useful as FAAH
inhibitors in the methods of the invention. The agents may be used in the inventive methods for the treatment or prevention of medical conditions, diseases, or disorders mediated through inhibition or modulation of FAAH, such as those described herein. Agents according to the invention may therefore be used as an analgesic, neuroprotectant, sedative, appetite stimulant, or contraceptive.
Exemplary medical conditions, diseases, and disorders include anxiety, pain, sleep disorders, eating disorders, inflammation, multiple sclerosis and other movement disorders, HIV wasting syndrome, closed head injury, stroke, Alzheimer's disease, epilepsy, Tourette's syndrome, epilepsy, Niemann-Pick disease, Parkinson's disease, Huntington's chorea, optic neuritis, autoimmune uveitis, symptoms of drug withdrawal, nausea, emesis, sexual dysfunction, post-traumatic stress disorder, or cerebral vasospasm.
Thus, the pharmaceutical agents may be used to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated through FAAH
activity. The term "treat" or "treating" as used herein is intended to refer to administration of an agent or composition of the invention to a subject for the purpose of effecting a therapeutic or prophylactic benefit through modulation of FAAH activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition mediated through modulation of FAAH activity. The term "subject" refers to a mammalian patient in need of such treatment, such as a human. "Modulators"
include both inhibitors and activators, where "inhibitors" refer to compounds that decrease, prevent, inactivate, desensitize or.down-regulate FAAH expression or activity, and "activators" are compounds that increase, activate, facilitate, sensitize, or up-regulate FAAH expression or activity.
inhibitors in the methods of the invention. The agents may be used in the inventive methods for the treatment or prevention of medical conditions, diseases, or disorders mediated through inhibition or modulation of FAAH, such as those described herein. Agents according to the invention may therefore be used as an analgesic, neuroprotectant, sedative, appetite stimulant, or contraceptive.
Exemplary medical conditions, diseases, and disorders include anxiety, pain, sleep disorders, eating disorders, inflammation, multiple sclerosis and other movement disorders, HIV wasting syndrome, closed head injury, stroke, Alzheimer's disease, epilepsy, Tourette's syndrome, epilepsy, Niemann-Pick disease, Parkinson's disease, Huntington's chorea, optic neuritis, autoimmune uveitis, symptoms of drug withdrawal, nausea, emesis, sexual dysfunction, post-traumatic stress disorder, or cerebral vasospasm.
Thus, the pharmaceutical agents may be used to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated through FAAH
activity. The term "treat" or "treating" as used herein is intended to refer to administration of an agent or composition of the invention to a subject for the purpose of effecting a therapeutic or prophylactic benefit through modulation of FAAH activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition mediated through modulation of FAAH activity. The term "subject" refers to a mammalian patient in need of such treatment, such as a human. "Modulators"
include both inhibitors and activators, where "inhibitors" refer to compounds that decrease, prevent, inactivate, desensitize or.down-regulate FAAH expression or activity, and "activators" are compounds that increase, activate, facilitate, sensitize, or up-regulate FAAH expression or activity.
Accordingly, the invention relates to methods of using the pharmaceutical agents described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated through FAAH activity, such as:
anxiety, pain, sleep disorders, eating disorders, inflammation, or movement disorders (e.g., multiple sclerosis).
Symptoms or disease states are intended to be included within the scope of "medical conditions, disorders, or diseases." For example, pain may be associated with various diseases, disorders, or conditions, and may include various etiologies. Illustrative types of pain treatable with a FAAH-modulating agent according to the invention include cancer pain, postoperative pain, GI
tract pain, spinal cord injury pain, visceral hyperalgesia, thalamic pain, headache (including stress headache and migraine), low back pain, neck pain, musculoskeletal pain, peripheral neuropathic pain, central neuropathic pain, neurogenerative disorder related pain, and menstrual pain. HIV wasting syndrome includes associated symptoms such as appetite loss and nausea.
Parkinson's disease includes, for example, levodopa-induced dyskinesia.
Treatment of multiple sclerosis may include treatment of symptoms such as spasticity, neurogenic pain, central pain, or bladder dysfunction. Symptoms of drug withdrawal may be caused by, for example, addiction to opiates or nicotine.
Nausea or emesis may be due to chemotherapy, postoperative, or opioid related causes. Treatment of sexual dysfunction may include improving libido or delaying ejaculation. Treatment of cancer may include treatment of glioma. Sleep disorders include, for example, sleep apnea, insomnia, and disorders calling for treatment with an agent having a sedative or narcotic-type effect. Eating disorders include, for example, anorexia or appetite loss associated with a disease such as cancer or HIV infection/AIDS.
In a treatment method according to the invention, an effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition.
An "effective amount" means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment.
Effective amounts or doses.of the agents of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. An exemplary dose is in the range of from about 0.001 to about 200 mg of agent per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.
Once improvement of the patient's disease, disorder, or condition has occurred, the dose may be adjusted for preventative or maintenance treatment.
For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Patients may, however, require interrnittent treatment on a long-term basis upon any recurrence of symptoms.
In addition, the agents of the invention may be used in combination with additional active compounds in the treatment of the above conditions. The additional compounds may be coadministered separately with an agent of Formula (f) or included with such an agent as an additional active ingredient in a pharmaceutical composition according to the invention. In an exemplary embodiment, additional active compounds are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by FAAH activity, such as another FAAH modulator or a compound active against another target associated with the particular condition, disorder, or disease.
The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an agent according to the invention), decrease one or more side effects, or decrease the required dose of the agent according to the invention. In one illustrative embodiment, a composition according to the invention may contain one or more additional active ingredients selected from opioids, NSAIDs (e.g., ibuprofen, cyclooxygenase-2 (COX-2) inhibitors, and naproxen), gabapentin, pregabalin, tramadol, acetaminophen, and aspirin.
The agents of the invention are used, alone or in combination with one or more other active ingredients, to formulate pharmaceutical compositions of the invention. A pharmaceutical composition of the invention comprises: (a) an effective amount of a pharmaceutical agent in accordance with the invention;
and (b) a pharmaceutically acceptable excipient.
A"pharrriaceutically acceptable excipient" refers to a substance that is not toxic, biologically intolerable, or otherwise biologically unsuitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of a pharmaceutical agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
Delivery forms of the pharmaceutical compositions containing one or more dosage units of the pharmaceutical agents may be prepared using suitable pharmaceutical excipients and compounding techniques now or later known or available to those skilled in the art. The compositions may be administered in the inventive methods by oral, parenteral, rectal, topical, or ocular routes, or by inhalation.
.
The preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or -'I8 -suppositories. Preferably, the compositions are formulated for intravenous infusion, topical administration, or oral administration.
For oral administration, the compounds of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. To prepare the oral compositions, the agents may be formulated to yield a dosage of, e.g., from about 0.05 to about 50 mg/kg daily, or from about 0.05 to about 20 mg/kg daily, or from about 0.1 to about 10 mg/kg daily.
Oral tablets may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, active ingredient may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the active ingredient with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water;
preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
The agents of this invention may also be administered by non-oral routes.
For example, the compositions may be formulated for rectal administration as a suppository. For parenteral use, including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in par`enterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms will be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses may range from about 1 to g/kg/minute of agent, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
For topical administration, the agents may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle.
Another mode of administering the agents of the invention may utilize a patch formulation to affect transdermal delivery.
Agents may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.
Exemplary agents useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation -z0-below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product.
Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent.
Unless otherwise specified, the variables are as defined above in reference to Formula (I).
SCHEME A
OP
Pd coupling f Bu3Sn N (III) (R')(RZ)-(Ar)-X
OP
R1 O 1) Deprotection (Ar)-{ I I (I) Ra' ~-N 2) Oxidation (IV) Referring to Scheme A, stannanes of formula (III), where P is a suitable hydroxyl protecting group, are prepared as previously described (Boger, J.
Med.
Chem. 2005, 48, 1849). Stannanes (II!) are coupled with various aryl or heteroaryl halides using Stille coupling procedures. Preferred conditions utilize Pd(PPh3)4 or Pd(P(t-Bu)3)2 as the catalyst. Compounds of formula (IV) are then deprotected (for example, where P is a silyl protecting group, with a silyl deprotecting agent such as TBAF) and oxidized to compounds of Formula (I) using oxidizing agents such as Dess-Martin periodinane or TPAP/NMO.
SCHEME B
Ra b N-(Ar)-R (VII) R
Ra Reduction \ N-(Ar)-R (VIII) 02N-(Ar)-R H2N-(Ar)-R -= b , (V) (VI) R -SO2 O R\
N-(Ar)-R (IX) R 'N Rb-~O
Referring to Scheme B, compounds of formula (V) may be obtained according to the methods shown in Scheme A. The nitro group may be reduced to an amino group (formula (VI)) using standard nitro reduction methods, such as exposure to SnC12 or by hydrogenation in the presence of a Pd catalyst. Amines (VI) may be alkylated via alkylation or reductive amination protocols to form amines (VII). Amines (VI) may be alternatively sulfonylated with the appropriately substituted sulfonyl chlorides to form compounds of formula (VIII). Reaction of amines (VI) with suitably substituted acid chlorides or via peptide coupling with appropriate acids (e.g. in the presence of HOAt/EDCI) generate amides (IX).
Installation of the Ra substituent may be accomplished before (via alkylation or reductive amination) or after (via alkylation) the sulfonylation/acylation step. One skilled in the art will recognize that Formula (I) includes compounds of formulae (VI), (VII), (VIII), and (IX).
SCHEME C
Hydrolysis Alkylation AcO-(Ar)-R -~- HO-(Ar)-R (C1-6alkyi)-O-(Ar)-R
(X) (XI) (XII) Referring to Scheme C, acetates of formula (X), where R is defined as in Scheme B, may be obtained according to the methods shown in Scheme A.
Deprotection of the acetate group, using, for example, a base such as LiOH or NaOMe, gives the corresponding alcohols (XI). These alcohols may in turn be converted to ethers of formula (XII) by treatment with an appropriate alkyl halide in the presence of a base, or with an appropriate alcohol under Mitsunobu conditions (for example, PPh3/DEAD). One skilled in the art will recognize that Formula (I) includes compounds of formulae (XI) and (XII).
SCHEME D
Hydrolysis Amide Formation (C~-4alkyt)02C-(Ar)-R ----- HO2C-(Ar)-R Rb(Ra)NOC-(Ar)-R
(XIII) (XIV) (XV) Referring to Scheme D, esters of formula (XIII), where R is defined as in Scheme B, and prepared according to Scheme A, may be hydrolyzed to acids (XIV) using a base such as LiOH. Acids (XIV) may be converted to their corresponding amides (XV) by reaction with a suitable amine under peptide coupling conditions (e.g. HOAt/EDCI). One skilled in the art will recognize that Formula (!) includes compounds of formulae (XIII), (XIV), and (XV).
One skilled in the art will recognize that transformations depicted for R' may analogously be performed for R2.
SCHEME E
OMe O
N O
~I ~
MeONJ N
(XVI) O O
HN~ O
O~N=J N
H (XV I I) Referring to Scheme E, pyrimidines (XVI), prepared according to Scheme A, may be converted to uracils (XVII) by treatment of a demethylating agent such as TMSI. One skilled in the art wilt recognize that Formula (I) includes compounds of formulae (XVI) and (XVII).
The following examples are provided to further illustrate the invention and various preferred embodiments.
Examples Chemistry:
In obtaining the characterization data described in the examples below, the following analytical protocols were followed as indicated.
NMR spectra were obtained on Bruker model DRX spectrometers. The format of the 'H NMR data below is: chemical shift in ppm downfield of the tetramethylsifane reference (multiplicity, coupling constant J in Hz, integration).
Silica gel was used for all chromatographic purification unless otherwise noted. Where solutions were "concentrated", they were concentrated using a rotary evaporator under reduced pressure. Unless otherwise specified, reaction solutions were stirred at room temperature (rt) under a nitrogen atmosphere.
Mass spectra were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in either positive or negative modes as indicated.
Calculated mass (mass calcd.) corresponds to the exact mass.
Thin-layer chromatography was performed using Merck= silica gel 60 F254 2.5 cm x 7.5 cm 250 pm or 5.0 cm x 10.0 cm 250 pm pre-coated silica gel plates.
Preparative thin-layer chromatography was performed using EM Science silica gel 60 F254 20 cm x 20 cm 0.5 mm pre-coated plates with a 20 cm x 4 cm concentrating zone.
Reversed-phase HPLC was performed on a Hewlett Packard HPLC Series 1100, with a Phenomenex Luna C18 (5 pm, 4.6x150 mm) column. Detection was done at,%= 230, 254 and 280 nm. The flow rate was 1 mL/min. The gradient was 10 to 99% acetonitrile/water (0.05% trifluoroacetic acid) over 5.0 min.
General Procedure A. 2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (1 equiv), Pd(PPh3)4 (0.1 equiv), and aryl halide (2 equiv) were dissolved in anhydrous 1,4-dioxane (8 mL) and the mixture was warmed to reflux for 24 h under argon. The mixture was diluted with EtOAc, washed with saturated aqueous NaCI and dried over Na2SO4. Evaporation in vacuo yielded the crude coupling product that was purified by flash chromatography (Si02).
General Procedure B. 2-(1-(tert Butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (1 equiv), Pd(P(tBu)3)2 (0.1 equiv), CsF (2.2 equiv) and aryl halide (2 equiv) were dissolved in anhydrous 1,4-dioxane (2 mL) and the mixture was warmed at 100 C in a sealed tube and stirred for 24 h. The mixture was diluted with EtOAc, washed with saturated aqueous NaCi and dried over Na2SO4. Evaporation in vacuo yielded the crude coupling product that was purified by flash chromatography (Si02).
General Procedure C. The TBS ether (1 equiv) was dissolved in THF (3 mL), treated with Bu4NF (1 M in THF, 1.2 equiv) and stirred at room temperature for h under argon. The reaction mixture was diluted with EtOAc, washed with saturated aqueous NaCI and dried over Na2SO4. Evaporation in vacuo yielded the crude alcohol that was filtered through a short silica gel pad. The silica gel pad was washed with 10% EtOAc/hexanes followed by 60% EtOAc/hexanes to afford the alcohol which required no further purification. The alcohol (1 equiv) was dissolved in CH2CI2 (3 mL) or THF (3 mL) and Dess-Martin periodinane (1.5 equiv) was added. The mixture was stirred at room temperature for 2 h before silica gel was added and the reaction mixture was evaporated in vacuo to afford the crude ketone absorbed on silica gel. This mixture was subsequently purified by flash chromatography (SiOa) yielding the pure a-ketoheterocycle.
General Procedure D. The TBS ether (1 equiv) was dissolved in THF (3 mL), treated with Bu4NF (I M in THF, 1.2 equiv) and stirred at room temperature for h under argon. The reaction mixture was diluted with EtOAc, washed with saturated aqueous NaCI and dried over Na2SO4. Evaporation in vacuo yielded the crude alcohol that was filtered through a short silica gel pad. The silica gel pad was washed with 10% EtOAc/hexanes followed by 60% EtOAc/hexanes to afford the alcohol which required no further purification. The alcohol (1 equiv) was dissolved in CH2CI2 (3 mL) and tetrapropylammonium perruthenate (TPAP, 0.2 equiv), N-morpholine oxide (NMO, 1.5 equiv) and 4 A molecular sieves (1.5 x weight of alcohol) were added. The mixture was stirred at room temperature for h before it was filtered through a pad of diatomaceous earth. This crude ketone was subsequently purified by flash chromatography (SiOZ) yielding the pure a-ketoheterocycle.
General Procedure E. The ester (1 equiv) was dissolved in a mixture of 3:2 THF/H20 (2 mL: 1.3 mL) and LiOH (3 equiv) was added. The reaction mixture stirred for 2 h at room temperature before the mixture was made acidic with the addition of aqueous 1 N HCI. The solution was diluted with EtOAc and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (3x). The combined organic extracts were washed with saturated aqueous NaCI and dried over Na2SO4. Evaporation in vacuo yielded the crude acid that was purified by chromatography (SiOZ).
General Procedure F. The nitro compound (1 equiv) was dissolved in EtOAc (2 mL) and 10% Pd/C (0.1 equiv) was added. The reaction mixture was stirred at room temperature under H2 (1 atm) for 4 h before it was filtered through a pad of diatomaceous earth. Evaporation in vacuo yielded the crude aniline that was purified by chromatography (Si02).
General Procedure G. 2-(7-Phenylheptanoyl)oxazole-5-carboxylic acid (1 equiv), EDCI (2 equiv) and HOAt (2 equiv) were dissolved in DMF (1 mL). The reaction mixture was cooled to 0 C and stirred for 10 min before the amine (1.5 equiv) was added. The reaction mixture was stirred for 16 h under argon, diluted with H20 and made acidic with the addition of aqueous 2 N HCI. The solution was extracted with ether (3x) and the ether layers were combined, washed with saturated aqueous NaCi and dried over Na2SO4. Evaporation in vacuo yielded the crude amide that was purified by chromatography (Si02).
General Procedure H. The pyrimdine (1 equiv) and Nal (4 equiv) were dissolved in MeCN (3 mL) before TMSCI (4 equiv) was added. The reaction was stirred for 16 h at room temperature under argon before it was diluted with EtOAc, washed with saturated aqueous NaZSZO3 and washed with saturated aqueous NaCI.
Evaporation in vacuo yielded the crude uracil that was purified by flash chromatography (Si02).
General Procedure 1. The TBS ether (1 equiv) was dissolved in THF (3 mL), treated with Bu4NF (1 M in THF, 1.2 equiv) and the mixture was stirred at room temperature for 2 h under argon. The reaction mixture was diluted with EtOAc, washed with saturated aqueous NaCI and dried over NaaSO4. Evaporation in vacuo yielded the crude alcohol that was purified by flash chromatography (Si02).
General Procedure J. The ester (1 equiv) was dissolved in methanolic ammonia (1 mL) and stirred for 2 h at room temperature under argon. Evaporation in vacuo yielded the crude alcohol that was purified by chromatography (Si02).
' N ~ O
Example 1; 1-(5-(2-Nitrophenyi)oxazol-2-yl)-7-phenylheptan-1-one Step 1 : 2-(1-(tert ButyldimethylsiiyloxY)-7_phenylheptyl)-5-(2-nitrophenYl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (75 mg, 0.113 mmol) and 1-iodo-2-nitrobenzene following General Procedure A. Flash chromatography (3-10% EtOAc/hexanes) yielded the title compound as a yellow oil (58 mg, 97%):'H NMR (CDCI3, 300 MHz) 8 7.82 (dd, 1H, J = 9.2, 6.3 Hz), 7.70 (dd, 1 H, J = 9.3, 6.0 Hz), 7.67-7.64 (m, 1 H), 7.51-7.49 (m, 1 H), 7.32-7.25 (m, 3H), 7.19-7.16 (m, 3H), 4.82 (t, 1 H, J = 6.7 Hz), 2.60 (t, 2H, J = 7.5 Hz), 1.88-1.86 (m, 2H), 1.64-1.60 (m, 2H), 1.35-1.26 (m, 6H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H); 13 C NMR (CDCI3, 75 MHz) 8 171.5, 152.5, 151.1, 148.0, 137.6, 134.6, 134.5, 133.6, 133.4, 131.3, 130.7, 129.6, 127.1, 73.8, 41.6, 41.1, 36.6, 34.3, 34.3, 30.9, 30.1, 23.4, 0.2, 0Ø
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(2-nitrophenyl)oxazole (54 mg, 0.109 mmo!) following General Procedure C. Flash chromatography (20%
EtOAc/hexanes) yielded the title compound as a light yellow solid (29 mg, 71 %):
1 H NMR (CDCI3, 400 MHz) 8 7.86 (d, 1 H, J= 8.8 Hz), 7.75 (dd, I H, J = 9.2, 6.4 Hz), 7.65-7.62 (m, 1 H), 7.55-7.51 (m, 1 H), 7.44 (s, 1 H), 7.21-7.18 (m, 2H), 7.11-7.09 (m, 3H), 3.00 (t, 2H, J = 7.6 Hz), 2.53 (t, 2H, J = 7.6 Hz), 1.71-1.68 (m, 2H), 1.58-1.54 (m, 2H), 1.36-1.32 (m, 4H); 13C NMR (CDCI3, 100 MHz) 6 188.4, 157.9, 148.8, 147.9, 142.9, 133.1, 131.0, 130.6, 128.6, 128.4, 128.2, 125.8, 124.9, 121.2, 39.4, 36.1, 31.5, 29.2, 29.2, 24.0; MALDI-FTMS m/z 379.1651 (M +
H+, C22H23N204, requires 379.1652).
Example 2; 1-(5-(3-Nitrophenyl)oxazot-2-yl)-7-phenylheptan-l-one Step 1: 2-(1-(tert-Butyld imethylsilyloxY)_7-phenylheptyl)-5-(3-nitrophenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyfoxy)-7-phenylheptyi)-5-(tributyistannyl)oxazole (191 mg, 0.288 mmol) and 1-iodo-3-nitrobenzene following General Procedure A. Flash chromatography (5-10% EtOAc/hexanes) yielded the title compound as a yellow oil (128 mg, 90%): ' H NMR (CDCI3, 500 MHz) S 8.57-8.56 (m, 1H), 8.26-8.24 (m, 1 H), 8.03-8.02 (m, 1 H), 7.69 (t, 1 H, J= 16 Hz), 7.51 (s, 1 H), 7.36-7.33 (m, 2H), 7.26-7.23 (m, 3H), 4.94 (t, 1 H, J= 6.0 Hz), 2.67.(t, 2H, J= 7.5 Hz), 2.05-1.96 (m, 2H), 1.72-1.66 (m, 2H), 1.57-1.44 (m, 6H), 0.99 (s, 9H), 0.19 (s, 3H), 0.09 (s, 3H); 13C NMR (CDCI3, 125 MHz) S 166.4, 149.3, 149.2, 143.2, 130.5, 130.1, 130.0, 128.8, 128.6, 126.0, 124.2, 123.2, 119.4, 69.1, 36.8, 36.3, 31.8, 29.6, 26.1, 26.1, 25.5, 18.6, -4.5, -4.6.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyi)-5-(3-nitrophenyl)oxazole (126 mg, 0.255 mmol) following General Procedure C. Flash chromatography (5-20%
EtOAc/hexanes) yielded the title compound as a light yellow solid (75 mg, 77%):
'H NMR (CDCI3, 500 MHz) S 8.67 (s, 1 H), 8.35-8.33 (m, 1 H), 8.19-8.17 (m, 1 H), 7.77-7.74 (m, 2H), 7.36-7.33 (m, 2H), 7.26-7.24 (m, 3H), 3.18 (t, 2H, J = 7.5 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.90-1.84 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.46 (m, 4H);
13C NMR (CDCI3, 125 MHz) 5 188.7, 158.0, 152.0, 149.2, 143.1, 131.1, 130.8, 128.8, 128.8, 127.7, 126.1, 125.8, 124.7, 120.5, 39.6, 36.3, 31.7, 29.4, 29.4, 24.3;
MALDI-FTMS m/z 379.1652 (M + H+, C22H23N204, requires 379.1652).
N
/
OZN /~ O
O
Example 3; 1-(5-(4-Nitrophenyl)oxazol-2-yl)-7-phenylheptan-1-one=
Step 1; 2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-nitrophenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (90 mg, 0.136 mmol) and 1-iodo-4-nitrobenzene following General Procedure A. Flash chromatography (5-10% EtOAc/hexanes) yielded the title compound as a yellow oil (67 mg, 100%): 1H NMR (CDCI3r 500 MHz) 5 8.28 (d, 2H, J= 9.0 Hz), 7.78 (d, 2H, J= 9.0 Hz), 7.48 (s, 1 H), 7.27-7.24 (m, 2H), 7.17-7.15 (m, 3H), 4.87 (t, 1 H, J = 6.0 Hz), 2.59 (t, 2H, J = 7.8 Hz), 2.00-1.88 (m, 2H), 1.67-1.58 (m, 2H), 1.40-1.34 (m, 6H), 0.91 (s, 9H), 0.11 (s, 3H), 0.01 (s, 3H);13C NMR (CDCI3i 125 MHz) S 166.6, 149.0, 147.1, 142.6, 1-33.7, 128.3, 128.2, 125.5, 125.1, 124.4, 124.3, 68.6, 36.3, 35.8, 31.3, 29.1, 25.6, 25.6, 25.0, 18.1, -5.0, -5.1.
Step 2. The title compound was prepared from 2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)-5-(4-nitrophenyl)oxazole (65 mg, 0.131 mmol) following General Procedure C. Flash chromatography (5-20%
EtOAc/hexanes) yielded the title compound as a light yellow solid (25 mg, 50%):
1H NMR (CDCI3, 600 MHz) S 8.32 (d, 2H, J = 8.4 Hz), 7.93 (d, 2H, J= 8.4 Hz), 7.69 (s, 1 H), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 3.09 (t, 2H, J= 7.2 Hz), 2.60 (t, 2H, J= 7.2 Hz), 1.79-1.77 (m, 2H), 1.65-1.62 (m, 2H), 1.44-1.39 (m, 4H);
NMR (CDC13r 150 MHz) 5 189.2, 158.8, 152.5, 149.0, 143.5, 133.3, 129.2, 129.1, 127.3, 126.7, 126.5, 125.4, 40.0, 36.7, 32.1, 29.8, 29.8, 24.7; MALDI-FTMS m/z 379.1645 (M + H+, C22H23N204, requires 379.1652).
N
(/~~
Example 4; 7-Phenyl-l-(5-(2-(2,2,2-trifluoroacetyl)phenyl)oxazol-2-yi)heptan-1-one Step 1 : 1 :~2-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenyl)-2,2,2-trifluoroethanone, The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (63 mg, 0.095 mmol) and 1-(2-chlorophenyl)-2,2,2-trifluoroethanone following General Procedure B. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (43 mg, 83%):'H NMR (CDCI3, 600 MHz) S 7.70-7.64 (m, 3H), 7.51-7.48 (m, 1 H), 7.26-7.24 (m, 3H), 7.16-7.15 (m, 3H), 4.79 (t, 1 H, J = 6.0 Hz), 2.58 (t, 2H, J = 7.5 Hz), 1.88-1.81 (m, 2H), 1.61-1.60 (m, 2H), 1.35-1.25 (m, 6H), 0.87 (s, 9H), 0.07 (s, 3H), -0.05 (s, 3H); 13C NMR (CDCI3, 150 MHz) S 186.2 (d, J= 35 Hz), 167.0, 149.4, 143.7, 133.6, 133.6, 131.1, 129.5, 129.4, 129.3, 129.1, 128.3, 126.4, 125.6, 116.4 (d, J= 285 Hz), 69.4, 37.3, 36.8, 32.3, 30.0, 26.5, 26.5, 25.8, 19.0, -4.2, -4.4.
Step 2. The title compound was prepared from 1-(2-(2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)oxazol-5-y1)phenyl)-2,2,2-trifluoroethanone (43 mg, 0.079 mmol) following General Procedure C. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (26 mg, 76%):
'H NMR (CDC13, 600 MHz) 8 7.80-7.79 (m, 2H), 7.72 (t, 1 H, J = 7.2 Hz), 7.60 (t, 1 H, J= 7.2 Hz), 7.47 (s, 1 H), 7.28-7.25 (m, 2H), 7.18-7.15 (m, 3H), 3.05 (t, 2H, J= 7.8 Hz), 2.60 (t, 2H, J= 7.8 Hz), 1.78-1.73 (m, 2H), 1.66-1.61 (m, 2H), 1.42-1.39 (m, 4H); 13C NMR (CDCI3, 150 MHz) S 188.9, 184.6 (d, J= 36 Hz), 158.6, 152.0, 143.6, 134.2, 131.3, 130.8, 130.8, 130.1, 129.3, 129.1, 129.1, 127.9, 127.7, 126.5, 116.5 (d, J= 290 Hz), 40.0, 36.7, 32.2, 29.8, 29.8, 24.6; MALDI-FTMS m/z 430.1626 (M + H+, ~'i24H23F3NO3, requires 430.1624).
Example 5; 7-Phenyl-l-(5-(3-(2,2,2-trifluoroacetyl)phenyl)oxazol-2-yl)heptan-1-one Step 1: 1-(3-(2-(1-(tert-Butyld imethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenyl)-2,2,2-trifluoroethanone. The title compound was prepared from 2-(1-(tert-butyldimethylsiiyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (37 mg, 0.056 mmol) and 1-(3-chlorophenyl)-2,2,2-trifluoroethanone following General Procedure B. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a clear oil (26 mg, 87%): 'H NMR (CDC13i 600 MHz) S 8.31 (s, IH), 8.01-7.94 (m, 2H), 7.61 (t, 1 H, J= 7.2 Hz), 7.38 (s, 1 H), 7.27-7.24 (m, 2H), 7.16-7.14 (m, 3H), 4.84 (t, 1 H, J = 6.0 Hz), 2.58 (t, 2H, J= 7.5 Hz), 1.95-1.88 (m, 2H), 1.64-1.55 (m, 2H), 1.37-1.34 (m, 6H), 0.90.(s, 9H), 0.10 (s, 3H), 0.00 (s, 3H); 13C
NMR (CDCI3, 150 MHz) S 181.0 (d, J = 35 Hz), 166.7, 150.2, 143.6, 131.5, 130.7, 130.4, 130.2, 129.2, 129.1, 129.0, 126.4, 126.2, 124.0, 117.7 (d, J = 289 Hz), 69.5, 37.2, 36.8, 32.3, 30.0, 26.6, 26.6, 26.0, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 1-(3-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenyl)-2,2,2-trifluoroethanone (36 mg, 0.066 mmol) following General Procedure C. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (17 mg, 61%):
' H NMR (CDCI3, 600 MHz) S 8.41 (s, 1 H), 8.12-8.08 (m, 2H), 7.69-7.63 (m, 2H), 7.28-7.26 (m, 2H), 7.17-7.16 (m, 3H), 3.09 (t, 2H, J= 7.8 Hz), 2.61 (t, 2H, J
= 7.8 Hz), 1.79-1.76 (m, 2H), 1.66-1.61 (m, 2H), 1.44-1.39 (m, 4H); 13C NMR (CDC13, 150 MHz) 8 189.2, 180.7 (d, ,! = 35 Hz), 158.4, 153.0, 143.5, 132.5, 131.8, 131.6, 130.9, 129.3, 129.1, 127.3, 126.5, 125.9, 117.7 (d, J= 289 Hz), 40.0, 36.7, 32.2, 29.9, 29.9, 24.8; MALDI-FTMS mfz 428.1475 (M - H', C24H21F3N03, requires 428.1479).
~ ~ / N
F3COC ~ O O
Example 6; 7-Phenyl-l-(5-(4-(2,2,2-trifluoroacetyl)phenyl)oxazol-2-yl)heptan-1-one Step 1: 1-(4-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)ghenyl)-2,2,2-trifluoroethanone. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributyistannyl)oxazole (55 mg, 0.083 mmol) and 1-(4-bromophenyl)-2,2,2-trifluoroethanone following General Procedure A. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (31 mg, 69%):'H NMR (CDCI3, 600 MHz) 8 8.13-8.12 (d, 2H, J = 7.8 Hz), 7.80-7.79 (d, 2H, J = 7.8 Hz), 7.49 (s, 1 H), 7.27-7.24 (m, 2H), 7.16-7.15 (m, 3H), 4.86 (t, 1 H, J= 6.0 Hz), 2.59 (t, 2H, J= 7.5 Hz), 1.95-1.91 (m, 2H), 1.61-1.59 (m, 2H), 1.37-1.34 (m, 6H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H); 13C NMR (CDC13, 150 MHz) 8 180.4 (d, J= 35 Hz), 167.5, 150.3, 143.6, 135.1, 131.8, 129.9, 129.2, 129.1, 126.5, 126.1, 125.1, 117.6 (d, J= 290 Hz), 69.6, 37.3, 36.8, 32.3, 30.0, 36.6, 26.6, 26.0, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 1-(4-(2-(1-(te-t-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenyl)-2,2, 2-trifluoroethanone (29 mg, 0.053 mmol) following General Procedure C. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (14 mg, 62%):
'H NMR (CDCI3, 600 MHz) S 8.16 (d, 2H, J = 7.8 Hz), 7.94 (d, 2H, J = 7.8 Hz), 7.69 (s, 1 H), 7.28-7.25 (m, 2H), 7.17-7.16 (m, 3H), 3.10 (t, 2H, J = 7.8 Hz), 2.61 (t, 2H, J= 7.8 Hz), 1.79-1.76 (m, 2H), 1.66-1.62 (m, 2H), 1.44-1.39 (m, 4H);
NMR (CDC13, 150 MHz) 8 189.2, 180.6 (d, J= 35 Hz), 152.9, 143.5, 133.7, 131.9, 131.8, 131.2, 129.3, 129.1, 127.4, 126.5, 126.4, 117.7 (d, J= 290 Hz), 40.0, 36.7, 32.1, 29.9, 29.9, 24.8; MALDI-FTMS m/z 428.1474 (M - H", C24H2lF3NO3, requires 428.1479).
N
Example 7; 2-(2-(7-Phenylheptanoy!)oxazol-5-yl)benzamide Step 1: 2-(2-(1-(tert-Butvidimethylsilyloxy)-7-phenylheptyi)oxazol-5-yl)benzamide. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (52 mg, 0.083 mmol) and 2-bromobenzamide following General Procedure A. Flash chromatography (20-40% EtOAc/hexanes) yielded the title compound as a white solid (39 mg, 100%): 'H NMR (CDC13, 600 MHz) 57.70 (d, 1H, J= 7.8 Hz), 7.60 (s, 1 H), 7.51-7.48 (m, 2H), 7.39-7.36 (m, 1 H), 7.25-7.23 (m, 2H), 7.16-7.13 (m, 3H), 6.48 (br s, 1 H), 6.19 (br s, 1 H), 4.88 (t, 1 H, J = 6.0 Hz), 2.57 (t, 2H, J = 7.5 Hz), 1.93-1.87 (m, 2H), 1.59-1.56 (m, 2H), 1.44-1.30 (m, 6H), 0.87 (s, 9H), 0.09 (s, 3H), -0.02 (s, 3H); 13C NMR (CDC13, 150 MHz) 5 170.4, 143.6, 137.6, 134.4, 132.5, 131.3, 130.7, 129.7, 129.2, 129.1, 128.6, 128.5, 126.4, 120.1, 69.3, 37.3, 36.8, 32.2, 30.0, 26.6, 26.6, 25.9, 19.0, -4.0, -4.3.
Step 2. The title compound was prepared from 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzamide (39 mg, 0.079 mmol) following General Procedure C. Flash chromatography (20-70% EtOAc/hexanes) yielded the title compound as a white solid (9 mg, 30%):'H NMR (CDCI3, 500 MHz) 5 7.89 (d, 1 H, J = 7.5 Hz), 7.68 (s, 1 H), 7.63-7.61 (m, 2H), 7.56-7.53 (m, 1 H), 7.36-7.34 (m, 2H), 7.26-7.25 (m, 3H), 6.16 (br s, 1 H), 5.99 (br s, 1 H), 3.15 (t, 2H, J = 7.8 Hz), 2.69 (t, 2H, J= 7.8 Hz), 1.87-1.81 (m, 2H), 1.75-1.69 (m,-2H), 1.54-1.47 (m, 4H); 13C NMR (CDC13, 125 MHz) S 188.8, 171.5, 157.7, 152.0, 143.1, 134.9, 131.0, 130.2, 128.9, 128.8, 128.7, 128.1, 127.5, 126.0, 124.7, 39.5, 36.3, 31.7, 29.4, 29.4, 24.3; MALDI-FTMS m/z 377.1858 (M + H+, C23H25N203, requires 377.1860).
HZNOC N
Q
Example 8; 3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzamide Step 1; 3-(2-(1-(tert-Butyidimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzamide. The title compound was prepared from 2-(1-(tert butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (72 mg, 0.109 mmol) and 3-bromobenzamide following General Procedure A. Flash chromatography (10-40% EtOAc/hexanes) yielded the title compound as a white solid (52 mg, 96%): 'H. NMR (CD30D, 600 MHz) b 8.23 (s, 1 H), 8.03 (s, 1 H), 7.83 (m, 1 H), 7.53 (m, 1 H), 7.35 (m, 1 H), 7.18-7.09 (m, 5H), 3.30 (t, 1 H, J=
6.0 Hz), 2.53 (t, 2H, J = 7.5 Hz), 1.92-1.86 (m, 2H), 1.65-1.55 (m, 2H), 1.34-1.29 (m, 6H), 0.87 (s, 9H), 0.09 (s, 3H), -0.03 (s, 3H); 13C NMR (CD3QD, 150 MHz) 5 166.2, 151.6, 143.3, 136.6, 135.4, 131.3, 130.8, 128.8, 128.7, 126.9, 126.1, 124.0, 122.9, 122.6, 69.2, 36.8, 36.3, 32.0, 29.6, 29.5, 25.7, 25.6, 18.5, -5.3, -5.4.
Step 2. The title compound was prepared from 3-(2-(1-(tert butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-y!)benzamide (48 mg, 0.097 mmol) following General Procedure C. Flash chromatography (10-70% EtOAc/hexanes) yielded the title compound as a white solid (15 mg, 41 %): "H NMR (THF-d8, 600 MHz) 8 8.31 (s, 1 H), 7.94-7.92 (m, I H), 7.76 (s, 1 H), 7.54-7.52 (m, 2H), 7.22-7.19 (m, 2H), 7.16-7.14 (m, 2H), 7.11-7.08 (m, 1 H), 6.77 (br s, 1 H), 3.05 (t, 2H, J = 7.8 Hz), 2.60 (t, 2H, J = 7.8 Hz), 1.74-1.71 (m, 2H), 1.66-1.61 (m, 2H), 1.44-1.39 (m, 4H); 13C NMR (THF-d8, 150 MHz) 6 187.7, 167.6, 158.4, 154.2, 143.3, 136.8, 129.7, 129.6, 129.0, 128.8, 128.0, 128.0, 126.2, 125.1, 124.7, 39.3, 36.6, 32.3, 29.9, 29.8, 24.6; MALDI-FTMS m/z 377.1864 (M + H+, C23H25N203, requires 377.1860). -Ip,N ~ I -O
Example 9; 4-(2-(7-Phenylheptanoyl)oxazot-5-yl)laenzamide Step 1; 4-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylhepty1)oxazol-5-yi)benzamide. The title compound was prepared from 2-(1-(tert butyldimethylsiiyioxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (47 mg, 0.071 mmol) and 4-bromobenzamide following General Procedure A. Flash chromatography (30-50% EtOAc/hexanes) yielded the title compound as a white solid (29 mg, 83%): 'H NMR (CDCI3, 600 MHz) S 7.67 (d, 2H, J = 7.8 Hz), 7.57 (d, 2H, J= 7.8 Hz), 7.38 (s, 1 H), 7.25-7.24 (m, 2H), 7.15-7.14 (m, 3H), 6.16 (br s, 2H), 4.84 (t, 1 H, J = 6.0 Hz), 2.58 (t, 2H, J = 7.5 Hz), 1.93-1.87 (m, 2H), 1.58-1.56 (m, 2H), 1.46-1.34 (m, 6H), 0.88 (s, 9H), 0.09 (s, 3H), -0.01 (s, 3H);
NMR (CDC13i 150 MHz) 6 169.5, 143.6, 132.8, 129.9, 129.5, 129.2, 129.1, 129.0, 128.3, 127.7, 126.4, 125.0, 69.4, 37.3, 36.8, 32.2, 30.0, 26.6, 26.0, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 4-(2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)oxazol-5-y!)benzamide (29 mg, 0.059 mmol) following General Procedure C. Flash chromatography (40-80% EtOAc/hexanes) yielded the title compound as a white solid (7 mg, 32%): 'H NMR (CD3OD, 500 MHz) 8 8.08 (d, 2H, J = 8.5 Hz), 8.02 (d, 2H, J = 8.5 Hz), 7.93 (s, 1 H), 7.32-7.29 (m, 2H), 7.25-7.20 (m, 3H), 3.17 (t, 2H, J = 7.8 Hz), 2.69 (t, 2H, J= 7.8 Hz), 1.85-1.80 (m, 2H), 1.75-1.70 (m, 2H), 1.55-1.45 (m, 4H); 13C NMR (CD3OD, 125 MHz) 8 188.6, 168.8, 160.8, 158.0, 153.5, 142.9, 128.6, 128.4, 128.2, 127.7, 125.6, 125.4, 125.2, 38.8, 35:8, 31.5, 29.0, 29.0, 23.9; MALDI-FTMS m/z 377.1864 (M +
H+, C23H25N203i requires 377.1860).
Example 10; 1-(5-(2-Fluorophenyl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 2-(1-(tert Butyldimethylsilyloxy)-7-phenylhep It )-L 5-(2-fluorouhenvl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (75 mg, 0.113 mmol) and 1-fluoro-2-iodobenzene following General Procedure A. Flash chromatography (2% EtOAc/hexanes) yielded the title compound as a clear oil (52 mg, 98%): 1 H NMR (CDCI3, 400 MHz) 7.77 (dt, 1 H, J = 9.6, 5.6 Hz), 7.42 (d, 1 H, J= 4.0 Hz), 7.31-7.21 (m, 4H), 7.18-7.13 (m, 4H), 4.85 (t, 1 H, J = 6.0 Hz), 2.59 (t, 2H, J= 7.2 Hz), 1.90-1.93 (m, 2H), 1.62-1.60 (m, 2H), 1.33-1.36 (m, 6H), 0.90 (s, 9H), 0.11 (s, 3H), 0.00 (s, 3H); 13C NMR (CDCI3, 100 MHz) S 169.7, 163.4 (d, J = 250 Hz), 150.6, 157.9, 134.4 (d, J 8.3 Hz), 133.5, 133.3, 131.2 (d, J
=
12.6 Hz), 131.1, 131.1, 130.7, 129.6 (d, J= 3.2 Hz), 121.7 (d, J= 13.0 Hz), 120.1 (d, J = 20.9 Hz), 73.8, 41.6, 41.0, 36.5, 34.3, 34.3, 30.9, 30.3, 23.3, 0.2, 0Ø
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(2-fluorophenyl)oxazole (40 mg, 0.086 mmol) following General Procedure C. Flash chromatography (10-20%
EtOAc/hexanes) yielded the title compound as a clear oil (20 mg, 67%): 'H NMR
(CDCI3, 500 MHz) S 8.02 (dt, 1 H, J = 9.2, 5.9 Hz), 7.73 (d, 1 H, J = 4.0 Hz), 7.49-7.46 (m, 1 H), 7.37-7.34 (m, 3H), 7.27-7.23 (m, 4H), 3.18 (t, 1 H, J = 7.4 Hz), 2.69 (t, 2H, J = 7.7 Hz), 1.89-1.85 (m, 2H), 1.73-1.71 (m, 2H), 1.52-1.47 (m, 4H);
NMR (CDCI3, 125 MHz) S 188.8, 159.5 (d, J= 251 Hz), 157.1, 149.0, 143.1, 131.6 (d, J = 8.3 Hz), 128.8, 128.7, 128.2 (d, J= 13.4 Hz), 127.6, 127.6, 126.0, 125.3 (d, J= 3.4 Hz), 116.5 (d, J= 20.6 Hz), 115.8 (d, J= 12.7 Hz), 39.5, 36.3, 31.7, 29.4, 29.4, 24.4; MALDI-FTMS m/z 352.1704 (M + H+, C22H23FN02, requires 352.1707).
F / \ ~ N \ !
`- O
Example 11; 1-(5-(3-Fluorophenyt)oxazol-2-yl)-7-phenytheptan-l-one Step 1 : 2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(3-fluorophenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyioxy)-7-phenylheptyl)-5-(tributylstannyl)oxazoie (75 mg, 0.113 mmol) and 1-fluoro-3-iodobenzene following General Procedure A. Flash chromatography (2% EtOAc/hexanes) yielded the title compound as a clear oil (53 mg, 98 Ao):'H NMR (CDCI3, 400 MHz) 7.43-7.33 (m, 3H), 7.29-7.25 (m, 3H), 7.18-7.15 (m, 3H), 7.04-7.00 (m, 1 H), 4.83 (t, 1 H, J= 6.0 Hz), 2.59 (t, 2H, J= 7.6 Hz), 1.96-1.88 (m, 2H), 1.63-1.59 (m, 2H), 1.47-1.35 (m, 6H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H); 13 C NMR (CDCI3, 100 MHz) 8 170.4, 167.3 (d, J = 245 Hz), 155.1, 147.9, 135.6 (d, J= 8.4 Hz), 135.2 (d, J= 8.5 Hz), 133.5, 133.3, 130.7, 127.7, 124.9 (d, J= 3.0 Hz), 120.2 (d, J= 21.1), 116.2 (d, J= 23.5), 73.8, 41.5, 41.0, 36.5, 34.3, 34.3, 30.8, 30.2, 23.3, 0.2, 0Ø
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(3-fluorophenyl)oxazole (50 mg, 0.106 mmol) following General Procedure C. Flash chromatography (2-10%
EtOAc/hexanes) yielded the title compound as a white solid (26 mg, 68%): 'H
NMR (CDCI3, 500 MHz) 8 7.65-7.60 (m, 2H), 7.56-7.49 (m, 2H), 7.37-7.34 (m, 2H), 7.27-7.25 (m, 3H), 7.21-7.18 (m, 1 H), 3.16 (t, 2H, J= 7.5 Hz), 2.69 (t, 2H, J= 7.5 Hz), 1.88-1.85 (m, 2H), 1..74-1.71 (m, 2H), 1.52-1.48 (m, 4H); 13C NMR
(CDCI3, 125 MHz) 8 188.7, 163.4 (d, J = 245 Hz), 157.7, 153.3, 143.1, 131.3 (d, J= 8.4 Hz), 129.1 (d, J= 8.5 Hz), 128.8, 128.7, 126.0, 124.9, 121.4 (d, J= 3.0 Hz), 117.3 (d, J= 21.1), 112.7 (d, J= 23.8), 39.5, 36.3, 31.7, 29.4, 29.4, 24.4;
MALDI-FTMS m/z 352.1706 (M + H+, C22H23FN02, requires 352.1707).
N
O
Example 12; 1-(5-(4-Fluorophenyl)oxazol-2-yi)-7-phenylheptan-l-one Step 1; 2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-fluorophenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (81 mg, 0.122 mmol) and 1-fluoro-4-iodobenzene following General Procedure A. Flash chromatography (2% EtOAc/hexanes) yielded the title compound as a clear oil (40 mg, 61 %): ' H NMR (CDCI3, 600 MHz) S 7.63-7.61 (m, 2H), 7.27-7.24 (m, 4H), 7.17-7.11 (m, 4H), 4.88 (t, 1 H, J= 6.0 Hz), 2.58 (t, 2H, J= 7.5 Hz), 1.95-1.90 (m, 2H), 1.62-1.59 (m, 2H), 1.46-1.35 (m, 6H), 0.89 (s, 9H), 0.10 (s, 3H), -0.01 (s, 3H); 13C NMR (CDCI3, 150 MHz) 8 165.9, 163.5 (d, J= 258 Hz), 151.5, 143.6, 129.2, 129.1, 127.1 (d, J= 8.3 Hz), 126.4, 124.8, 1 2 1 . 1 , 117.0 (d, J= 22 Hz), 69.4, 37.3, 36.8, 32.3, 30.0, 26.6, 26.6, 25.9, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)-5-(4-fluorophenyl)oxazole (60 mg, 0.110 mmol) following General Procedure C. Flash chromatography (2-10%
EtOAc/hexanes) yielded the title compound as a white solid (24 mg, 62%): ' H
NMR (CDC13, 600 MHz) 5 7.77-7.74 (m, 2H), 7.44 (s, I H), 7.28-7.25 (m, 2H), 7.17-7.14 (m, 3H), 3.07 (t, 2H, J= 7.8 Hz), 2.60 (t, 2H, J = 7.8 Hz), 1.78-1.76 (m, 2H), 1.65-1.62 (m, 2H), 1.45-1.38 (m, 4H); 13C NMR (CDCI3, 150 MHz) S 189.2, 164.6 (d, J= 250 Hz), 158.0, 154.2, 143.5, 129.3, 129.1, 128.3 (d, J= 8.6 Hz), 126.5, 124.2, 123.9, 117.2 (d, J= 22 Hz), 39.8, 36.7, 32.2, 29.9, 29.9, 24.9;
MALDI-FTMS m/z 352.1701 (M + H+, C22H23FN02, requires 352.1707).
N
Example 13; 1-(5-(2-Methoxyphenyl)oxazol-2-yl)-7-phenylheptan-l-one Step 1: 2-(1-(tert-Butyldimethyisilyloxy)-7-phenylheptyl)-5-(2-methoxvphenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (140 mg, 0.211 mmol) and 1-iodo-2-methoxybenzene following General Procedure A. Flash chromatography (2% EtOAc/hexanes) yielded the title compound as a white solid (78 mg, 77%): ' H NMR (CDCI3, 400 MHz) 8 7.81 (dd, 1 H, J = 9.2, 6.0 Hz), 7.49 (s, 1 H), 7.30-7.27 (m, 3H), 7.19-7.16 (m, 3H), 7.07-7.05 (m, 1 H), 6.99 (d, 1 H, J=
8.4 Hz), 4.85 (t, 1 H, J= 6.8 Hz), 3.98 (s, 3H), 2.58 (t, 2H, J= 8.0 Hz), 1.95-1.91 (m, 2H), 1.63-1.60 (m, 2H), 1.38-1.34 (m, 6H), 0.91 (s, 9H), 0.11 (s, 3H), 0.00 (s, 3H); *13C NMR (CDCI3: 100 MHz) S 168.8, 160.7, 152.7, 148.0, 134.0, 133.5, 133.3, 131.0, 130.9, 130.7, 125.9, 122.4, 115.9, 73.8, 60.5, 41.6, 41.1, 36.6, 34.3, 34.3, 30.9, 30.3, 23.3, 0.2, 0Ø
Step 2. The title compound was prepared from 2-(1-(tert butyldimethylsilyloxy)-7-phenylheptyl)-5-(2-methoxyphenyl)oxazole (78 mg, 0.163 mmol) following General Procedure C. Flash chromatography (10% 1 -EtOAc/hexanes) yielded the title compound as a white solid (42 mg, 71 %): ' H
NMR (CDCI3, 400 MHz) 8 7.92 (dd, 1 H, J = 9.2, 6.0 Hz), 7.68 (s, 1 H), 7.37-7.33 (m, 1 H), 7.26-7.22 (m, 2H), 7.16-7.14 (m, 3H), 7.04 (t, 1 H, J= 7.2 Hz), 6.97 (d, 1 H, J = 8.4 Hz), 3.95 (s, 3H), 3.06 (t, 2H, J = 7.2 Hz), 2.58 (t, 2H, J = 7.6 Hz), 1.77-1.73 (m, 2H), 1.63-1.59 (m, 2H), 1.42-1.37 (m, 4H); 13C NMR (CDCI3, 100 MHz) S 188.6, 156.7, 156.2, 151.1, 142.9, 131.0, 128.6, 128.4, 128.0, 127.4, 125.8, 121.2, 116.1, 111.1, 55.7, 39.2, 36.1, 31.5, 29.2, 29.2, 24.3; MALDI-FTMS
m/z 364.1904 (M + H+, C23H26NO3, requires 364.1907).
H3CQ \ ~ ~ \ I
Example 14; 1-(5-(3-Methoxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 2-(1-(tert-Butvidimethylsilyloxv)-7-phenylheptyl)-5-(3-methoxyphenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (190 mg, 0.287 mmol) and 1-iodo-3-methoxybenzene following General Procedure A. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (107 mg, 78%): 'H NMR (CDCI3, 500 MHz) S 8.40 (m, 1 H), 8.07 (d, 1 H, J= 8.0 Hz), 7.90 (d, 1 H, J = 8.0 Hz), 7.58 (t, 1 H, J= 7.6 Hz), 7.44 (s, 1 H), 7.35-7.32 (m, 2H), 7.25-7.23 (m, 3H), 4.93 (t, 1 H, J = 6.0 Hz), 4.03 (s, 3H), 2.67 (t, 2H, J = 7.4 Hz), 2.04-1.99 (m, 2H), 1.75-1.68 (m, 2H), 1.45-1.37 (m, 6H), 1.00 (s, 9H), 0.20 (s, 3H), 0.10 (s, 3H); 13C NMR (CDCI3, 125 MHz) 8 166.9, 165.7, 150.6, 143.1, 131.4, 129.7, 129.5, 128.9, 128.8, 128.6, 128.6, 126.1, 125.8, 123.5, 69.1, 52.7, 36.8, 36.4, 31.8, 29.6, 29.6, 26.2, 25.6, 14.1, -4.5, -4.6.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(3-methoxyphenyl)oxazole (105 mg, 0.219 mmol) following General Procedure C. Flash chromatography (5-20%
EtOAc/hexanes) yielded the title compound as a white solid (53 mg, 66%): 'H
NMR (CDCl3, 500 MHz) 5 8.48 (m, 1 H), 8.15 (d, 1 H, J = 7.5 Hz), 8.03 (d, 1 H, J
8.5 Hz), 7.66 (s, 1 H), 7.62 (t, 1 H, J = 8.0 Hz), 7.34 (t, 2H, J = 8.5 Hz), 7.26-7.24 (m, 3H), 4.04 (s, 3H), 3.17 (t, 2H, J = 7.6 Hz), 2.69 (t, 2H, J== 7.6 Hz), 1.87-1.83 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.46 (m, 4H); 13C NMR (CDC13, 125 MHz) S
188.7, 166.6, 157.7, 153.5, 143.1, 131.6, 131.2, 129.8, 129.7, 128.8, 128.7, 127.5, 126.7, 126.0, 124.9, 52.9, 39.5, 36.3, 31.7, 29.4, 29.4, 24.4; MALDI-FTMS
m/z 364.1908 (M + H+, C23H26N03, requires 364.1907).
/ ~ ~ N
H3CO ~
Example 15; 1-(5-(4-Methoxyphenyl)oxazol-2-yl)-7-phenylheptan-l-one Step 1; .2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-methoxyphenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributykstannyl)oxazole (67 mg, 0.101 mmol) and 1-bromo-4-methoxybenzene following General Procedure B. Flash chromatography (5% EtOAc/hexanes) yielded the title compound as a clear oil (41 mg, 84%): 1 H NMR (CDCI3i 500 MHz) 6 7.66 (d, 2H, J = 9.0 Hz), 7.37-7.34 (m, 3H), 7.27-7.23 (m, 3H), 7.03 (d, 2H, J = 9.0 Hz), 4.91 (t, 1 H, J = 5.5 Hz), 3.93 (s, 3H), 2.68 (t, 2H, J = 7.5 Hz), 2.06-1.96 (m, 2H), 1.71-1.68 (m, 2H), 1.46-1.42 (m, 6H), 0.98 (s, 9H), 0.19 (s, 3H), 0.08 (s, 3H); 13C NMR (CDCI3, 125 MHz) 8 164.6, 160.2, 151.6, 143.2, 128.8, 128.7, 126.1, 126.0, 121.3, 120.3, 114.8, 69.1, 55.8, 36.8, 36.3, 31.9, 29.6, 26.2, 26.2, 25.6, 18.7, -4.5, -4.7.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-methoxyphenyl)oxazole (39 mg, 0.081 mmol) following General Procedure C. Flash chromatography (5-10%
EtOAc/hexanes) yielded the title compound as a white solid (18 mg, 60%): iH
NMR (CDCI3, 600 MHz) 87.70 (d, 2H, J= 9.0 Hz), 7.38 (s, 1 H), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 6.96 (d, 2H, J= 9.0 Hz), 3.85 (s, 3H), 3.06 (t, 2H, J=
7.2 Hz), 2.60 (t, 2H, J= 7.2 Hz), 1.79-1.75 (m, 2H), 1.65-1.61 (m, 2H), 1.44-1.37 (m, 4H); 13C NMR (CDCI3, 150 MHz) S 189.1, 161.8, 157.6, 155.3, 143.6, 129.3, 129.1, 127.8, 126.4, 123.2, 120.2, 115.4, 56.3, 39.7, 36.8, 32.2, 29.9, 29.9, 25.0;
MALDI-FTMS m/z 364.1908 (M + H+, C23H26NO3, requires 364.1907).
N
CO
GN Example 16; 2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzonitrile Step 1; 2-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzonitrile. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (60 mg, 0.091 mmol) and 2-bromobenzonitrile following General Procedure A. Flash chromatography (2-5% EtOAc/hexanes) yielded the title compound as a clear oil (35 mg, 81 %): 'H NMR (CDCI3i 600 MHz) 8 7.90 (s, 1 H), 7.85 (d, 1 H, J= 7.8 Hz), 7.74 (d, 1 H, J = 7.8 Hz), 7.66 (t, 1 H, J = 7.8 Hz), 7.40 (t, 1 H, J = 7.8 Hz), 7.27-7.25 (m, 2H), 7.16-7.15 (m, 3H), 4.87 (t, 1 H, J = 6.0 Hz), 2.59 (t, 2H, J =
7.8 Hz), 1.96-1.90 (m, 2H), 1.62-1.60 (m, 2H), 1.38-1.36 (m, 6H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H);13C NMR (CDCI3, 150 MHz) 8 166.7, 148.06, 143.6, 135.0, 134.1, 131.7, 129.2, 129.1, 129.0, 127.3, 126.9, 126.4, 124.2, 119.2, 108.3, 69.5, 37.3, 36.8, 32.3, 30.0, 26.6, 26.6, 26.0, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzonitrile (33 mg, 0.070 mmol) following General Procedure C. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (16 mg, 64%): 'H NMR (CDCI3, 600 MHz) S 8.12 (s, 1 H), 8.03 (d, 1 H, J = 8.4 Hz), 7.79 (d, 1 H, J = 7.8 Hz), 7.72 (t, 1 H, J = 7.8 Hz), 7.51 (t, 1 H, J = 7.8 Hz), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 3.11 (t, 2H, J = 7.2 Hz), 2.61 (t, 2H, J = 7.2 Hz), 1.79-1.77 (m, 2H), 1.65-1.62 (m, 2H), 1.44-1.41 (m, 4H); 13C NMR (CDCI3, 150 MHz) 5 189.3, 158.1, 150.7, 143.5, 135.1, 134.3, 130.5, 130.4, 129.3, 129.1, 128.8, 128.2, 126.5, 118.9, 109.4, 40.1, 36.7, 32.2, 29.8, 29.8, 24.7; MALDI-FTMS m/z 359.1750 (M + Ht, C23H23N202, requires 359.1754).
NC / N
Example 17; 3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzonitrile Step 1; 3-(2-(1-(tert-Butyfdimethylsilyloxy)-7-phenylheptyl)oxazol-5-yi)benzonitrile. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributyfstannyl)oxazofe (60 mg, 0.091 mmol) and 3-bromobenzonitrile following General Procedure A. Flash chromatography (2-5% EtOAc/hexanes) yielded the title compound as a clear oi1 (31 mg, 72%): 'H NMR (CDC13, 600 MHz) 8 7.91 (s, 1 H), 7.84 (d, 1 H, J = 7.8 Hz), 7.59 (d, 1 H, J = 7.8 Hz), 7.53 (t, 1 H, J = 7.8 Hz), 7.36 (s, 1 H), 7.27-7.24 (m, 2H), 7.16-7.15 (m, 3H), 4.83 (t, 1 H, J= 6.0 Hz), 2.58 (t, 2H, J= 7.8 Hz), 1.95-1.88 (m, 2H), 1.65-1.59 (m, 2H), 1.36-1.33 (m, 6H), 0.89 (s, 9H), 0.10 (s, 3H), -0.01 (s, 3H); 13C NMR (CDC13, 150 MHz) S 166.8, 149.8, 143.6, 132.3, 130.7, 130.2, 129.2, 129.1, 128.9, 128.3, 126.5, 124.2, 119.1, 114.2, 69.5, 37.3, 36.8, 32.3, 30.0, 26.6, 26.6, 26.0, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 3-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzonitrile (29 mg, 0.061 mmol) following General Procedure C. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (14 mg, 64%):'H NMR (CDCI3, 600 MHz) 5 8.05 (s, 1 H), 8.00 (d, 1 H, J = 7.8 Hz), 7.68 (d, 1 H, J= 7.8 Hz), 7.59-7.58 (m, 2H), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 3.08 (t, 2H, J = 7.2 Hz), 2.60 (t, 2H, J= 7.2 Hz), 1.78-1.76 (m, 2H), 1.64-1.62 (m, 2H), 1.43-1.39 (m, 4H); 13C
NMR (CDCl3i 150 MHz) 6 189.1, 158.4, 152.5, 143.5, 133.8, 133.8, 131.0, 130.0, 129.4, 129.3, 129.1, 128.9, 126.5, 125.9, 118.7, 114.6, 40.0, 36.7, 32.1, 29.9, 29:9, 24.8; MALDI-FTMS msz 359.1767 (M + H+, C23H23N202, requires 359.1754).
/ N
NC r-- O
O
Example 18; 4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzonitrile Step 1: 4-(2-(1-(tert-Butyldimethylsilyioxy)-7-phenylheptvl)oxazol-5-yI)benzonitrile.' The title compound was prepared from 2-(1-(terf-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (53 mg, 0.080 mmol) and 4-bromobenzonitrile following General Procedure A. Flash chromatography (5-10% EtOAc/hexanes) yielded the title compound as a clear oil (30 mg, 79%): 1H NMR (CDC13, 500 MHz) S 7.82-7.78 (m, 4H), 7.50 (s, 1 H), 7.36-7.33 (m, 2H), 7.26-7.23 (m, 3H), 4.93 (t, 1 H, J = 5.5 Hz), 2.67 (t, 2H, J = 7.5 Hz), 2.06-1.95 (m, 2H), 1.75-1.67 (m, 2H), 1.47-1.40 (m, 6H), 0.98 (s, 9H), 0.19 (s, 3H), 0.08 (s, 3H); 13C NMR (CDCI3, 125 MHz) 8 166.7, 149.7, 143.2, 133.2, 132.4, 128.8, 128.7, 126.0, 124.8, 124.8, 119.0, 112.0, 69.1, 36.8, 36.3, 31.8, 29.6, 28.3, 26.1, 25.5, 18.6, -4.5, -4.7.
Step 2. The title compound was prepared from 4-(2-('I -(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzonitrile (51 mg, 0.107 mmol) following General Procedure C. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (13 mg, 33%): 'H NMR (CDCI3, 600 MHz) S 7.87 (d, 2H, J = 8.4 Hz), 7.75 (d, 2H; J = 8.4 Hz), 7.63 (s, I H), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 3.08 (t, 2H, J = 7.2 Hz), 2.60 (t, 2H, J = 7.2 Hz), 1.79-1.75 (m, 2H), 1.65-1.61 (m, 2H), 1.44-1.37 (m, 4H); 13C NMR (CDCI3, 150 MHz) 6 189.2, 158.6, 152.8, 143.5, 133.8, 131.5, 129.3, 129.1, 126.8, 126.5, 126.5, 40.0, 36.7, 32.1, 29.9, 29.9, 24.8; MALDI-FTMS m/z 359.1755 (M + H+, C23H23N202, requires 359.1754).
N
Example 19; 2-(2-(7-Phenylheptanoyl)oxazol-5-y1)benzenesulfonamide Step 1; 2-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yI)benzenesulfonamide. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (71 mg, 0.107 mmol) and 2-iodobenzenesulfonamide following General Procedure A. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (25 mg, 44%): 'H NMR (CDCI3, 400 MHz) 5 8.18 (d, 1 H, J= 7.6 Hz), 7.62-7.59 (m, 2H), 7.54-7.51 (m, 1 H), 7.42-7.39 (m, 1 H), 7.36 (s, 1 H), 7.24-7.22 (m, 2H), 7.16-7.12 (m, 2H), 5.29 (ex s, 2H), 4.88 (t, 1 H, J = 6.7 Hz), 2.56 (t, 2H, J
= 7.6 Hz), 1.86-1.84 (m, 2H), 1.62-1.59 (m, 2H), 1.31-1.29 (m, 6H). 0.86 (s, 9H), 0.09 (s, 3H), 0.00 (s, 3H);13C NMR (CDCI3, 100 MHz) 8 170.7, 153.6, 148.0, 144.9, 137.9, 135.7, 134.6, 134.3, 133.6, 133.4, 133.3, 131.0, 130.8, 42.3, 41.1, 36.3, 34.9, 34.3, 34.3, 31.0, 30.0, 23.5, 0.4, 0Ø
Step 2. The title compound was prepared from 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzenesulfonamide (23 mg, 0.043 mmol) following General Procedure C. Flash chromatography (10-30 10 EtOAc/hexanes) yielded the title compound as a white solid (12 mg, 67%):'H
NMR (CDC13, 400 MHz) 8 8.19-8.17 (m, 1 H), 7.61-7.53 (m, 3H), 7.48 (s, 1 H), 7.20-7.19 (m, 2H), 7.12-7.10 (m, 3H), 5.50 (ex s, 2H), 3.04 (t, 2H, J= 7.2 Hz), 2.54 (t, 2H, J = 7.2 Hz), 1.70-1.69 (m, 2H), 1.58-1.56 (m, 2H), 1.37-1.33 (m, 4H);
13C NMR (CDCI3, 100 MHz) 8 189.2, 157.8, 152.1, 143.1, 141.2, 133.1, 131.1, 131.1, 130.0, 128.8, 128.7, 128.3, 127.4, 126.0, 39.0, 36.3, 31.7, 29.4, 29.4, 24.1;
MALDI-FTMS m/z 413.1537 (M + H+, C22H25N204S, requires 413.1529).
H2NO2S \ ~ N \ I
~ p ~ r Example 20; 3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzenesulfonamide Step 1: 3-(2-(1-(tert-Butvldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzenesulfonamide. The title compound was prepared from 2-(1-(tert butyldimethy(silyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (75 mg, 0.113 mmol) and 3-bromobenzenesulfonamide following General Procedure A. Flash chromatography (10-30% EtOAc/hexanes) yielded the title compound as a white solid (55 mg, 91%):'H NMR (CD3OD, 500 MHz) 8 8.24 (m, 1 H), 7.92 (d, 1 H, J=
8.0 Hz), 7.74 (d, 1 H, J = 8.0 Hz), 7.64 (t, 1 H, J = 7.6 Hz), 7.58 (s, 1 H), 7.24-7.20 (m, 2H), 7.14-7.13 (m, 3H), 4.88 (ex s, 2H), 3.32-3.31 (m, 1 H), 2.58 (t, 2H, J=
7.6 Hz), 1.98-1.86 (m, 2H), 1.69-1.60 (m, 2H), 1.38-1.34 (m, 6H), 0.90 (s, 9H), 0.12 (s, 3H), 0.00 (s, 3H); 13C NMR (CDCI3, 100 MHz) 8 165.9, 150.3, 142.7, 130.7, 128.9, 128.8, 128.6, 128.2, 128.2, 128.0, 125.4, 124.7, 122.3, 36.1, 35.6, 31.4, 28.9, 28.8, 28.0, 25.0, 24.9, 17.8, -6.0, -6.1.
Step 2. The title compound was prepared from 3-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzenesulfonamide (55 mg, 0.104 mmol) following General Procedure C. Flash chromatography (20-60%
EtOAc/hexanes) yielded the title compound as a white solid (27 mg, 65%): IH
NMR (CD3OD, 500 MHz) 8 8.41-8.40 (m, 1 H), 8.10-8.09 (m, 1 H), 8.03-8.01 (m, 1 H), 7.90 (s, 1 H), 7.74 (t, 1 H, J= 8.0 Hz),'7.31-7.28 (m, 2H), 7.23-7.17 (m, 3H), 3.17-3.14 (t, 2H, J = 7.5 Hz) 2.69-2.66 (t, 2H, J = 7.6 Hz), 1.85-1.79 (m, 2H), 1.74-1.68 (m, 2H), 1.54-1.44 (m, 4H); 13C NMR (CD3OD, 125 MHz) S 188.5, 157.9, 152.9, 145.4, 142.9, 130.2, 128.5, 128.4, 128.3, 128.1 127.2, 125.6, 125.2, 122.7, 38.8, 35.8, 31.5, 29.0, 29.0, 23.8; MALDI-FTMS m/z 413.1540 (M + H+, C22H25N204S, requires 413.1529).
/ ~ ~ N
HZN02S ~
O
Example 21; 4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzenesulfonamide Step 1; 4-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptYl)oxazol-5-yl)benzenesulfonamide. The title compound was prepared from 2-(1-(tert-' butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (63 mg, 0.095 mmol) and 4-bromobenzenesulfonamide following General Procedure A. Flash chromatography (2-20% EtOAc/hexanes) yielded the title compound as a white solid (41 mg, 82%): 1H NMR (CDC13, 500 MHz) S 8.05 (d, 2H, J = 8.5 Hz), 7.83 (d, 2H, J= 8.5 Hz), 7.49 (s,,1 H), 7.36-7.32 (m, 2H), 7.25-7.22 (m, 3H), 5.39 (s, 2H), 4.92 (t, 1 H, J = 6.0 Hz), 2.67 (t, 2H, J = 7.5 Hz), 2.03-1.96 (m, 2H), 1.74-1.67 (m, 2H), 1.46-1.38 (m, 6H), 0.97 (s, 9H), 0.18 (s, 3H), 0.07 (s, 3H); 13C NMR
(CDCI3, 125 M Hz) S 166.6, 149.9, 141.7, 132.8, 129.6, 128.8, 128.7, 128.4, 127.6, 126.0, 124.9, 124.5, 69.1, 36.8, 36.3, 31.8, 29.6, 26.1, 26.1, 25.5, 18.6, -4.5, -4.6.
Step 2. The title compound was prepared from 4-(2-(1-(tert butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-y!)benzenesulfonamide (39 mg, 0.074 mmol) following General Procedure C. Flash chromatography (40%
EtOAc/hexanes) yielded the title compound as a white solid (17 mg, 54%): 'H
NMR (CD3OD, 500 MHz) S 8.08-8.07 (m, 4H), 7.96 (s, 1H), 7.32-7.38 (m, 5H), 3.17 (t, 2H, J = 7.0 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.84-1.81 (m, 2H), 1.73-1.69 (m, 2H), 1.51-1.43 (m, 4H); 13C NMR (CD3OD, 125 MHz) 8 188.6, 158.1, 152.9, 142.9, 132.4, 130.5, 130.4, 128.4, 128.3, 127.1, 125.9, 125.6, 38.8, 35.8, 31.5, 29.0, 29.0, 23.8; MALDI-FTMS m/z 413.1539 (M + H+, Ca4H25NO4r requires 413.1529).
N
Co2CH3 0 Example 22; Methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate Step 1; Methyl 2-(2-(1-(tert-butyldimethVlsilyloxV)-7-phenylheptyl)oxazol-5-yl)benzoate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (166 mg, 0.251 mmol) and methyl 2-iodobenzoate following General Procedure A. Flash chromatography (2-20% EtOAc/hexanes) yielded the title compound as a clear oil (125 mg, 99%): 'H NMR (CDCI3, 400 MHz) 5 7.75 (d, 1 H, J= 7.6 Hz), 7.62 (d, 1 H, J = 8.0 Hz), 7.53 (t, 1 H, J = 7.6 Hz), 7.41 (t, 1 H, J = 7.6 Hz), 7.28-7.24 (m, 3H), 7.17-7.15 (m, 3H), 4.83 (t, 1 H, J= 6.8 Hz), 3.85 (s, 3H), 2.60 (t, 2H, J= 7.4 Hz), 1.92-1.90 (m, 2H), 1.64-1.60 (m, 2H), 1.38-1.33 (m, 6H), 0.90 (s, 9H), 0.11 (s, 3H), 0.00 (s, 3H); 13C NMR (CDCIa, 100 MHz) 8 173.5, 170.3, 154.6, 147.9, 136.5, 135.1, 135.0, 134.9, 133.7, 133.5, 133.4, 132.3, 130.7, 129.8, 73.8, 57.6, 41.6, 41.1, 36.6, 34.3, 34.3, 30.9, 30.1, 23.4, 0.2, 0Ø
Step 2. The title compound was prepared from methyl 2-(2-(1-(tert butyfdimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzoate (125 mg, 0.246 mmol) following General Procedure C. Flash chromatography (10-20% EtOAc/hexanes) yielded the title compound as a white solid (77 mg, 79%): 'H NMR (CDCI3: 400 MHz) 5 7.81 (dd, 1 H, J = 9.2, 6.4 Hz), 7.66 (dd, 1 H, J = 9.2, 6.4 Hz), 7.57-7.44 (m, 3H), 7.26-7.22 (m, 2H), 7.15-7.13 (m, 3H), 3.85 (s, 3H), 3.05 (t, 2H, J =
7.6 Hz), 2.58 (t, 2H, J= 7.6 Hz), 1.76-1.71 (m, 2H), 1.63-1.59 (m, 2H), 1.40-1.37 (m, 4H); 13C NMR (CDCI3, 100 MHz) S 188.4, 167.9, 157.5, 152.7, 142.9, 131.8, 130.6, 130.4, 130.1, 129.7, 128.6, 128.4, 126.9, 126.4, 125.8, 52.8, 39.2, 36.1, 31.5, 29.2, 29.2, 24.1; MALDI-FTMS m/z 392.1854 (M + H4*, C24H26NO4, requires 392.1856).
H3COZC \ ~ N \ I
Example 23; Methyl 3-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate Step 1; Methyl 3-(2-(1-(tert-butyldimethylsityloxy)-7-phenvlheptyl)oxazol-5-y)benzoate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstanny{)oxazole (188 mg, 0.284 mmol) and methyl 3-bromobenzoate following General Procedure A. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (110 mg, 76%): ' H NMR (CDCI3i 500 MHz) S 8.40 (m, 1 H), 8.07 (d, 1H, J= 8.0 Hz), 7.90 (d, 1 H, J = 8.0 Hz), 7.58 (t, '! H, J = 7.6 Hz), 7.44 (s, 1 H), 7.35-7.32 (m, 2H), 7.25-7.23 (m, 3H), 4.93 (t, 1 H, J = 6.0 Hz), 4.03 (s, 3H), 2.67 (t, 2H, J= 7.4 Hz), 2.04-1.99 (m, 2H), 1.75-1.68 (m, 2H), 1.45-1.37 (m, 6H), 1.00 (s, 9H), 0.20 (s, 3H), 0.10 (s, 3H); 13C NMR (CDCI3, 125 MHz) 5 166.9, 165.7, 150.6, 143.1, 131.4, 129.7, 129.5, 128.9, 128.8, 128.6, 128.6, 126.1, 125.8, 123.5, 69.1, 52.7, 36.8, 36.4, 31.8, 29.6, 29.6, 26.2, 25.6, 14.1, -4.5, -4.6.
Step 2. The title compound was prepared from methyl 3-(2-(1-(tert-butyldirnethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzoate (106 mg, 0.209 mmol) following General Procedure C. Flash chromatography (10-20% EtOAc/hexanes) yielded the title compound as a white solid (64 mg, 77%):'H NMR (CDCI3, 500 MHz) 8 8.48 (m, 1 H), 8.15 (d, 1 H, J = 7.5 Hz), 8.03 (d, 1H, J = 8.5 Hz), 7.66 (s, 1 H), 7.62 (t, 1 H, J= 8.0 Hz), 7.34 (t, 2H, J = 8.5 Hz), 7.26-7.24 (m, 3H), 4.04 (s, 3H), 3.17 (t, 2H, J= 7.6 Hz), 2.69 (t, 2H, J= 7.6 Hz), 1.87-1.83 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.46 (m, 4H);13C NMR (CDCI,, 125 MHz) 8 188.7, 166.6, 157.7, 153.5, 143.1, 131.6, 131.2, 129.8, 129.7, 128.8, 128.7, 127.5, 126.7, 126.0, 124.9, 52.9, 39.5, 36.3, 31.7, 29.4, 29.4, 24.4; MALDI-FTMS mfz 392.1860 (M + H+, C24H26N04, requires 392.1856).
N
r'igcOZC /:>
Example 24; Methyl 4-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate Step 1; Methyl 4-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzoate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (85 mg, 0.128 mmol) and methyl 4-bromobenzoate following General Procedure A. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (44 mg, 68%):'H NMR (CDCI3, 500 MHz) S 8.17 (d, 2H, J= 8.5 Hz), 7.77 (d, 2H, J = 8.5 Hz), 7.47 (s, 1 H), 7.36-7.33 (m, 2H), 7.26-7.23 (m, 3H), 4.93 (t, 1 H, J =
6.0 Hz), 4.02 (s, 3H), 2.67 (t, 2H, J= 7.5 Hz), 2.05-1.97 (m, 2H), 1.75-1.68 (m, 2H), 1.47-1.40 (m, 6H), 0.99 (s, 9H), 0.19 (s, 3H), 0.09 (s, 3H); 13C NMR
(CDCI3, 125 MHz) S 166.9, 166.2, 150.6, 143.2, 132.5, 130.7, 130.0, 128.8, 128.6, 126.0, 124.3, 124.1, 69.1, 52.6, 36.8, 36.3, 31.8, 29.6, 26.2, 26.2, 25.5, 18.6, -4.5, -4.7.
Step 2. The title compound was prepared from methyl 4-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzoate (42 mg, 0.083 mmol) following General Procedure C. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a white solid (24 mg, 75%): 'H NMR (CDC13, 500 MHz) 5 8.20 (d, 2H, J = 8.5 Hz), 7.92 (d, 2H, J = 8.5 Hz), 7.69 (s, I H), 7.36-7.33 (m, 2H), 7.26-7.25 (m, 3H), 3.17 (t, 2H, J = 7.5 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.89-1.83 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.46 (m, 4H); 13C NMR (CDCI3, 125 MHz) 5 188.7, 166.6, 158.0, 153.4, 143.1, 131.5, 131.0, 130. 8, 128.8, 128.7, 126.0, 125.7, 125.5, 52.8, 39.4, 36.3, 31.7, 29.4, 29.4, 24.4; MALDI-FTMS m/z 392.1855 (M + H+, C24H26NO4, requires 392.1856).
N
O
O
COZH
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzoic acid The title compound was prepared from methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate (10 mg, 0.026 mmol) following General Procedure E. Preparative thin layer chromatography (EtOAc) yielded the title compound as a white solid (8 mg, 80%): 'H NMR (CD3OD, 600 MHz) 8 7.62 (s, 1 H), 7.22-7.19 (m, 2H), 7.14-7.09 (m, 3H), 3.04 (t, 2H, J= 7.5 Hz), 2.58 (t, 2H, J=
7.5 Hz), 1.71-1.68 (m, 2H), 1.62-1.59 (m, 2H), 1.41-1.32 (m, 4H);13C NMR
(CD3OD, 150 MHz) S 189.0, 159.4, 159.4, 143.3, 143.3, 134.6, 128.9, 128.7, 126.1, 39.6, 36.3, 32.0, 29.5, 29.4, 23.9; MALDI-FTMS m/z 378.1705 (M + H+, C23H24NO4, requires 378.1700).
O
Example 25; 3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzoic acid The title compound was prepared from methyl 3-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate (29 mg, 0.074 mmol) following General Procedure E. Preparative thin layer chromatography (EtOAc) yielded the title compound as a white= solid (22 mg, 79%): 'H NMR (THF-d8i 500 MHz) S 8.55 (s, 1 H), 8.16 (d, 1 H, J= 7.5 Hz), 8.09 (d, 1 H, J = 8.0 Hz), 7.88 (s, 1 H), 7.66 (t, I H, J= 8.0 Hz), 7.32-7.29 (m, 2H), 7.25-7.24 (m, 2H), 7.20-7.18 (m, 1 H), 3.15 (t, 2H, J= 7.0 Hz), 2.70 (t, 2H, J = 7.5 Hz), 1.84-1.81 (m, 2H), 1.77-1.71 (m, 2H), 1.54-1.49 (m, 4H); '3C NMR (THF-d8, 125 MHz) S 187.2, 166.9, 158.0, 153.4, 142.9, 133.1, 130.9, 129.4, 128.9, 128.5, 128.4, 127.8, 126.4,.125.7, 124.8, 38.9, 36.1, 31.8, 29.4, 29.4, 24.2; MALDI-FTMS m/z 378.1699 (M + H+, C23H24NO4, requires 378.1700).
/ ~ / N
HO2C ~ O
O
Example 26; 4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzoic acid The title compound was prepared from methyl 4-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate (10 mg, 0.026 mmol) following General Procedure E. Preparative thin layer chromatography (EtOAc) yielded the title compound as a white solid (8 mg, 83%):'H NMR (THF-ds, 500 MHz) S 8.21 (d, 2H, J = 8.5 Hz), 8.00 (d, 2H, J 8.5 Hz),. 7.90 (s, 1 H), 7.32-7.18 (m, 5H), 3.15 (t, 2H, J = 7.5 Hz), 2.70 (t, 2H, J 7.5 Hz), 1.80-1.71 (m, 2H), 1.52-1.50 (m, 2H), 1_44-1.38 (m, 4H); '3C NMR (THF-d8, 500 MHz) S 187.3, 165.4, 158.2, 153.2, 142.9, 132.2, 131.1, 130.7, 128.5, 128.4, 126.9, 125.7, 125.1, 38.9, 36.1, 31.6, 31.6, 29.4, 24.1; MALDI-FTMS m/z 378.1697 (M + H+, C23H24NO4, requires 378.1700).
N .
NH2 Exampl e 27; 1-(5-(2-Aminophenyl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 2-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-I aniline. The title compound was prepared from 2-(1-(tert-butyldimethylsilyfoxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (188 mg, 0.284 mmol) and 2-iodoaniline following General Procedure A. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a clear oil (122 mg, 90%): 'H NMR (CDCI3r 400 MHz) S 7.48 (dd, 1 H, J = 6.4, 9.3 Hz), 7.29-7.25 (m, 2H), 7.21 (s, 1 H), 7.18-7.13 (m, 4H), 6.84-6.80 (m, 1 H), 6.77-6.75 (m, 1 H), 4.85 (t, 1 H, J = 6.0 Hz), 3.81 (br s, 2H), 2.60 (t, 2H, J = 7.5 Hz), 1.97-1.89 (m, 2H), 1.68-1.59 (m,- 2H), 1.40-1.29 (m, 6H), 0.91 (s, 9H), 0.11 (s, 3H), 0.00 (s, 3H);13C NMR (CDCI3, 100 MHz) 8 169.1, 155_2, 148.5, 147.9, 134.8, 133.5, 133.4, 132.5, 130.7, 127.8, 123.8, 121.9, 118.4, 73.8, 41.6, 41.1, 36.5, 34.3, 34.3, 30.9, 30.3, 23.3, 0.2, 0Ø
Step 2. The title compound was prepared from 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)aniline (74 mg, 0.159 mmol) following General Procedure D. Flash chromatography (10-20% EtOAc/hexanes) yielded the title compound as a yellow oil (3 mg, 5%): 'H NMR (CDCI3, 500 MHz) S 7.65 (dd, 1 H, J = 6.2, 9.0 Hz), 7.57 (s, 1 H), 7.37-7.31 (m, 6H), 7.25 (m, 2H), 6.99-6.95 (m, 2H), 3.14 (t, 2H, J = 7.5 Hz), 2.69 (t, 2H, J= 7.5 Hz), 1.84=1.81 (m, 2H), 1.74-1.69 (m, 2H), 1.51-1.46 (m, 4H); 13C NMR (CDCI3, 125 MHz) S 188.5, 161.9, 156.9, 145.9, 143.1, 135.8, 131.6, 128.8, 128.7, 128.5, 126.0, 125.0, 120.1, 118.6, 39.3, 36.3, 31.7, 30.1, 29.4, 24.4; MALDI-FTMS m1z 349.1916 (M +
H C22H25N202, requires 349.1910).
H2N u f N \ I
O
r Example 28; 1-(S-(3-Aminophenyl)oxazol-2-yl)-7-phenylheptan-1-one The title compound was prepared from 1-(5-(3-nitrophenyl)oxazol-2-yl)-7-phenylheptan-l-one (22 mg, 0.159 mmol) following General Procedure F. Flash chromatography (10-30% EtOAc/hexanes) yielded the title compound as a yellow oil (10 mg, 40%): 'H NMR (CDC13r 500 MHz) S 7.52 (s, 1H), 7.37-7.31 (m, 3H), 7.26-7.20 (m, 5H), 6.82 (d, I H, J = 6.5 Hz), 3.56 (br s, 2H), 3.15 (t, 2H, J
= 7.5 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.88-1.82 (m, 2H), 1.75-1.69 (m, 2H), 1.55-1.46 (m, 4H); 13C NMR (CDC13, 125 MHz) 6 188.8, 157.4, 154.8, 147.1, 143.1, 130.5, 128.8, 128.7, 128.0, 126.0, 124.1, 117.2, 116.2, 111.9, 39.4, 36.3, 31.7, 29.5, 29.5, 24.5; MALDI-FTMS m/z 349.1915 (M + H+, C22H25N202, requires 349.1910)_ H2N/,~~ON
~
Q
Example 29; 1-(5-(4-Aminophenyl)oxazof-2-yl)-7-phenylheptan-l-one The title compound was prepared from 1-(5-(4-nitrophenyl)oxazol-2-yl)-7-phenylheptan-l-one (9 mg, 0.024 mmol) following General Procedure F.
Preparative thin layer chromatography (40% EtOAc/hexanes) yielded the title compound as a yellow oil (3 mg, 36%): 'H NMR (CD3OD, 500 MHz) S 8.07 (d, 2H, J = 8.5 Hz), 7.90 (s, 1 H), 7.56 (d, 2H, J = 8.4 Hz), 7.32-7.29 (m, 2H), 7.25-7.20 (m, 3H), 3_16 (t, 2H, J= 7.5 Hz), 2.69 (t, 2H, J= 7.5 Hz), 1.84-1.81 (m, 2H), 1.75-1.70 (m, 2H), 1.53-1.47 (m, 4H); '3C NMR (CD3OD, 125 MHz) S 188.6; 157.8, 153.0, 142.9, 128.4, 128.3, 127.0, 126.1, 125.6, 124.9, 123.5, 118.8, 38.8, 35.8, 31.6, 29.0, 29.0, 23.9; MALDI-FTMS m/z 349.1898 (M + H+, C22H25N202, requires 349.1910).
N
OH O
Exa m ple 30; 1 -(5-(2-Hydroxyphenyl)oxazol-2-yl)-7-phenyi hepta n-1-one Step 1; 2-(211-(tert-Buty,IdimethylsilYloxyZ 7-phenylhept rLI)oxazol-5-I henol. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazo(e (88 mg, 0.134 mmol) and 2-lodophenol following General Procedure A. Flash chromatography (10-30% EtOAc/hexanes) yielded the title compound as a clear oil (21 mg, 34%):'H NMR (CDCI3, 500 MHz) S 7.80-7.76 (m, 1 H), 7.62 (s, 1 H), 7.56 (br s, 1 H), 7.36-7.20 (m, 6H), 7.09-7.04 (m, 2H), 4.94 (t, 1 H, J = 6.0 Hz), 2.62 (t, 2H, J = 7.5 Hz), 2.05-1.93 (m, 2H), 1.68-1.65 (m, 2H), 1.47-1.32 (m, 6H), 0.97 (s, 9H), 0.17 (s, 3H), 0.07 (s, 3H);13C
NMR
(CDC13, 125 MHz) 8 166.3, 154.3, 148.8, 143.2, 130.0, 128.8, 128.6, 126.5, 126.0, 124.9, 119.2, 116.8, 115.6, 70.1, 37.0, 35.3, 31.8, 29.6, 26.2, 26.2, 25.5, 18.6, -4.4, -4.6.
Step 2. The title compound was prepared from 2-(2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenol (44 mg, 0.094 mmol) following General Procedure D. Preparative thin layer chromatography (30%
EtOAc) yielded the title compound as a white solid (3.4 mg, 12%):'H NMR
(CDC13, 500 MHz) 6 7.94-7.93 (m, 1 H), 7.82 (br s, 1 H), 7.38-7.34 (m, 4H), 7.26-7.25 (m, 3H), 7.12 (t, 1 H, J = 15.0 Hz), 7.00 (d, 1 H, J = 8.0 Hz), 3.18 (t, 2H, J =
7.5 Hz), 2.69 (t, 2H, J= 7.5 Hz), 1.89-1.83 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.46 (m, 4H);13C NMR (CDCIJ, 125 MHz) 8 188.8, 153.4, 151.7, 143.1, 131.3, 128.8, 128.7, 127.7, 127.5, 126.0, 121.7, 116.9, 114.5, 39.4, 36.3, 31.7, 29.5, 29.4, 24.5;
MALDI-FTMS m/z 350.1751 (M + H+, C22H24NO3, requires,350.1751).
HO / \ ~ N \ I
O
~
Example 31; 1-(5-(3-Hydroxyphenyl)oxazol-2-yl)-7-phenylheptan-l-one Step 1; 3-(2-(1-(tert-Butyldimethylsilvioxy)-7-phenylheptyl)oxazol-5-yl)phenol. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (99 mg, 0.149 mmol) and 3-iodophenol following General Procedure A. Flash chromatography (10-30% EtOAc/hexanes) yielded the title compound as a clear oil (29 mg, 41 %): 'H NMR (CDCI3, 500 MHz) & 7.79-7.77 (m, 1 H), 7.62 (s, 1 H), 7.56 (br s, 1 H), 7.39-7.35 (m, 2H), 7.29-7.24 (m, 4 H), 7.09-7.04 (m, 2H), 4.95 (t, 1 H, J= 6.0 Hz), 2.65 (t, 2H, J= 7.5 Hz), 2.05-1.95 (m, 2H), 1.67-1.64 (m, 2H), 1.47-1.34 (m, 6H), 0.97 (s, 9H), 0.17 (s, 3H), 0.07 (s, 3H);13C NMR (CDC13, 125 MHz) S 164.3, 153.1, 148.8, 143.2, 129.7, 128.8, 128.6, 126.5, 126.0, 124.8, 121.0, 116.8, 115.6, 69.0, 37.0, 36.3, 31.8, 30.1, 26.2, 26.2, 25.5, 18.6, -4.5, -4.7.
Step 2. The title compound was prepared from 3-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenol (29 mg, 0.062 mmol) following General Procedure D. Preparative thin layer chromatography (30%
EtOAc) yielded the title compound as a white solid (5.2 mg, 27%): 'H NMR
(CD3OD, 500 MHz) 8 7.74 (s, I H), 7.38-7.37 (m, 2H), 7.32-7.29 (m, 3H), 7.24-7.23 (m, 2H), 7.21-7.20 (m, 1 H), 6.95-6.94 (m, 1 H), 3.14 (t, 2H, J= 7.0 Hz), 2.69 (t, 2H, J= 7.5 Hz), 1.85-1.79 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.42 (m, 4H);
NMR (CD3OD, 125 MHz) S 188.5, 158.4, 157.4, 154.7, 142.9, 130.5, 128.4, 128.2, 128.2, 125.6, 123.9, 117.2, 116.5, 111.7, 38.7, 35.8, 31.5, 29.0, 29.0, 23.9;
MALDI-FTMS mAz 350.1752 (M + H+, C22H24NO3, requires 350.1751).
N
/ ~ /
H ~
O
Example 32; 1-(5-(4-Hydroxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 4-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenyiheptyl)oxazol-5-yi)phenyl acetate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylhepty!)-5-(tributylstannyl)oxazole (74 mg, 0.112 mmol) and 4-iodophenyl acetate following General Procedure A. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a clear oil (31 mg, 54%): 1 H NMR (CDCI3, 600 MHz) S 7.65 (d, 2H, J = 7.8 Hz), 7.27-7.24 (m, 3H), 7.16-7.14 (m, 5H), 4.82 (t, I H, J = 6.0 Hz), 2.58 (t, 2H, J = 7.5 Hz), 2.32 (s, 3H), 1.97-1.87 (m, 2H), 1.65-1.60 (m, 2H), 1.45-1.34 (m, 6H), 0.89 (s, 9H), 0.09 (s, 3H), -0.02 (s, 3H); 13C NMR (CDC13, 150 MHz) S 170.2, 165.8, 151.4, 151.3, 143.7, 129.2, 129.1, 126.7, 126.4, 126.2, 123.1, 122.4, 69.5, 37.3, 36.8, 32.3, 30.0, 26.6, 26.6, 26.0, 22.1, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 4-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenyl acetate (30 mg, 0.059 mmol) following General Procedure D except the reaction with Bu4NF stirred for h. Preparative thin layer chromatography (40% EtOAc) yielded the title compound as a white solid (2.4 mg, 10%):'H NMR (CDC13, 600 MHz) S 7.66 (d, 2H, J= 8.4 Hz), 7.37 (s, 1 H), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 6.91 (d, 2H, J= 8.4 Hz), 3.06 (t, 2H, J= 7.5 Hz), 2.60 (t, 2H, J = 7.5 Hz), 1.79-1.75 (m, 2H), 1.65-1.61 (m, 2H), 1.43-1.38 (m, 4t-I);13C NMR (CD3OD, 125 MHz) 8188.7, 161.1, 159.2, 157.7, 143.1, 128.8, 128.7, 127.6, 126.0, 122.7, 120.0, 116.6, 39.3, 36.3, 31.7, 29.5, 29.4, 24.5; MALDI-FTMS m/z 350.1748 (M + H+, C22HP-4NO3, requires 350.1751).
~ ) 0~ \
~
Example 33; Methyl 6-(2-(7-phenytheptanoyl)oxazol-5-yl)picolinate Step 1; Methyl 6-(2-(1-(terf-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)picolinate. The title compound was prepared from 2-(1-(tert-butyldimethylsityloxy)-7-phenylheptyl)-5-(tributylstannyi)oxazole (94 mg, 0.142 mmol) and methyl 6-chloropicolinate following General Procedure A. Flash chromatography (5-10% EtOAc/hexanes) yielded the title compound as a clear oil (72 mg, 100%): 'H NMR (CDC13, 500 MHz) 8 8.12-8.10 (m, 1 H), 7.99 (t, 1H, J=
7.8 Hz), 7.90-7.89 (m, 1 H), 7.86 (s, 1 H), 7.35-7.32 (m, 2H), 7.25-7.22 (m, 3H), 4.94 (t, 1 H, J= 7.0 Hz), 4.10 (s, 3H), 2.67 (t, 2H, J= 7.5 Hz), 2.04-1.96 (m, 2H), 1.74-1.67 (m, 2H), 1.55-1.39 (m, 6H), 0.97 (s, 9H), 0.17 (s, 3H), 0.07 (s, 1 H);13C
NMR (CDC13, 125 MHz) S 166.5, 165.8, 150.3, 148.7, 148.2, 143.3, 138.4, 128.8, 128.6, 126.8, 126.0, 124.3, 122_5, 69.2, 53.4, 36.8, 36.3, 31.8, 29.6, 26.1, 26.1, 25.5, 14.0, -4.5, -4.7.
Step 2. The title compound was prepared from methyl 6-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)picolinate (70 mg, 0.138 mmol) following General Procedure C. Flash chromatography (10-30% EtOAc) yielded the title compound as a white solid (19 mg, 35%):'H NMR (CDCI3, 500 MHz) S
8.19 (d, 1 H, J= 7.0 Hz ), 8.12-8.09 (m, 2H), 8.06-8.03 (m, 1 H), 7.36-7.33 (m, 2H), 7.26-7.24 (m, 3H), 4.11 (s, 3H), 3.19 (t, 2H, J= 7.0 Hz), 2.69 (t, 2H, J=
7.5 Hz), 1.89-1.83 (m, 2H), 1.75-1.69 (m, 2H), 1.55-1.47 (m, 4H); 13C NMR (CDC13i 125 MHz) S 188.9, 165.5, 158.0, 152.7, 149.0, 147.0, 143.1, 138.7, 128.8, 128.7, 128.4, 126.0, 125.6, 123.7, 53.5, 39.6, 36.3, 31.7, 29.4, 29.4, 24.3; MALDI-FTMS
m/z 393.=1796 (M + H+, C23H25N204, requires 393.1809).
N /~
O
Example 34; Methyl 6-(2-(7-phenylheptanoyl)oxazol-5-yl'nicotinate Step 1: Methyl 6-(2-(1-(tert butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)nicotinate. The title compound was prepared from 2-(1-(tert-butyldimethylsi(yloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (83 mg, 0.125 mmol) and methyl 6-chloronicotinate following General Procedure A. Flash chromatography (5-10% EtOAc/hexanes) yielded the title compound as a clear oil (46 mg, 72%): ' H NMR (CDCI3, 500 MHz) 6 9.28 (d, 1 H, J= 2.0 Hz), 8.43 (dd, 1 H, J= 10.0, 6.0 Hz), 7.84 (s, 1 H), 7.78 (d, 1 H, J= 8.5 Hz), 7.35-7.32 (m, 2H), 7.25-7.22 (m, 3H), 4.95 (t, 1 H, J = 7.0 Hz), 4.04 (s, 3H), 2.67 (t, 2H, J = 7.5 Hz), 2.05-1.98 (m, 2H), 1.74-1.67 (m, 2H), 1.48-1.40 (m, 6H), 0.98 (s, 9H), 0.18 (s, 3H), 0.08 (s, 3H); 13C NMR (CDC13r 125 MHz) S 167.1, 165.8, 151.6, 151.0, 150.5, 143.2, 138.5, 128.8, 128.6, 127.9, 126.0, 125.0, 118.7, 69.2, 52.9, 36.9, 36.3, 31.8, 29.6, 26.1, 26.1, 25.5, 18.6, -4.5, -4.7.
Step 2. The title compound was prepared from methyl 6-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)nicotinate (44 mg, 0.086 mmol) following General Procedure C. Flash chromatography (10-20% EtOAc) yielded the title compound as a white solid (19 mg, 56%):'H NMR (CDCI3, 500 MHz) S
9.32 (d, 1 H, J= 2.0 Hz ), 8.48 (dd, 1 H, J= 8.5, 2.0 Hz), 8.06 (s, 1 H), 8.00 (d, 1 H, J = 8.5 Hz), 7.36-7.33 (m, 2H), 7.26-7.24 (m, 3H), 4.07 (s, 3H), 3.19 (t, 2H, J =
7.0 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.89-1.84 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.47 (m, 4H); 13C NMR (CDCI3, 125 MHz) 5 188.9, 165.5, 158.2, 152.8, 151.7, 149.8, 143.1, 138.7, 129.1, 128.8, 128.7, 126.3, 126.0, 120.1, 53.0, 39.6, 36.3, 31.7, 29.4, 29.4, 24.3; MALDI-FTMS m/z 393.1811 (M + H+, C23H25N204, requires 393.1809).
~ ~ / N
O
"~ O
Example 35; Methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)isonicotinate Step 1; Methyl 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-YI? isonicotinate. The title compound was prepared from 2-(1-(te+t-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (130 mg, 0.196 mmol) and methyl 2-chloroisonicotinate following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (72 mg, 71%): ' H NM R(C DCI3, 400 MHz) 8 8.77 (d, IH, J= 5.0 Hz), 8.20 (s, 1 H), 7.77 (dd, 1 H, J = 5.0, 1.5 Hz), 7.70 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 4.88 (dd, 1 H, J = 7.0, 5.9 Hz), 4.00 (s, 3H), 2.60 (t, 2H, J= 7.8 Hz), 1.95 (m, 2H), 1.61 (m, 2H), 1.36 (m, 4H), 0.92 (s, 9H), 0.11 (s, 3H)~, 0.02 (s, 3H); 13C NMR
(CDC13, 100 MHz) 8 166.2, 165.2, 150.7, 150.1, 148.4, 142.7, 138.3, 128.3, 128.2, 126.0, 125.5, 121.8, 118.3, 68.7, 52.8, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 18.2, -5.0, -5.1.
Step 2. The title compound was prepared from methyl 2-(2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)isonicotinate (36 mg, 0.071 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (15 mg, 56%): 1H
NMR (CDC13, 400 MHz) 5 8.82 (dd, 1 H, J = 5.0, 0.9 Hz), 8.39 (d, 1 H, J = 0.9 Hz), 7.93 (s, 1 H), 7.87 (dd, 1 H, J= 5.0, 1.4 Hz), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 4.02 (s, 3H), 3.13 (t, 2H, J = 7.5 Hz), 2.60 (t, 2H, J = 7.8 Hz), 1.80 (quint, 2H, J
7.3 Hz), 1.65 (quint, 2H, J = 7.4 Hz), 1.48-1.40 (m, 4H); '3C NMR (CDC13, 100 MHz) S 188.5, 164.9, 157.6, 152.6, 151.0, 147.3, 142.7, 138.7, 128.4, 128.2, 127.6, 125.6, 123.2, 119.5, 53.0, 39.2, 35.8, 31.3, 29.0, 29.0, 23.9; MALDI-FTMS
mlz 393.1811 (M + H+, C23H25N204, requires 393.1809).
QN / N O
Example 36; Methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)nicotinate Step 1; Methyl 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)nicotinate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (83 mg, 0.125 mmol) and methyl 2-chloronicotinate following General Procedure A. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a white solid (60 mg, 94%): 'H NMR (CDCI3i 500 MHz) 6 8.80 (dd, 1 H, J = 6.4, 3.0 Hz), 8.02 (dd, 1 H, J= 10.0, 6.0 Hz), 7.72 (s, 1 H), 7.39-7.32 (m, 3H), 7.25-7.23 (m, 3H), 4.91 (t, I H, J = 7.0 Hz), 4.01 (s, 3H), 2.66 (t, 2H, J = 7.5 Hz), 2.03-1.91 (m, 2H), 1.74-1.68 (m, 2H), 1.46-1.35 (m, 6H), 0.96 (s, 9H), 0.17 (s, 3H), 0.05 (s, 3H);13C NMR (CDCI3, 125 MHz) S 168.0, 166.5, 151.5, 149.9, 145.2, 143.2, 137.5, 128.8, 128.6, 128.0, 126.4, 126.0, 122.7, 69.1, 53.3, 37.0, 36.3, 31.8, 29.6, 26.2, 26.2, 25.5, 18.6, -4.5, -4.8.
Step 2. The title compound was prepared from methyl 2-(2-(1-(tert=
butyidimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)nicotinate (30 mg, 0.059 mmol) following General Procedure C. Flash chromatography (10-30 fo EtOAc) yielded the title compound as a white solid (17 mg, 73%):'H NMR (CDCI3, 500 MHz) S
8.85-8.84 (m, 1 H), 8.10 (dd, 1 H, J= 8.0, 1.5 Hz), 7.94 (s, 1 H), 7.49-7.47 (m, 1 H), 7.36-7.33 (m, 2H), 7.26-7.25 (m, 3H), 4.07 (s, 3H), 3.17 (t, 2H, J= 7.0 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.88-1.82 (m, 2H), 1.75-1.69 (m, 2H), 1.53-1.47 (m, 4H);
NMR (CDCI3, 125 MHz) 8 188.5, 167.6, 152.3, 151.8, 144.3, 143.1, 137.7, 129.5, 128.8, 128.7, 127.5, 126.0, 123.9, 53.7, 39.5, 36.3, 31.7, 29.4, 29.4, 24.2;
MALDI-FTMS m/z 393.1799 (M + H+, C23H25N204, requires 393.1809).
FiO2C N 7 N
Z
Exarnple 37; 6-(2-(7-Phenylheptanoyl)oxazol-5-yl)picolinic acid The title compound was prepared from methyl 6-(2-(7-phenylheptanoyl)oxazol-5-yl)picolinate (9 mg, 0.059 mmol) following General Procedure E. Preparative thin layer chromatography (2% AcOH/EtOAc) yielded the title compound as a white solid (5 mg, 57%): 'H NMR (THF-d8, 500 MHz) S
8.11-8.04 (m, 4H), 7.22-7.08 (m, 5H), 3.08 (t, 2H, J = 7.5 Hz), 2.61 (t, 2H, J
= 7.5 Hz), 1.76-1.68 (m, 2H), 1.68-1.62 (m, 2H), 1.45-1.41 (m, 4H); 13C NMR (THF-d8, 125 MHz) 8 185.6, 163.1, 156.4, 151.4, 147.6, 144.7, 141.0, 137.1, 126.7, 126.5, 126.1, 123.9, 122.8, 121.1, 37.1, 34.3, 30.0, 27.6, 27.5, 22.2; MALDI-FTMS m/z 379.1645 (M + H+, C22H23N204, requires 379.1652).
N / N
HOzC O
Example 38; 6-(2-(7-Phenylheptanoyl)oxazol-5-yl)nicotinic acid The title compound was prepared from methyl 6-(2-(7-phenylheptanoyl)oxazol-5-yl)nicotinate (10 mg, 0.025 mmol) following General Procedure E. Preparative thin layer chromatography (2% AcOH/EtOAc) yielded the title compound as a white solid (4 mg, 40%): 'H NMR (THF-d8, 500 MHz) S
9.18 (s, 1 H), 8.41 (d, 1 H, J = 8.0 Hz), 7.97-7.94 (m, 2H), 7.22-7.09 (m, 5H), 3.08 (t, 2H, J = 7.5 Hz), 2.61 (t, 2H, J = 7.5 Hz), 1.74-1.69 (m, 2H), 1.67-1.61 (m, 2H), 1.47-1.40 (m, 4H); 13C NMR (THF-d8, 125 MHz) S 185.6, 163.6, 156.7, 151.1, 149.8, 147.9, 141.0, 136.7, 126.7, 126.5, 125.0, 123.9, 117.7, 37.2, 34.3, 29.9, 27.6, 27.5, 22.2; MALDI-FTMS m/z 379.1645 (M + H+, C22H23N204, requires 379.1652).
Example 39; 2-(2-(7-Phenylheptanoyl)oxazol-5-yl)isonicotinic acid The title compound was prepared from methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)isonicotinate (12 mg, 0.025 mmol) following General Procedure E. Preparative thin layer chromatography (2% AcOH/EtOAc) yielded the title compound as a white solid (2 mg, 17%):'H NMR (CDCI3, 600 MHz) 8.85 (d, 1 H, J= 4.2 Hz), 8.42 (s, 1 H), 7.93-7.90 (m, 2H), 7.26-7.30 (m, 2H), 7.17-7.16 (m, 3H), 3.12 (t, 2H, J = 7.5 Hz), 2.61 (t, 2H, J = 7.6 Hz), 1.79 (quint, 2H, J = 7.4 Hz), 1.65 (quint, 2H, J= 7.5 Hz), 1.44-1.40 (m, 4H); MALDI-FTMS m/z 377.1523 (M - H-, C22H21N204i requires 377.1507).
(N N
O
Example 40; 2-(2-(7-Phenylheptanoyl)oxazol-5-yl)nicotinic acid The title compound was prepared from methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)nicotinate (8 mg, 0.020 mmol) following General Procedure E. Preparative thin layer chromatography (2% AcOH/EtOAc) yielded the title compound as a white solid (3 mg, 38%): 'H NMR (THF-dB, 600 MHz) S
8.71 (d, 1 H, J= 4.8 Hz), 8.09 (d, 1 H, J= 7.8 Hz), 7.79 (s, 1 H), 7.45-7.44 (m, 2H), 7.22-7.19 (m, 2H), 7.16-7.14 (m, 2H), 7.11-7.08 (m, 1 H), 3.05 (t, 2H, J = 7.8 Hz), 2.60 (t, 2H, J = 7.2 Hz), 1.73-1.69 (m, 2H), 1.66-1.61 (m, 2H), 1.43-1.39 (m, 4H);
13C NMR (THF-de, 150 MHz) S 185.5, 165.6, 156.4, 150.9, 149.5, 142.7, 141.1, 135.7, 127.0, 126.7, 126.5, 125.9, 123.9, 121.9, 37.1, 24.3, 30.0, 27.6, 27.5, 22.2;
MALDI-FTMS mOz 379.1646 (M + H+, C22H23N204, requires 379.1652).
N
O
~ O
Example 41; 1-(5-(6-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-l-one Step 1: 2-(1-(tert-Butyldimethvlsilyloxv)-7-phenylheotyl)-5-(6-methylpyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (70 mg, 0.106 mmol) and 2-br6mo-6-methylpyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a white solid (26 mg, 57%): 'H NMR (CDCIa, 400 MHz) 8 7.64 (s, 1 H), 7.64 (t, 1 H, J =
7.6 Hz), 7.47 (d, 1 H, J= 7.6 Hz), 7.30-7.26 (m, 2H), 7.19-7.16 (m, 3H), 7.08 (d, 1 H, J
= 7.6 Hz), 4.85 (dd, 1 H, J = 7.3, 5.8 Hz), 2.60 (t, 2H, J = 7.6 Hz), 2.59 (s, 3H), 1.93 (m, 2H), 1.65 (m, 2H), 1.36 (m, 4H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H);
13C NMR (CDC13, 100 MHz) S 165.4, 158.8, 150.9, 146.8, 142.8, 137.0, 128.4, 128.2, 125.5, 124.8, 122.5, 116.1, 68.7, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 24.5, 13.6, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(6-methylpyridin-2-yi)oxazole (20 mg, 0.043 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (12 mg, 80%):1 H
NMR (CDCI3, 400 MHz) 7.87 (s, 1 H), 7.69 (m, 2H), 7.30-7.26 (m, 2H), 7.19-7.16 (m, 4H), 3.11 (t, 2H, J = 7.5 Hz), 2.62 (t, 2H, J = 7.8 Hz), 2.61 (s, 3H), 1.78 (quint, 2H, J= 7.4 Hz), 1.64 (quint, 2H, J= 7.4 Hz), 1.51-1.34 (m, 4H); 13C NMR
(CDC13, 100 MHz) 5 188.5, 159.2, 157.2, 153.6, 145.6, 142.7, 137.1, 128.4, 128.2, 126.6, 125.6, 123.9, 117.5, 39.0, 35.8, 31.3, 29.0, 29.0, 24.5, 23.9; MALDI-FTMS m/z 349.1917 (M + H+, C21H23N202, requires 349.191).
N / N
O
Example 42; 1-(5-(5-Methylpyridin-2-yl)oxazol-2-yl)-7-phenytheptan-1-one Step 1: 2-(1-(tert-Butyldimethvlsilyloxy)-7-phenylheptyl)-5-{5-methylpyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (100 mg, 0.106 mmol) and 2-bromo-5-methylpyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (42 mg, 61 %): ' H NMR (CDC13, 400 MHz) 8 7.64 (s, 1 H), 7.64 (t, 1 H, J= 7.6 Hz), 7.47 (d, 1 H, J= 7.6 Hz), 7.30-7.26 (m, 2H), 7.19-7.16 (m, 3H), 7.08 (d, 1 H, J=
7.6 Hz), 4.85 (dd, 1 H, J= 7.3, 5.8 Hz), 2.60 (t, 2H, J= 7.6 Hz), 2.59 (s, 3H), 1.93 (m, 2H), 1.65 (m, 2H), 1.36 (m, 4H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H);
NMR (CDC13i 100 MHz) 5 165.4, 158.8, 150.9, 146.8, 142.8, 137.0, 128.4, 128.2, 125.5, 124.8, 122.5, 116.1, 68.7, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 24.5, 13.6, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(1-(fert-butyldimethyisiiyloxy)-7-phenylheptyl)-5-(5-methylpyridin-2-yl)oxazole (20 mg, 0.043 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (8 mg, 89%):'H NMR
(CDCI3, 400 MHz) 8.5 (s, 1 H), 7.83 (s, 1 H), 7.78 (d, 1 H, J= 7.9 Hz), 7.63 (dd, 1 H, J = 7.9, 2.0 Hz), 7.30-7.26 (m, 2H), 7.19-7.17 (m, 3H), 3.11 (t, 2H, J= 7.5 Hz), 2.62 (t, 2H, J = 7.6 Hz), 2.41 (s, 3H), 1.78 (m, 2H), 1.65 (m, 2H), 1.47 (m, 4H); 13C
NMR (CDC13, 100 MHz) 6 188.6, 157.1, 153.5, 150.6, 143.7, 142.7, 137.5, 134.3, 128.4, 128.2, 126.2, 125.6, 120.0, 39.0, 35.9, 31.3, 29.0, 29.0, 24.0, 18.6;
MALDI-FTMS m/z 349.1903 (M + H+, C21H23N202i requires 349.191).
N N
70~
O
Example 43; 1-(5-(4-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-l-one Step 1: 2-(1-(tert Butyldimethylsilyloxy)-7-phenylheptYl)-5-(4-methylQyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyidimethylsiiyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (130 mg, 0.196 mmol) and 2-bromo-4-methylpyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (41 mg, 59%): iH NMR (CDCI3, 400 MHz) 5 8.48 (d, 1 H, J = 5 Hz), 7.63 (s, 1 H), 7.50 (d, 1 H, J= 0.6 Hz), 7.29-7.25 (m, 2H), 7.18-7.15 (m, 3H), 7.05 (ddd, 1 H, J=
5.0, 1.5, 0.6 Hz), 4.86 (dd, 1 H, J = 7.3, 5.8 Hz), 2.59 (t, 2H, J = 7.8 Hz), 2.41 (s, 3H), 1.93 (m, 2H), 1.61 (m, 2H), 1.36 (m, 4H), 0.91 (s, 9H), 0.11 (s, 3H), 0.01 (s, 3H); 13C NMR (CDCI3, 100 MHz) 5 165.5, 150.7, 149.6, 148.1, 147.2, 142.7, 128.2; 125.5, 125.0, 123.8, 119.9, 68.7, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 21.1, 18.2, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-methylpyridin-2-yl)oxazole (27 mg, 0.058 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (16 mg, 84%):1 H
NMR (CDCI3, 400 MHz) 8.52 (d, 1 H, J= 5.0 Hz), 7.87 (s, 1 H), 7.72 (d, 1 H, J
= 0.9 Hz), 7.30-7.26 (m, 2H), 7.19-7.16 (m, 4H), 7.14 (dd, IH, J = 5.0, 0.6 Hz), 3.11 (t, 2H, J = 7.5 Hz), 2.62 (t, 2H, J = 7.6 Hz), 2.44 (s, 3H), 1.79 (quint, 2H, J =
7.4 Hz), 1.65 (quint, 2H, J = 7.5 Hz), 1.51-1.34 (m, 4H); 13C NMR (CDCI3, 100 MHz) S
188.6, 157.2, 153.4, 149.8, 148.6, 146.0, 142.7, 128.4, 128.2, 126.7, 125.6, 125.1, 121:3, 39.0, 35.8, 31.3, 29.0, 29.0, 23.9, 21.1; MALDI-FTMS m/z 349.1904 (M + H+, C21H23N2 Z,requires 349.191).
N /ON
' O
Example 44; 1-(5-(3-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(3-methylpyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (130 mg, 0.196 mmol) and 2-bromo-3-methylpyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (28 mg, 40%): 1 H NMR (CDC13, 400 MHz) S 8.52 (dd, 1 H, J= 4.7, 1.5 Hz), 7.57 (ddd, 1 H, J = 7.6, 1.4, 0.6 Hz), 7.55 (s, 1 H), 7.29-7.24 (m, 2H), 7.18-7.15 (m, 4H), 4.89 (dd, 1 H, J = 7.6, 5.9 Hz), 2.59 (t, 2H, J = 7.8 Hz), 2.55 (s, 3H), 1.93 (m, 2H), 1.61 (m, 2H), 1.36 (m, 4H), 0.89 (s, 9H), 0.10 (s, 3H), -0.02 (s, 3H);13C
NMR
(CDC13, 100 MHz) S 165.6, 150.9, 147.1, 146.0, 142.8, 139.3, 130.3, 128.3, 128.2, 127.1, 125.5, 122.6, 68.6, 36.5, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 20.4, 18.2, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(3-methylpyridin-2-yl)oxazole (25 mg, 0.097 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (13 mg, 70%): 'H
NMR (CDCI3, 500 MHz) S 8.55 (dd, 1 H, J = 4.4, 1.1 Hz), 7.82 (s, 1 H), 7.62 (dd, .20 1 H, J = 7.7, 1.1 Hz), 7.29-7.23 (m, 3H), 7.19-7.16 (m, 3H), 3.12 (t, 2H, J = 7.5 Hz), 2.64 (s, 3H), 2.62 (t, 2H, J= 7.9 Hz), 1.79 (quint, 2H, J= 7.6 Hz), 1.65 (quint, 2H, J= 7.5 Hz), 1.51-1.34 (m, 4H);13C NMR (CDCI3, 125 MHz) 8 188.3, 157.4, 153.9, 147.4, 144.9, 142.7, 139.6, 131.7, 128.7, 128.4, 128.2, 125.6, 123.8, 39.1, 35.8, 31.2, 29.0, 29.0, 23.9, 20.1; MALDI-FTMS mfz 349.1913 (M + H+, C21H23N2 2, requires 349.191).
N
o Example 45; 1-(5-(4-Methoxypyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-methoxypyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(terf-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (144 mg, 0.302 mmol) and 2-chioro-4-methoxypyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (88 mg, 61 H NMR (CDCI3, 400 MHz) 8 8.43 (d, 1 H, J = 5.6 Hz), 7.63 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.75 (dd, 1 H, J= 5.8, 2.6 Hz), 4.85 (dd, 1 H, J = 7.3, 5.8 Hz), 3.9 (s, 3H), 2.59 (t, 2H, J = 7.6 Hz), 1.93 (m, 2H), 1.61 (m, 2H), 1.36 (m, 4H), 0.90 (s, 9H), 0.10 (s, 3H), 0.01 (s, 3H); '3C NMR (CDCI3i MHz) S 166.3, 165.5, 151.1, 150.6, 148.9, 142.7, 128.3, 128.2, 125.5, 125.3, 109.0, 105.1, 68.7, 55.3, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 18.2, -5.0, -5.1.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-methoxypyridin-2-yl)oxazole (70 mg, 0.146 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (51 mg, 96%): ' H
NMR (CDCI3, 400 MHz) S 8.49 (d, 1 H, J = 5.3 Hz), 7.88 (s, I H), 7.39 (d, I H, J
2.3 Hz), 7.29-7.26 (m, 2H), 7.19-7.16 (m, 3H), 6.84 (dd, 1 H, J= 5.9, 2.6 Hz), 3.94 (s, 3H), 3.12 (t, 2H, J Y 7.5 Hz), 2.62 (t, 2H, J = 7.8 Hz), 1.79 (quint, 2H, J
7.3 Hz), 1.65 (quint, 2H, J= 7.9 Hz), 1.47-1.39 (m, 4H);13C NMR (CDC13, 100 MHz) 6188.6,175.3,166.6,157.2,153.1,151.3,147.6,142.7,128,4,128.2, 127.1, 125.6, 110.5, 106.4, 55.6, 39.1, 35.9, 31.3, 29.0, 23.9, 20.6; MALDI-FTMS
m/z 365.1863 (M + H+, C22H25N203, requires 365.186).
/ N /ON
..--NC
Example 46; 2-(2-(7-Phenylheptanoyl)oxazol-5-yl)isonicotinonitrile Step 1; 2-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenyiheptyl)oxazol-5-yl)isonicotinonitrile. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (110 mg, 0.166 mmol) and 2-chloro-4-cyanopyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (72 mg, 75%): ' H NMR (CDCI3, 400 MHz) 58.79 (dd, 1H, J= 5.0, 0.9 Hz), 7.84 (s, 1 H), 7.74 (s, 1 H), 7.43 (dd, 1 H, J= 5.0, 1.4 Hz), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 4.88 (dd, 1 H, J = 7.3, 6.6 Hz), 2.60 (t, 2H, J = 7.8 Hz), 1.93 (m, 2H), 1.61 (m, 2H), 1.36 (rri, 4H), 0.91 (s, 9H), 0.12 (s, 3H), 0.01 (s, 3H);13C NMR (CDCI3i M Hz) 8 166.7, 150.8, 149.0, 148.6, 142.7, 128.3, 128.2, 127.1, 125.5, 123.7, 121.4, 120.2, 116.1, 68.6, 36.4, 35.8, 31.3, 29.0, 25.6, 25.6, 25.0, 18.1, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(2-(1-(tert-butyldimethylsi{yloxy)-7-phenylheptyl)oxazol-5-yl)isonicotinonitrile (46 mg, 0.097 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (24 mg, 69%): 'H
NMR (CDCI3, 400 MHz) 8 8.84 (d, 1 H, J= 5.0 Hz), 8.07 (s, 1 H), 7.96 (s, 1 H), 7.53 (d, 1 H, J= 5.0, 1.5 Hz), 7.29-7.26 (m, 2H), 7.19-7.16 (m, 3H), 6.84 (dd, 1 H, J=
5.9, 2.6 Hz), 3.12 (t, 2H, J= 7.5 Hz), 2.62 (t, 2H, J= 7.6 Hz), 1.80 (quint, 2H, J=
7.2 Hz), 1.65 (quint, 2H, J= 7.3 Hz), 1.42 (m, 4H); 13C NMR (CDCI3, 100 MHz) 6 188.3, 157.8, 151.3, 151.1, 147.6, 142.6, 128.5, 128.4, 128.2, 125.6, 125.2, 121.8, 121.5, 115.7, 39.2, 35.8, 31.2, 28.9, 23.8; MALDI-FTMS m/z 360.1717 (M
+ H+, C22H22N302, requires 360.1706).
l N /
O
~
Example 47; 7-Phenyl-l-(5-(4-(trifluoromethyl)pyridin-2-yl)oxazol-2-yi)heptan-1-one Step 1; 2-(1-(tert-Butyldimethylsilyioxy)-7-phenylheptyl)-5-(4-(trifluoromethyl)pYridin-2-Lrl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (130 mg, 0.196 mmol) and 2-chloro-4-(trifiuoromethyl)pyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (80 mg, 77%): 'H NMR (CDCI3, 400 MHz) 8 8.79 (d, 1 H, J= 5.0 Hz), 7.84 (s, 1 H), 7.73 (s, 1 H), 7.43 (dd, 1 H,. J= 5.0, 0.9 Hz), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 4.88 (dd, 1 H, J = 7.3, 5.9 Hz), 2.60 (t, 2H, J = 7.8 Hz), 1.93 (m, 2H), 1.61 (m, 2H), 1.36 (m, 4H), 0.91 (s, 9H), 0.11 (s, 3H), 0.01 (s, 3H); 13C NMR
(CDCI3, 100 MHz) 8 166.5, 150.9, 149.6, 148.6, 142.8, 139.3 (q, J = 33.9 Hz), 128.4, 128.2, 126.6, 125.6, 118.1 (q, J = 3.5 Hz), 114.6 (q, J = 3.0 Hz), 68.7, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 18.2, -5.0, -5.1.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-(trifluoromethyl)pyridin-2-yl)oxazole (51 mg, 0.098 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (32 mg, 80%):'H
NMR (CDCI3, 400 MHz) S 8.85 (d, 1 H, J = 5.0 Hz), 8.06 (s, 1 H), 7.96 (s, 1 H), 7.54 (d, 1 H, J = 5.0 Hz), 7.29-7.26 (m, 2H), 7.19-7.16 (m, 3H), 3.13 (t, 2H, J=
7.5 Hz), 2.62 (t, 2H, J = 7.8 Hz), 1.80 (quint, 2H, J = 7.4 Hz), 1.65 (quint, 2H, J =
7.8 Hz), 1.47-1.40 (m, 4H); 13C NMR (CDCI3, 100 MHz) S 188.5, 157.7, 152.0, 151.1, 147.5, 142.6, 139.6 (q, J= 34.9 Hz), 128.4, 128.2, 128.0, 125.6, 123.7, 121.0, 119.4 (q, J= 3.0 Hz), 115.9 (q, J= 4.6 Hz), 39.2, 35.8, 31.2, 29.0, 29.0, 23.9;
MALDI-FTMS rrr/z 403.1628 (M + Ht, C22H22F3N202, requires 403.1628).
~ N
Example 48; 1-(5-(4-Nitropyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 2-(1-(tert-Butyldirnethylsilyloxy)-7-phenylheptyl)-5-(4-nitropyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (190 mg, 0.287 mmol) and 2-chloro-4-nitropyridine following General Procedure A. Flash chromatography (10%o EtOAc/hexanes) yielded the title compound as a thick oil (98 mg, 66%): 'H NMR (CDCI3, 400 MHz) S 8.91 (dd, 1 H, J = 5.3, 0.6 Hz), 8.33 (d, 1 H, J= 2.1), 7.93 (dd, 1 H, J = 5.3, 2.1 Hz), 7.78 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 4.90 (dd, 1 H, J= 7.3, 5.8 Hz), 2.60 (t, 2H, J= 7.8 Hz), 1.96 (m, 2H), 1.62 (m, 2H), 1.36 (m, 4H), 0.92 (s, 9H), 0.12 (s, 3H), 0.03 (s, 3H); 13C NMR
(CDCI3, 100 MHz) S 166.9, 154.6, 152.2, 150.1, 149.1, 142.7, 128.3, 128.2, 127.5, 125.5, 114.8, 111.4, 68.7, 36.4, 35.9, 31.3, 29.1, 25.7, 25.7, 25.0, 18.2, -5.0,-5.1.
Step 2. The title compound was prepared from 2-(1-(tert-butyldirnethylsilyloxy)-7-phenylheptyl)-5-(4-nitropyridin-2-yl)oxazole (88 mg, 0.178 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yieided the title compound as a white solid (40 mg, 63%): ' H
NMR (CDCI3, 400 MHz) 8 8.96 (dd, 1 H, J = 5.8, 0.6 Hz), 8.53 (d, 1 H, J = 2.0 Hz), 8.03 (dd, 1 H, J= 5.3, 2.1 Hz), 8.00 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 3.14 (t, 2H, J = 7.5 Hz), 2.62 (t, 2H, J = 7.8 Hz), 1.81 (quint, 2H, J = 7.3 Hz), 1.65 (quint, 2H, J= 7.4 Hz), 1.48-1.40 (m, 4H); 13C NMR (CDCI3, 100 MHz) S 188.3, 157.8, 154.6, 152.4, 151.3, 149.0, 128.7, 128.3, 128.2, 125.6, 116.1, 112.7, 39.2, 35.8, 31.2, 28.9, 28.9, 23.8; MALDI-FTMS m/z 380.1609 (M + Ht, C2lH22N304, requires 380.1605).
I N I N
O
O
Exam ple 49; 1-(5-(4-Aminopyriidin-2-yl)oxazol-2-yl)-7-phenyiheptan-1-one The title compound was prepared from 1-(5-(4-nitropyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one (8 mg, 0.021 mmol) following General Procedure F.
Flash chromatography (50% EtOAc/hexanes) yielded the title compound as a white solid (6 mg, 80%): 'H NMR (CDCl3 /CD3OD, 400 MHz) S 8.26 (d, 1 H, J= 5.6 Hz), 7.82 (s, 1 H), 7.35 (d, 1 H, J= 2.1 Hz), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.78 (dd, 1 H, J= 5.9, 2.4 Hz), 3.07 (t, 2H, J = 7.3 Hz), 2.58 (t, 2H, J = 7.8 Hz), 1.74 (quint, 2H, J = 7.3 Hz), 1.60 (quint, 2H, J = 7.3 Hz), 1.48-1.40 (m, 4H);
'3C
NMR (CDCI3/CD3OD, 100 MHz) S 189.0, 158.0, 157.0, 153.3, 149.8, 128.3, 128.1, 126.7, 125.5, 107.6, 104.3, 38.9, 35.7, 31.2, 28.9, 28.9, 23.8; MALDI--FTMS mlz 350.1862 (M + H+, C21H22N304, requires 350.1863).
/ N N
O
F
Example 50; 1-(5-(4-Nitropyridin-2-yl)oxazol-2-yl)-7-phenylheptan-l-one Step 1; 2-(1-(tert-ButyldimethylsilVloxy)-7-phenylheptyl)-5-(4-fluoropyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (130 mg, 0.196 mmol) and 2-chloro-4-fluoropyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (48 mg, 51 %): ' H NMR (CDCI3, 400 MHz) 6 8.59 (dd, 1 H, J = 8.5, 5.6 Hz), 7.69 (s, 1 H), 7.38 (dd, 1 H, J= 9.4, 2.3 Hz), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.96 (ddd, 1 H, J= 8.2, 5.6, 2.4 Hz), 4.87 (dd, 1 H, J = 7.0, 6.2 Hz), 2.60 (t, 2H, J = 7.6 Hz), 1.96 (m, 2H), 1.62 (m, 2H), 1.36 (m, 4H), 0.91 (s, 9H), 0.11 (s, 3H), 0.01 (s, 3H); 13C NMR (CDCI3i 100 MHz) S 170.4, 167.8, 166.1, 152.4 (d, J = 7.6 Hz), 150.2, (d, J 7.6 Hz), 149.8 (d, J 4.6 Hz), 142.7, 128.3, 128.2, 126.2, 125.5, 110.5 (d, J 15.2 Hz), 106.9 (d, J 18.2 Hz), 68.7, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 18.2, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(1-(terf-butyfdimethyfsilyloxy)-7-phenylheptyl)-5-(4-fluoropyridin-2-yl)oxazole (44 mg, 0.094 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (23 mg, 70%): 'H
NMR (CDCI3, 400 MHz) 5 8.63 (dd, 1 H, J= 7.9, 5.6 Hz), 7.90 (d, 1 H, J = 0.9 Hz), 7.60 (dd, 1 H, J= 9.4, 2.4 Hz), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.96 (dddd, 1 H, J= 7.4, 5.6, 2.4, 0.6 Hz), 3.11 (t, 2H, J= 7.3 Hz), 2.62 (t, 2H, J= 7.6 Hz), 1.79 (quint, 2H, J = 7.3 Hz), 1.67 (quint, 2H, J = 7.3 Hz), 1.48-1.40 (m, 4H);
NMR (CDCI3, 100 MHz) 6 188.4, 170.4, 167.8, 157.5, 152.6 (d, J = 6.1 Hz), 152.2, (d, J= 4.6 Hz), 149.0 (d, J= 7.6 Hz), 142.6, 128.4, 128.2, 127.7, 125.6, 111.8 (d, J= 16.7 Hz), 108.4 (d, J= 19.7 Hz), 39.1, 35.8, 31.2, 28.9, 28.9, 23.8; MALDI-FTMS m/z 353.1681 (M + H+, C21H22FN202, requires 353.1665).
H3C0 N / N ~ I
NrJ
O
Example 51; 1-(5-(2,6-Dimethoxypyrimidin-4-yl)oxazol-2-yl)-7-phenylheptan-1-one Step 1: 2-(1-(tert-Butvldimethylsilyloxy)-7-phenylheptyl)-5-(2,6-dimethoxypyrimidin-4-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (200 mg, 0.302 mmol) and 6-chloro-2,4-dimethoxypyrimidine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (138 mg, 90%): 'H NMR (CDCI3, 400 MHz) S 7.73 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.67 (s, 1 H), 4.85 (dd, 1 H, J = 7.3, 5.9 Hz), 4.03 (s, 3H), 4.00 (s, 3H), 2.59 (t, 2H, J= 7.6 Hz), 1.96 (m, 2H), 1.62 (m, 2H), 1.36 (m, 4H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H); 13C NMR (CDCI3r 100 MHz) 5 172.3, 166.6, 165.4, 155.2, 149.0, 142.6, 128.3, =128.1, 128.0, 125.5, 95.8, 68.6, 54.8, 53.9, 36.2, 35.8, 31.3, 29.0, 25.6, 25.6, 24.9, 18.1, -5.1, -5.2.
Step 2. The title compound was prepared from 2-(1 -(tert-butyld im ethylsilyloxy)-7-phenylheptyl)-5-(2,6-dimethoxypyri mid in-4-yl)oxazole (130 mg, 0.254 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (88 mg, 88%): ' H
NMR (CDCI3, 400 MHz) S 7.94 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.88 (s, 1 H), 4.07 (s, 3H), 4.04 (s, 3H), 3.11 (t, 2H, J= 7.3 Hz), 2.63 (t, 2H, J= 7.7 Hz), 1.80 (quint, 2H, J = 7.7 Hz), 1.66 (quint, 2H, J = 7.5 Hz), 1.48-1.40 (m, 4H);
13C NMR (CDCI3, 100 MHz) 5 188.3, 172.5, 165.5, 157.7, 154.1, 142.5, 129.1, 128.3, 128.3, 128.1, 125.5, 97.4, 54.9, 54.2, 39.1, 35.7, 31.1, 28.9, 28.9, 23.7;
MALDI-FTMS mlz 396.1913 (M + H+, C22H26N304, requires 396.1918).
ON / N
HN O
O
Example 52; 6-(2-(7-Phenylheptanoyl)oxazol-5-yl)pyrimidine-2,4(1 H,3H)-dione The title compound was prepared from 1-(5-(2,6-dimethoxypyrimidin-4-yl)oxazol-2-yi)-7-phenylheptan-l-one (20 mg, 0.051 mmol) following General Procedure H. Flash chromatography (EtOAc) yielded the title compound as a white solid (16 mg, 90%): 'H NMR (CDCI3/CD3OD, 500 MHz) 5 7.92 (s, 1H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.19 (s, 1 H), 3.06 (t, 2H, J= 7.4 Hz), 2.58 (t, 2H, J= 7.7 Hz), 1.73 (quintet, 2H, J = 7.3 Hz), 1.61 (quintet, 2H, J = 7.4 Hz), 1.38-1.36 (m, 4H); 13C NMR (CDC13r 125 MHz) S 188.3, 163.8, 158.0, 151.7, 144.9, 142.5, 139.1, 129.8, 128.3, 128.1, 125.5, 98.8, 39.2, 35.7, 31.1, 28.81, 28.78, 23.5;
MALDI-FTMS m/z 368.1595 (M + H+, C20H22N304i requires 368.1605).
N
N
H3CON p Example 53; 1-(5-(2,4-Dimethoxypyrimidin-5-yl)oxazol-2-y1)-7-phenylheptan-1-one Step 1; 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(2 4-dimethoxypyrimidin-5-yl)oxazofe. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (130 mg, 0.196 mmol) and 5-iodo-2:,6-dimethoxypyrimidine following General Procedure A.
Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a 'thick oil (85 mg, 83%): 'H NMR (CDCI3, 400 MHz) 8 8.67 (s, 1 H), 7.34 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.14 (m, 3H), 4.85 (dd, 1 H, J= 7.4, 5.9 Hz), 4.13 (s, 3H), 4.05 (s, 3H), 2.59 (t, 2H, J= 7.8 Hz), 1.93 (m, 2H), 1.60 (m, 2H), 1.41 (m, 4H), 0.89 (s, 9H), 0.09 (s, 3H), 0.01 (s, 3H);13C NMR (CDCI3, 100 MHz) S 166.4, 164.3, 154.1, 143.9, 142.7, 128.3, 128.1, 125.5, 125.2, 104.9, 68.5, 55.0, 54.4, 36.3, 35.8, 31.3, 29.1, 25.6, 25.6, 25.0, 18.1, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(1-(tett-butyldimethylsilyloxy)-7-phenylheptyl)-5-(2,4-dimethoxypyrimidin-5-y1)oxazole (85 mg, 0.166 mmof) foflowing General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (43 mg, 66%): 'H
NMR (CDCI3, 400 MHz) 5 8.82 (s, 1 H), 7.57 (s, 1 H), 7.28-7.24 (m, 2H), 7.14-7.18 (m, 3H), 4.17 (s, 3H), 4.07 (s, 3H), 3.08 (t, J = 7.5 Hz), 2.61 (t, 2H, J =
7.6 Hz), 1.77 (quint, 2H, J = 7.3 Hz), 1.64 (quint, 2H, J = 7.4 Hz), 1.45-1.38 (m, 4H);
NMR (CDCI3, 100 MHz) 8 188.2, 166.9, 165.1, 156.4, 156.0, 147.4, 142.6, 128.3, 128.2, 126.9, 125.5, 103.6, 55.3, 54.6, 38.9, 35.8, 31.2, 28.9, 28.9, 23.9;
MALDi-FTMS m/z 396.1920 (M + H+, C22H26N3O4, requires 396.1918).
O
O N
H
Example 54; 5-(2-(7-Phenylheptanoyl)oxazol-5-yl)pyrimidine-2,4(1H,3H)-dione The title compound was prepared from 1-(5-(2,4-dimethoxypyrimidin-5-yl)oxazol-2-yl)-7-phenylheptan-l-one (15 mg, 0.038 mmol) following General Procedure H. Flash chromatography (EtOAc) yielded the title compound as a white solid (10 mg, 71 %): 'H NMR (CDCI3, 400 MHz) S 7.90 (s, 1 H), 7.71 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.14 (m, 3H), 2.99 (t, J = 7.5 Hz), 2.52 (t, 2H, J=
7.8 Hz), 1.67 (quint, 2H, J= 7.3 Hz), 1.55 (quint, 2H, J = 7.4 Hz), 1.33-1.31 (m, 4H);
13C NMR (CDCI3, 100 MHz) S 188.8, 160.9, 155.4, 150.6, 147.4, 142.5, 139.0, 128,2, 128.0, 126.0, 125.4, 102.6, 38.6, 35.6, 31.1, 28.8, 28.8, 23.8; MALDI-FTMS m/z 368.1613 (M + H+, C20H2jN304, requires 368.1610).
N
/o H3CO2C ' Example 55; Methyl 5-(2-(7-phenylheptanoyl)oxazol-5-yl)furan-2-carboxylate Step 1: Methyl 5-(2-(1-(tert-butyldimethyisil)tloxy)-7-phenylheptyl)oxazol-5-yl)furan-2-carboxylate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (82 mg, 0.125 mmol) and methyl 5-bromofuran-2-carboxylate following,General Procedure A.
Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (62 mg, 99%):'H NMR (CDCI3, 400 MHz) 5 7.42 (s, 1 H), 7.29-7.25 (m, 3H), 7.19-7.16 (m, 3H), 6.70 (d, 1 H, J = 3.6 Hz), 4.83 (t, 1 H, J= 6.0 Hz), 3.92 (s, 3H), 2.60 (t, 2H, J= 7.6 Hz), 1.96-1.85 (m, 2H), 1.71-1.57 (m, 2H), 1.40-1.33 (m, 6H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H); 33C NMR (CDCI3, 100 MHz) S
163.8, 151.9, 149.1, 147.8, 147.5, 133.4, 133.2, 130.6, 129.3, 124.6, 113.6, 113.5, 73.6, 57.1, 41.3, 40.9, 36.4, 34.1, 30.7, 30.7, 30.1, 23.2, 0.0, -0.1.
Step 2. The title compound was prepared from methyl 5-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)furan-2-carboxylate (60 mg, 0.121 mmol) following General Procedure C. Flash chromatography (10-20 fo EtOAc/hexanes) yielded the title compound as a white solid (29 mg, 63%): 'H
NMR (CDCI3i 500 MHz) S 7.72 (s, 1 H), 7.36-7.33 (m, 4H), 7.25-7.23 (m, 2H), 7.04-7.03 (d, J = 3.5 Hz, 1 H), 4.02 (s, 3H), 3.16 (t, 2H, J = 7.5 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.88-1.82 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.44 (m, 4H); 13C NMR
(CDC{3, 125 MHz) 8 188.5, 162.3, 159.0, 145.9, 145.8, 143.1, 128.8, 128.7, 128.7, 126.1, 126.0, 119.9, 111.7, 52.7, 39.6, 36.3, 31.7, 29.4, 29.4, 24.3;
MALDI-FTMS m/z 382.1640 (M + H+, C2ZHZ4NO5, requires 382.1649).
N
O O
Ho2c Example 56; 5-(2-(7-Phenylheptanoyl)oxazol-5-yl)furan-2-carboxylic acid The title compound was prepared from methyl 5-(2-(7-phenylheptanoyl)oxazol-5-yl)furan-2-carboxylate (7 mg, 0.018 mmol) following General Procedure E. Preparative thin layer chromatography (10%
MeOH/CH2CI2) yielded the title compound as a white solid (6 mg, 85%): ~ H NMR
(THF-de, 500 MHz) S 7.68 (s, 1 H), 7.27 (d, 1 H, J = 3.5 Hz), 7.22-7.07 (m, 5H), 7.04 (d, 1 H, J= 4.0 Hz), 3.05 (t, 2H, J = 7.0 Hz), 2.60 (t, 2H, J = 7.5 Hz), 1.73-1.71 (m, 2H), 1.65-1.61 (m, 2H), 1.42-1.40 (m, 4H); 13C NMR NMR (THF-d8, 125 MHz) 5 187.6, 164.6, 158.3, 146.2, 145.8, 143.5, 129.1, 128.9, 128.9, 126.3, 126.0, 119.7, 111.7, 39.6, 36.7, 32.4, 30.0, 30.0, 24.6; MALDI-FTMS m/z 368.1501 (M + H}, C21 H22NO5, requires 368.1492).
N ,\ I
H3CO2C (Slo O
Example 57; Methyl 5-(2-(7-phenylheptanoyl)oxazol-5-yl)thiophene-2-carboxylate Step 1: Methyl 5-(2-(1-(tert butyldimeth rlsilyloxy)-7-phenylheptyl)oxazol-5-yl)thiophene-2-carboxylate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (89 mg, 0.134 mmol) and methyl 5-bromothiophene-2-carboxylate following General Procedure A. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (65 mg, 94%): ?H NMR (CDCI3, 400 MHz) 8 7.72 (d, 1 H, J = 3.6 Hz), 7.26-7.23 (m, 4H), 7.17-7.14 (m, 3H), 4.80 (t, 1 H, J= 6.0 Hz), 3.89 (s, 3H), 2.58 (t, 2H, J= 7.6 Hz), 1.95-1.87 (m, 2H), 1.68-1.56 (m, 2H), 1.38-1.27 (m, 6H), 0.88 (s, 9H), 0.09 (s, 3H), 0.00 (s, 3H);13C NMR (CDCI3i 100 MHz) S 167.4, 150.8, 147.9, 141.3, 139.2, 137.7, 133.5, 133.3, 130.7, 129.2, 129.2, 128.5, 73.7, 57.5, 41.4, 41.0, 36.5, 34.2, 30.8, 30.9, 30.2, 23.3, 0.2, 0Ø
Step 2. The title compound was prepared from methyl 5-(2-(1-(tert-butyldi-methylsilyloxy)-7-phenylheptyl)oxazol-5-yl)thiophene-2-carboxylate (63 mg, 0.123 mmol) following General Procedure C. Flash chromatography (5-20%
EtOAc/hexanes) yielded the title compound as a white solid (25 mg, 50%): ' H
NMR (CDCI3, 500 MHz) S 7.85 (d, 1 H, J = 4.0 Hz), 7.54-7.53 (m, 2H), 7.36-7.33 (m, 2H), 7.26-7.24 (m, 3H), 4.00 (s, 3H), 3.15 (t, 2H, J = 7.5 Hz), 2.69 (t, 2H, J
7.5 Hz), 1.86-1.82 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.44 (m, 4H); 13C NMR
15(CDCI3i 125 MHz) S 188.4, 162.4, 157.4, 148.9, 143.1, 135.3, 134.7, 134.5, 128.8, 128.7, 127.0, 126.0, 125.4, 53.0, 39.5, 36.3, 31.7, 29.4, 29.4, 24.4;
MALDI-FTMS m/z 398.1407 (M + H+, C22Hz4NO4S, requires 398.1420).
N
Example 58; 5-(2-(7-Phenylheptanoyl)oxazol-5-yl)thiophene-2-carboxylic acid The title compound was prepared from methyl 5-(2-(7-phenylheptanoyl)oxazol-5-yl)thiophene-2-carboxylate (7 mg, 0.018 mmol) following General Procedure E. Preparative thin layer chromatography (10%
MeOH/CH2CI2) yielded the title compound as a white solid (3 mg, 41%): 'H NMR
(THF-d8, 500 MHz) S 7.73 (d, 1 H, J= 3.5 Hz), 7.72 (s, 1 H), 7.55 (d, 1 H, J =
4.0 Hz), 7.22-7.08 (m, 5H), 3.03 (t, 2H, J = 7.0 Hz), 2.60 (t, 2H, J= 7.5 Hz), 1.73-1.71 (m, 2H), 1.65-1.61 (m, 2H), 1.42-1.40 (m, 4H);13C NMR NMR (THF-d8, 125 MHz) S 185.1, 164.0, 155.8, 147.0, 141.0, 134.8, 132.7, 132.1, 126.7, 126.5, ? 24.9, 123.9, 123.3, 37.0, 34.3, 30.0, 27.6, 27.5, 22.2; MALDI-FTMS rn/z 384.1272 (M + H+, CZ1H22N04S, requires 384.1264).
N
H2NO2S o Example 59; 5-(2-(7-Phenylheptanoyl)oxazol-5-yl)thiophene-2-sulfonamide Step 1: 5-(2-(1-(tert-Bu Idimethylsilyloxy)-7_phenylheptyl)oxazol-5-yI)thiophene-2-sulfonamide. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (54 mg, 0.081 mmol) and 5-bromothiophene-2-sulfonamide following General Procedure A.
Flash chromatography (10-20% EtOAc/hexanes) yielded the title compound as a white solid (33 mg, 75%): 'H NMR (CDCI3, 500 MHz) S 7.68 (d, 1 H, J = 4.0 Hz), 7.36-7.33 (m, 3H), 7.29 (d, 1 H, J= 3.5 Hz), 7.26-7.23 (m, 3H), 5.29 (s, 2H), 4.89 (t, 1 H, J = 6.0 Hz), 2.67 (t, 2H, J= 7.5 Hz), 2.02-1.95 (m, 2H), 1.74-1.59 (m, 2H), 1.40-1.38 (m, 6H), 0.97 (s, 9H), 0.17 (s, 3H), 0.08 (s, 3H); 13C NMR (CDCI3, MHz) S 166.2, 145.2, 143.2, 142.5, 136.4, 132.7, 128.8, 128.7, 126.0, 124.2, 123.8, 68.9, 36.7, 36.3, 31.8, 29.6, 26.1, 26.1, 25.5, 18.6, -4.5,-4.7.
Step 2. The title compound was prepared from 5-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)thiophene-2-suIfonamide (30 mg, 0.056 mmol) following General Procedure C. Flash chromatography (30-60%
EtOAc/hexanes) yielded the title compound as a white solid (11 mg, 46%): ' H
NMR (CDCI3i 500 MHz) 5 7.71 (d,. 1 H, J = 3.5 Hz), 7.55 (s, 1 H), 7.50 (d, 1 H, J
3.5 Hz), 7.90 (s, 1 H), 7.37-7.34 (m, 2H), 7.26-7.24 (m, 3H), 5.36 (s, 2H), 3.15 (t, 2H, J = 7.0 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.87-1.82 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.46 (m, 4H);73C NMR (CDCI3, 500 MHz) S 188.5, 144.9, 143.1, 143.5, 133.3, 132.6, 128.8, 128.7, 126.4, 126.1, 125.7, 125.6, 39.6, 36.3, 31.7, 29.4, 29.4, 24.3; MALDI-FTMS m/z 419.1093 (M + H+, C20H22N204S2, requires 419.1094).
c02H
O-cc Example 60; 2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzoic acid The following compounds in Examples 61 and 62 may be prepared using methods analogous to those described in the preceding examples.
~
CN'IN I /
N O
Example 61; 1-[5-(1-Methyl-lH-imidazol-2-yl)-oxazol-2-yl]-7-phenyl-heptan-l-one N,N~N
N_N
Example 62; 1-[5-(1-Methyl-1H-tetrazol-5-yl)-oxazol-2-yl]-7-phenyl-heptan-l-one The title compounds per se of Comparative Examples 1 and 2 are known and are provided for comparative purposes. Compounds in Comparative Examples 1 and 2 were prepared according to the general procedures described above or according to the procedures described in WO 04/033652.
o-cc O
Comparative Example 1; 7-Phenyi-l-(5-pyridin-2-yl-oxazol-2-yl)-heptan-l-one % N
Comparative Example 2; 1-(5-Furan-2-yl-oxazol-2-yl)-7-phenyl-heptan-l-one Biological Testing:
Assay Method 1A
All enzyme assays were performed at 20-23 C using a solubilized liver plasma membrane extract containing FAAH in a reaction buffer of 125 mM Tris, 1 mM EDTA, 0.2% glycerol, 0.02% Triton X-100, 0.4 mM HEPES, pH 9.0 buffer (Patricelli, M.P. et al. Bioorg. Med. Chem. Lett. 1998, 8, 613-618; Patterson, J.E., et al. J. Am Chem. Soc. 1996, 118, 5938-5945). The initial rates of hydrolysis were monitored by following the breakdown of14C-olearnide to oleic acid as described previously (Cravatt, B.F. et al. Science 1995, 268, 1506-1509;
Patricelli, M.P. et al., 1998). The inhibition was reversible, non time-dependent. Linear least squares fits were used for all reaction progress curves and R2 values were consistently >0.97. IC50 values were determined from the inhibition observed at 3-5 different test compound concentrations (from three or more trials at each concentration) using the formula IC50 =[I]/[K&1K;)-1], where Ko is the control reaction rate without inhibitor and K; is the rate with test compound at concentration [I] (Conde-Frieboes, K., et al. J. Am. Chem. Soc. 1996, 118, 5525). K; values were determined by the Dixon Method (x-intercepts of weighted linear fits of [I] versus 1/rate plots at constant substrate concentration, which were converted to K; values using the formula K; =-x;,,t/[1+[S]/{tm]). Results for compounds tested in this assay are presented in presented in Table 1.
Table 1 Ex. Assay 1A Ex. Assay 1A
K, (nM) K, (nM) 10 110 40 >50 14 40 43 . 1 36 >50 60 6000 Assay Method 1 B
A. Transfection of Cells with Human FAAH
A 10-cm tissue culture dish with a confluent monolayer of SK-N-MC cells was split 2 days (d) prior to transfection. Using sterile technique, the media was removed and the cells were detached from the dish by the addition of trypsin.
One fifth of the cells were then placed onto a new 10-cm dish. Cells were grown in a 37 C incubator with 5% CO2 in Minimal Essential Media Eagle with 10%
Fetal Bovine Serum. After 2 d, cells were approximately 80% confluent. These cells were removed from the dish with trypsin and pelleted in a clinical centrifuge.
The pellet was re-suspended in 400 L complete media and transferred to an electroporation cuvette with a 0.4 cm gap between the electrodes. Supercoiled human FAAH cDNA (1 pg) was added to the cells and mixed. The voltage for the electroporation was set at 0.25 kV, and the capacitance was set at 960 F.
After electroporation, the cells were diluted into complete media (10 mL) and plated onto four 10-cm dishes. Because of the variability in the efficiency of electroporation, four different concentrations of cells were plated. The ratios used were 1:20, 1:10, and 1:5, with the remainder of the cells being added to the fourth dish. The cells were allowed to recover for 24 h before adding the selection media (complete media with 600 g/mL G418). After 10 d, dishes were analyzed for surviving colonies of celis. Dishes with well-isolated colonies were used.
Cells from individual colonies were isolated and tested. The clones that showed the most FAAH activity, as measured by anandamide hydrolysis, were used for further study.
B. FAAH Assay T84 frozen cell pellets or transfected SK-N-MC cells (contents of I x 15 cm culture dishes) were homogenized in 50 mL of FAAH assay buffer (125 mM
Tris, 1 mM EDTA, 0.2% Glycerol, 0.02% Triton X-100, 0.4 mM Hepes, pH 9). The assay mixture consisted of 50 L of the cell homogenate, 10 L of the test compound, and 40 L of anandamide [1 3H-ethanolamine] (3H-AEA, Perkin-Elmer, 10.3 Ci/mmol), which was added last, for a final tracer concentration of 80 nM. The reaction mixture was incubated at rt for 1 h. During the incubation, well Multiscreen filter plates (catalog number MAFCNOB50; Millipore, Bedford, MA, USA) were loaded with 25 L of activated charcoal (Multiscreen column loader, catalog number MACL09625, Millipore) and washed once with 100 L of MeOH. Also during the incubation, 96-well DYNEX MicroLite plates (catalog number NL510410) were loaded with 100 pL of MicroScint40 (catalog number 60'! 3641, Packard Bioscience, Meriden, CT, USA). After the I h incubation, 60 pL of the reaction mixture were transferred to the charcoal plates, which were then assembled on top of the DYNEX plates using Centrifuge Alignment Frames (catalog number MACF09604, Millipore). The unbound labeled ethanolamine was centrifuged through to the bottom plate (5 min at 2000 rpm), which was preloaded with the scintillant, as described above. The plates were sealed and left at rt for 1 h before counting on a Hewlett Packard TopCount. Results for compounds tested in this assay are presented in Table 2.
Assay Method 2 A. Transfection of Cells with Rat FAAH
A 10-cm tissue culture dish with a confluent monolayer of SK-N-MC cells was split 2 days (d) prior to transfection. Using sterile technique, the media was removed and the cells were detached from the dish by the addition of trypsin.
One fifth of the cells were then placed onto a new 10-cm dish. Cells were grown in a 37 C incubator with 5% CO2 in Minimal Essential Media Eagle with 10%
Fetal Bovine Serum. After 2 d, cells were approximately 80% confluent. These cells were removed from the dish with trypsin and pelleted in a clinical centrifuge.
The pellet was re-suspended in 400 L complete media and transferred to an electroporation cuvette with a 0.4 cm gap between the electrodes. Supercoiled rat FAAH cDNA (1 pg) was added to the cells and mixed. The voltage for the electroporation was set at 0.25 kV, and the capacitance was set at 960 F.
After electroporation, the cells were diluted into complete media (10 mL) and plated onto four 10-cm dishes. Because of the variability in the efficiency of electroporation, four different concentrations of cells were plated. The ratios used were 1:20, 1:10, and 1:5, with the remainder of the cells being added to the fourth dish. The cells were allowed to recover for 24 h before adding the selection media (complete media with 600 g/mL G418). After 10 d, dishes were analyzed for surviving colonies of cells. Dishes with well-isolated colonies were used.
Cells from individual colonies were isolated and tested. The clones that showed the most FAAH activity, as measured by anandamide hydrolysis, were used for further study.
B. FAAH Assay T84 frozen cell pellets or transfected SK-N-MC cells (contents of 1 x 15 cm culture dishes) were homogenized in 50 mL of FAAH assay buffer (125 mM Tris, 1 mM EDTA, 0.2% Glycerol, 0.02% Triton X-1 00, 0.4 mM Hepes, pH 9). The assay mixture consisted of 50 L of the cell homogenate, 10 L of the test compound, and 40 L of anandamide [1-3H-ethanolamine] (3H-AEA, Perkin-Elmer, 10.3 Ci/mmol), which was added last, for a final tracer concentration of 80 nM. The reaction mixture was incubated at rt for I h. During the incubation, well Multiscreen filter plates (catalog number MAFCNOB50; Millipore, Bedford, MA, USA) were loaded with 25 L of activated charcoal (Multiscreen column loader, catalog number MACL09625, Millipore) and washed once with 100 L of MeOH. Also during the incubation, 96-well DYNEX MicroLite plates (catalog number NL51041 0) were loaded with 100 pL of MicroScint40 (catalog number 6013641, Packard Bioscience, Meriden, CT, USA). After the 1 h incubation, 60 pL of the reaction mixture were transferred to the charcoal plates, which were then assembled on top of the DYNEX plates using Centrifuge Alignment Frames (catalog number MACF09604, Millipore). The unbound labeled ethanolamine was centrifuged through to the bottom plate (5 min at 2000 rpm), which was preloaded with the scintillant, as described above. The plates were sealed and left at rt for 1 h before counting on a Hewlett Packard TopCount. Results for compounds tested in this assay are presented in Table 2.
Table 2 Ex. Assay 1 B Assay 2 Ex. Assay 1 B Assay 2 tC50 (nM) ICro (nM) IC5o (nM) IC50 (nM) 13 1900 10000 37 0.4 11 14 100 4500 38 0.2 2 770 4000 52 0.1 1.5 18 290 220 56 0.8 2 Physical Chemical Properties Solubility determinations were made by mixing the test compound in water at 5 mg/mL, 1 mg/mL, and 0.1 mg/mL concentrations. The pH of the resulting solutions was 7-8.5. Results for compounds tested are presented in Table 3.
Table 3 Ex. Solubility Comp. Ex. 1 < 0.1 mg/mL
Comp. Ex. 2 < 0.1 mg/mL
37 > 5.0 mg/mL
38 > 5.0 mg/mL
56 > 5.0 mg/mL
Pharmacokinetic Testing For each test compound, two male Sprague Dawley Rats (Charles River Laboratories; approx. 300 g body weight) were used. Animals were individually housed, provided food and water ad libitum, and were maintained on a 12 h light and dark cycle. Animals received from the vendor were surgically cannulated by the vendor with right jugular vein and left carotid artery catheters. Animals were acclimatized for at least 5 days after receipt from the vendor prior to investigations.
Animals received a bolus intravenous dose of the test compound at a dose of 1 mg/mL in a volume of 2 mL/kg via the right jugular vein catheter. The intravenous dosing solution was prepared in 55% pharmasolve, 20% cremophor, and 75% physiological saline, or 100% saline adjusted to pH 8Ø
Following intravenous administration, blood was collected (sampled 0.35 mL per time point from the left carotid artery catheter) at 0.083, 0.25, 0.5, 1, 2, 4, and 6 h post-dose. Blood was collected into tubes containing EDTA and stored at 4 C for not more than 2 h. The samples were centrifuged at 10,000 rpm in a micro-centrifuge for 5 min to obtain a plasma fraction. The plasma was stored at between -20 and -80 C until processed for analysis. These samples were analyzed by LC-MS/MS to determine the plasma level of the compound.
Plasma level vs. time plots were created and WinNonlin (Pharsight Corp.) was used to analyze the data. A non-compartmental pharmacokinetic model was used to determine the pharmacokinetic parameters, including clearance, volume of distribution (Vd), and half-life (t112). Data for compounds tested in this assay are presented in Table 4.
Table 4 Ex. Clearance (L/hr/kg) Vd (L/kg) t1,2 (hr) Comp. Ex. 1 5.9 27.3 3.23 Comp. Ex. 2 3.8 22.9 3.49 37 0.46 0.86 1.24 38 6.7 1.4 0.15 While the invention has been illustrated by reference to exemplary and preferred embodiments, it will be understood that the invention is intended not to be limited to the foregoing detailed description, but to be defined by the appended claims as properly construed under principles of patent law.
anxiety, pain, sleep disorders, eating disorders, inflammation, or movement disorders (e.g., multiple sclerosis).
Symptoms or disease states are intended to be included within the scope of "medical conditions, disorders, or diseases." For example, pain may be associated with various diseases, disorders, or conditions, and may include various etiologies. Illustrative types of pain treatable with a FAAH-modulating agent according to the invention include cancer pain, postoperative pain, GI
tract pain, spinal cord injury pain, visceral hyperalgesia, thalamic pain, headache (including stress headache and migraine), low back pain, neck pain, musculoskeletal pain, peripheral neuropathic pain, central neuropathic pain, neurogenerative disorder related pain, and menstrual pain. HIV wasting syndrome includes associated symptoms such as appetite loss and nausea.
Parkinson's disease includes, for example, levodopa-induced dyskinesia.
Treatment of multiple sclerosis may include treatment of symptoms such as spasticity, neurogenic pain, central pain, or bladder dysfunction. Symptoms of drug withdrawal may be caused by, for example, addiction to opiates or nicotine.
Nausea or emesis may be due to chemotherapy, postoperative, or opioid related causes. Treatment of sexual dysfunction may include improving libido or delaying ejaculation. Treatment of cancer may include treatment of glioma. Sleep disorders include, for example, sleep apnea, insomnia, and disorders calling for treatment with an agent having a sedative or narcotic-type effect. Eating disorders include, for example, anorexia or appetite loss associated with a disease such as cancer or HIV infection/AIDS.
In a treatment method according to the invention, an effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition.
An "effective amount" means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment.
Effective amounts or doses.of the agents of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. An exemplary dose is in the range of from about 0.001 to about 200 mg of agent per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.
Once improvement of the patient's disease, disorder, or condition has occurred, the dose may be adjusted for preventative or maintenance treatment.
For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Patients may, however, require interrnittent treatment on a long-term basis upon any recurrence of symptoms.
In addition, the agents of the invention may be used in combination with additional active compounds in the treatment of the above conditions. The additional compounds may be coadministered separately with an agent of Formula (f) or included with such an agent as an additional active ingredient in a pharmaceutical composition according to the invention. In an exemplary embodiment, additional active compounds are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by FAAH activity, such as another FAAH modulator or a compound active against another target associated with the particular condition, disorder, or disease.
The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an agent according to the invention), decrease one or more side effects, or decrease the required dose of the agent according to the invention. In one illustrative embodiment, a composition according to the invention may contain one or more additional active ingredients selected from opioids, NSAIDs (e.g., ibuprofen, cyclooxygenase-2 (COX-2) inhibitors, and naproxen), gabapentin, pregabalin, tramadol, acetaminophen, and aspirin.
The agents of the invention are used, alone or in combination with one or more other active ingredients, to formulate pharmaceutical compositions of the invention. A pharmaceutical composition of the invention comprises: (a) an effective amount of a pharmaceutical agent in accordance with the invention;
and (b) a pharmaceutically acceptable excipient.
A"pharrriaceutically acceptable excipient" refers to a substance that is not toxic, biologically intolerable, or otherwise biologically unsuitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of a pharmaceutical agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
Delivery forms of the pharmaceutical compositions containing one or more dosage units of the pharmaceutical agents may be prepared using suitable pharmaceutical excipients and compounding techniques now or later known or available to those skilled in the art. The compositions may be administered in the inventive methods by oral, parenteral, rectal, topical, or ocular routes, or by inhalation.
.
The preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or -'I8 -suppositories. Preferably, the compositions are formulated for intravenous infusion, topical administration, or oral administration.
For oral administration, the compounds of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. To prepare the oral compositions, the agents may be formulated to yield a dosage of, e.g., from about 0.05 to about 50 mg/kg daily, or from about 0.05 to about 20 mg/kg daily, or from about 0.1 to about 10 mg/kg daily.
Oral tablets may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, active ingredient may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the active ingredient with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water;
preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
The agents of this invention may also be administered by non-oral routes.
For example, the compositions may be formulated for rectal administration as a suppository. For parenteral use, including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in par`enterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms will be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses may range from about 1 to g/kg/minute of agent, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
For topical administration, the agents may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle.
Another mode of administering the agents of the invention may utilize a patch formulation to affect transdermal delivery.
Agents may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.
Exemplary agents useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation -z0-below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product.
Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent.
Unless otherwise specified, the variables are as defined above in reference to Formula (I).
SCHEME A
OP
Pd coupling f Bu3Sn N (III) (R')(RZ)-(Ar)-X
OP
R1 O 1) Deprotection (Ar)-{ I I (I) Ra' ~-N 2) Oxidation (IV) Referring to Scheme A, stannanes of formula (III), where P is a suitable hydroxyl protecting group, are prepared as previously described (Boger, J.
Med.
Chem. 2005, 48, 1849). Stannanes (II!) are coupled with various aryl or heteroaryl halides using Stille coupling procedures. Preferred conditions utilize Pd(PPh3)4 or Pd(P(t-Bu)3)2 as the catalyst. Compounds of formula (IV) are then deprotected (for example, where P is a silyl protecting group, with a silyl deprotecting agent such as TBAF) and oxidized to compounds of Formula (I) using oxidizing agents such as Dess-Martin periodinane or TPAP/NMO.
SCHEME B
Ra b N-(Ar)-R (VII) R
Ra Reduction \ N-(Ar)-R (VIII) 02N-(Ar)-R H2N-(Ar)-R -= b , (V) (VI) R -SO2 O R\
N-(Ar)-R (IX) R 'N Rb-~O
Referring to Scheme B, compounds of formula (V) may be obtained according to the methods shown in Scheme A. The nitro group may be reduced to an amino group (formula (VI)) using standard nitro reduction methods, such as exposure to SnC12 or by hydrogenation in the presence of a Pd catalyst. Amines (VI) may be alkylated via alkylation or reductive amination protocols to form amines (VII). Amines (VI) may be alternatively sulfonylated with the appropriately substituted sulfonyl chlorides to form compounds of formula (VIII). Reaction of amines (VI) with suitably substituted acid chlorides or via peptide coupling with appropriate acids (e.g. in the presence of HOAt/EDCI) generate amides (IX).
Installation of the Ra substituent may be accomplished before (via alkylation or reductive amination) or after (via alkylation) the sulfonylation/acylation step. One skilled in the art will recognize that Formula (I) includes compounds of formulae (VI), (VII), (VIII), and (IX).
SCHEME C
Hydrolysis Alkylation AcO-(Ar)-R -~- HO-(Ar)-R (C1-6alkyi)-O-(Ar)-R
(X) (XI) (XII) Referring to Scheme C, acetates of formula (X), where R is defined as in Scheme B, may be obtained according to the methods shown in Scheme A.
Deprotection of the acetate group, using, for example, a base such as LiOH or NaOMe, gives the corresponding alcohols (XI). These alcohols may in turn be converted to ethers of formula (XII) by treatment with an appropriate alkyl halide in the presence of a base, or with an appropriate alcohol under Mitsunobu conditions (for example, PPh3/DEAD). One skilled in the art will recognize that Formula (I) includes compounds of formulae (XI) and (XII).
SCHEME D
Hydrolysis Amide Formation (C~-4alkyt)02C-(Ar)-R ----- HO2C-(Ar)-R Rb(Ra)NOC-(Ar)-R
(XIII) (XIV) (XV) Referring to Scheme D, esters of formula (XIII), where R is defined as in Scheme B, and prepared according to Scheme A, may be hydrolyzed to acids (XIV) using a base such as LiOH. Acids (XIV) may be converted to their corresponding amides (XV) by reaction with a suitable amine under peptide coupling conditions (e.g. HOAt/EDCI). One skilled in the art will recognize that Formula (!) includes compounds of formulae (XIII), (XIV), and (XV).
One skilled in the art will recognize that transformations depicted for R' may analogously be performed for R2.
SCHEME E
OMe O
N O
~I ~
MeONJ N
(XVI) O O
HN~ O
O~N=J N
H (XV I I) Referring to Scheme E, pyrimidines (XVI), prepared according to Scheme A, may be converted to uracils (XVII) by treatment of a demethylating agent such as TMSI. One skilled in the art wilt recognize that Formula (I) includes compounds of formulae (XVI) and (XVII).
The following examples are provided to further illustrate the invention and various preferred embodiments.
Examples Chemistry:
In obtaining the characterization data described in the examples below, the following analytical protocols were followed as indicated.
NMR spectra were obtained on Bruker model DRX spectrometers. The format of the 'H NMR data below is: chemical shift in ppm downfield of the tetramethylsifane reference (multiplicity, coupling constant J in Hz, integration).
Silica gel was used for all chromatographic purification unless otherwise noted. Where solutions were "concentrated", they were concentrated using a rotary evaporator under reduced pressure. Unless otherwise specified, reaction solutions were stirred at room temperature (rt) under a nitrogen atmosphere.
Mass spectra were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in either positive or negative modes as indicated.
Calculated mass (mass calcd.) corresponds to the exact mass.
Thin-layer chromatography was performed using Merck= silica gel 60 F254 2.5 cm x 7.5 cm 250 pm or 5.0 cm x 10.0 cm 250 pm pre-coated silica gel plates.
Preparative thin-layer chromatography was performed using EM Science silica gel 60 F254 20 cm x 20 cm 0.5 mm pre-coated plates with a 20 cm x 4 cm concentrating zone.
Reversed-phase HPLC was performed on a Hewlett Packard HPLC Series 1100, with a Phenomenex Luna C18 (5 pm, 4.6x150 mm) column. Detection was done at,%= 230, 254 and 280 nm. The flow rate was 1 mL/min. The gradient was 10 to 99% acetonitrile/water (0.05% trifluoroacetic acid) over 5.0 min.
General Procedure A. 2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (1 equiv), Pd(PPh3)4 (0.1 equiv), and aryl halide (2 equiv) were dissolved in anhydrous 1,4-dioxane (8 mL) and the mixture was warmed to reflux for 24 h under argon. The mixture was diluted with EtOAc, washed with saturated aqueous NaCI and dried over Na2SO4. Evaporation in vacuo yielded the crude coupling product that was purified by flash chromatography (Si02).
General Procedure B. 2-(1-(tert Butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (1 equiv), Pd(P(tBu)3)2 (0.1 equiv), CsF (2.2 equiv) and aryl halide (2 equiv) were dissolved in anhydrous 1,4-dioxane (2 mL) and the mixture was warmed at 100 C in a sealed tube and stirred for 24 h. The mixture was diluted with EtOAc, washed with saturated aqueous NaCi and dried over Na2SO4. Evaporation in vacuo yielded the crude coupling product that was purified by flash chromatography (Si02).
General Procedure C. The TBS ether (1 equiv) was dissolved in THF (3 mL), treated with Bu4NF (1 M in THF, 1.2 equiv) and stirred at room temperature for h under argon. The reaction mixture was diluted with EtOAc, washed with saturated aqueous NaCI and dried over Na2SO4. Evaporation in vacuo yielded the crude alcohol that was filtered through a short silica gel pad. The silica gel pad was washed with 10% EtOAc/hexanes followed by 60% EtOAc/hexanes to afford the alcohol which required no further purification. The alcohol (1 equiv) was dissolved in CH2CI2 (3 mL) or THF (3 mL) and Dess-Martin periodinane (1.5 equiv) was added. The mixture was stirred at room temperature for 2 h before silica gel was added and the reaction mixture was evaporated in vacuo to afford the crude ketone absorbed on silica gel. This mixture was subsequently purified by flash chromatography (SiOa) yielding the pure a-ketoheterocycle.
General Procedure D. The TBS ether (1 equiv) was dissolved in THF (3 mL), treated with Bu4NF (I M in THF, 1.2 equiv) and stirred at room temperature for h under argon. The reaction mixture was diluted with EtOAc, washed with saturated aqueous NaCI and dried over Na2SO4. Evaporation in vacuo yielded the crude alcohol that was filtered through a short silica gel pad. The silica gel pad was washed with 10% EtOAc/hexanes followed by 60% EtOAc/hexanes to afford the alcohol which required no further purification. The alcohol (1 equiv) was dissolved in CH2CI2 (3 mL) and tetrapropylammonium perruthenate (TPAP, 0.2 equiv), N-morpholine oxide (NMO, 1.5 equiv) and 4 A molecular sieves (1.5 x weight of alcohol) were added. The mixture was stirred at room temperature for h before it was filtered through a pad of diatomaceous earth. This crude ketone was subsequently purified by flash chromatography (SiOZ) yielding the pure a-ketoheterocycle.
General Procedure E. The ester (1 equiv) was dissolved in a mixture of 3:2 THF/H20 (2 mL: 1.3 mL) and LiOH (3 equiv) was added. The reaction mixture stirred for 2 h at room temperature before the mixture was made acidic with the addition of aqueous 1 N HCI. The solution was diluted with EtOAc and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (3x). The combined organic extracts were washed with saturated aqueous NaCI and dried over Na2SO4. Evaporation in vacuo yielded the crude acid that was purified by chromatography (SiOZ).
General Procedure F. The nitro compound (1 equiv) was dissolved in EtOAc (2 mL) and 10% Pd/C (0.1 equiv) was added. The reaction mixture was stirred at room temperature under H2 (1 atm) for 4 h before it was filtered through a pad of diatomaceous earth. Evaporation in vacuo yielded the crude aniline that was purified by chromatography (Si02).
General Procedure G. 2-(7-Phenylheptanoyl)oxazole-5-carboxylic acid (1 equiv), EDCI (2 equiv) and HOAt (2 equiv) were dissolved in DMF (1 mL). The reaction mixture was cooled to 0 C and stirred for 10 min before the amine (1.5 equiv) was added. The reaction mixture was stirred for 16 h under argon, diluted with H20 and made acidic with the addition of aqueous 2 N HCI. The solution was extracted with ether (3x) and the ether layers were combined, washed with saturated aqueous NaCi and dried over Na2SO4. Evaporation in vacuo yielded the crude amide that was purified by chromatography (Si02).
General Procedure H. The pyrimdine (1 equiv) and Nal (4 equiv) were dissolved in MeCN (3 mL) before TMSCI (4 equiv) was added. The reaction was stirred for 16 h at room temperature under argon before it was diluted with EtOAc, washed with saturated aqueous NaZSZO3 and washed with saturated aqueous NaCI.
Evaporation in vacuo yielded the crude uracil that was purified by flash chromatography (Si02).
General Procedure 1. The TBS ether (1 equiv) was dissolved in THF (3 mL), treated with Bu4NF (1 M in THF, 1.2 equiv) and the mixture was stirred at room temperature for 2 h under argon. The reaction mixture was diluted with EtOAc, washed with saturated aqueous NaCI and dried over NaaSO4. Evaporation in vacuo yielded the crude alcohol that was purified by flash chromatography (Si02).
General Procedure J. The ester (1 equiv) was dissolved in methanolic ammonia (1 mL) and stirred for 2 h at room temperature under argon. Evaporation in vacuo yielded the crude alcohol that was purified by chromatography (Si02).
' N ~ O
Example 1; 1-(5-(2-Nitrophenyi)oxazol-2-yl)-7-phenylheptan-1-one Step 1 : 2-(1-(tert ButyldimethylsiiyloxY)-7_phenylheptyl)-5-(2-nitrophenYl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (75 mg, 0.113 mmol) and 1-iodo-2-nitrobenzene following General Procedure A. Flash chromatography (3-10% EtOAc/hexanes) yielded the title compound as a yellow oil (58 mg, 97%):'H NMR (CDCI3, 300 MHz) 8 7.82 (dd, 1H, J = 9.2, 6.3 Hz), 7.70 (dd, 1 H, J = 9.3, 6.0 Hz), 7.67-7.64 (m, 1 H), 7.51-7.49 (m, 1 H), 7.32-7.25 (m, 3H), 7.19-7.16 (m, 3H), 4.82 (t, 1 H, J = 6.7 Hz), 2.60 (t, 2H, J = 7.5 Hz), 1.88-1.86 (m, 2H), 1.64-1.60 (m, 2H), 1.35-1.26 (m, 6H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H); 13 C NMR (CDCI3, 75 MHz) 8 171.5, 152.5, 151.1, 148.0, 137.6, 134.6, 134.5, 133.6, 133.4, 131.3, 130.7, 129.6, 127.1, 73.8, 41.6, 41.1, 36.6, 34.3, 34.3, 30.9, 30.1, 23.4, 0.2, 0Ø
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(2-nitrophenyl)oxazole (54 mg, 0.109 mmo!) following General Procedure C. Flash chromatography (20%
EtOAc/hexanes) yielded the title compound as a light yellow solid (29 mg, 71 %):
1 H NMR (CDCI3, 400 MHz) 8 7.86 (d, 1 H, J= 8.8 Hz), 7.75 (dd, I H, J = 9.2, 6.4 Hz), 7.65-7.62 (m, 1 H), 7.55-7.51 (m, 1 H), 7.44 (s, 1 H), 7.21-7.18 (m, 2H), 7.11-7.09 (m, 3H), 3.00 (t, 2H, J = 7.6 Hz), 2.53 (t, 2H, J = 7.6 Hz), 1.71-1.68 (m, 2H), 1.58-1.54 (m, 2H), 1.36-1.32 (m, 4H); 13C NMR (CDCI3, 100 MHz) 6 188.4, 157.9, 148.8, 147.9, 142.9, 133.1, 131.0, 130.6, 128.6, 128.4, 128.2, 125.8, 124.9, 121.2, 39.4, 36.1, 31.5, 29.2, 29.2, 24.0; MALDI-FTMS m/z 379.1651 (M +
H+, C22H23N204, requires 379.1652).
Example 2; 1-(5-(3-Nitrophenyl)oxazot-2-yl)-7-phenylheptan-l-one Step 1: 2-(1-(tert-Butyld imethylsilyloxY)_7-phenylheptyl)-5-(3-nitrophenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyfoxy)-7-phenylheptyi)-5-(tributyistannyl)oxazole (191 mg, 0.288 mmol) and 1-iodo-3-nitrobenzene following General Procedure A. Flash chromatography (5-10% EtOAc/hexanes) yielded the title compound as a yellow oil (128 mg, 90%): ' H NMR (CDCI3, 500 MHz) S 8.57-8.56 (m, 1H), 8.26-8.24 (m, 1 H), 8.03-8.02 (m, 1 H), 7.69 (t, 1 H, J= 16 Hz), 7.51 (s, 1 H), 7.36-7.33 (m, 2H), 7.26-7.23 (m, 3H), 4.94 (t, 1 H, J= 6.0 Hz), 2.67.(t, 2H, J= 7.5 Hz), 2.05-1.96 (m, 2H), 1.72-1.66 (m, 2H), 1.57-1.44 (m, 6H), 0.99 (s, 9H), 0.19 (s, 3H), 0.09 (s, 3H); 13C NMR (CDCI3, 125 MHz) S 166.4, 149.3, 149.2, 143.2, 130.5, 130.1, 130.0, 128.8, 128.6, 126.0, 124.2, 123.2, 119.4, 69.1, 36.8, 36.3, 31.8, 29.6, 26.1, 26.1, 25.5, 18.6, -4.5, -4.6.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyi)-5-(3-nitrophenyl)oxazole (126 mg, 0.255 mmol) following General Procedure C. Flash chromatography (5-20%
EtOAc/hexanes) yielded the title compound as a light yellow solid (75 mg, 77%):
'H NMR (CDCI3, 500 MHz) S 8.67 (s, 1 H), 8.35-8.33 (m, 1 H), 8.19-8.17 (m, 1 H), 7.77-7.74 (m, 2H), 7.36-7.33 (m, 2H), 7.26-7.24 (m, 3H), 3.18 (t, 2H, J = 7.5 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.90-1.84 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.46 (m, 4H);
13C NMR (CDCI3, 125 MHz) 5 188.7, 158.0, 152.0, 149.2, 143.1, 131.1, 130.8, 128.8, 128.8, 127.7, 126.1, 125.8, 124.7, 120.5, 39.6, 36.3, 31.7, 29.4, 29.4, 24.3;
MALDI-FTMS m/z 379.1652 (M + H+, C22H23N204, requires 379.1652).
N
/
OZN /~ O
O
Example 3; 1-(5-(4-Nitrophenyl)oxazol-2-yl)-7-phenylheptan-1-one=
Step 1; 2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-nitrophenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (90 mg, 0.136 mmol) and 1-iodo-4-nitrobenzene following General Procedure A. Flash chromatography (5-10% EtOAc/hexanes) yielded the title compound as a yellow oil (67 mg, 100%): 1H NMR (CDCI3r 500 MHz) 5 8.28 (d, 2H, J= 9.0 Hz), 7.78 (d, 2H, J= 9.0 Hz), 7.48 (s, 1 H), 7.27-7.24 (m, 2H), 7.17-7.15 (m, 3H), 4.87 (t, 1 H, J = 6.0 Hz), 2.59 (t, 2H, J = 7.8 Hz), 2.00-1.88 (m, 2H), 1.67-1.58 (m, 2H), 1.40-1.34 (m, 6H), 0.91 (s, 9H), 0.11 (s, 3H), 0.01 (s, 3H);13C NMR (CDCI3i 125 MHz) S 166.6, 149.0, 147.1, 142.6, 1-33.7, 128.3, 128.2, 125.5, 125.1, 124.4, 124.3, 68.6, 36.3, 35.8, 31.3, 29.1, 25.6, 25.6, 25.0, 18.1, -5.0, -5.1.
Step 2. The title compound was prepared from 2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)-5-(4-nitrophenyl)oxazole (65 mg, 0.131 mmol) following General Procedure C. Flash chromatography (5-20%
EtOAc/hexanes) yielded the title compound as a light yellow solid (25 mg, 50%):
1H NMR (CDCI3, 600 MHz) S 8.32 (d, 2H, J = 8.4 Hz), 7.93 (d, 2H, J= 8.4 Hz), 7.69 (s, 1 H), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 3.09 (t, 2H, J= 7.2 Hz), 2.60 (t, 2H, J= 7.2 Hz), 1.79-1.77 (m, 2H), 1.65-1.62 (m, 2H), 1.44-1.39 (m, 4H);
NMR (CDC13r 150 MHz) 5 189.2, 158.8, 152.5, 149.0, 143.5, 133.3, 129.2, 129.1, 127.3, 126.7, 126.5, 125.4, 40.0, 36.7, 32.1, 29.8, 29.8, 24.7; MALDI-FTMS m/z 379.1645 (M + H+, C22H23N204, requires 379.1652).
N
(/~~
Example 4; 7-Phenyl-l-(5-(2-(2,2,2-trifluoroacetyl)phenyl)oxazol-2-yi)heptan-1-one Step 1 : 1 :~2-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenyl)-2,2,2-trifluoroethanone, The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (63 mg, 0.095 mmol) and 1-(2-chlorophenyl)-2,2,2-trifluoroethanone following General Procedure B. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (43 mg, 83%):'H NMR (CDCI3, 600 MHz) S 7.70-7.64 (m, 3H), 7.51-7.48 (m, 1 H), 7.26-7.24 (m, 3H), 7.16-7.15 (m, 3H), 4.79 (t, 1 H, J = 6.0 Hz), 2.58 (t, 2H, J = 7.5 Hz), 1.88-1.81 (m, 2H), 1.61-1.60 (m, 2H), 1.35-1.25 (m, 6H), 0.87 (s, 9H), 0.07 (s, 3H), -0.05 (s, 3H); 13C NMR (CDCI3, 150 MHz) S 186.2 (d, J= 35 Hz), 167.0, 149.4, 143.7, 133.6, 133.6, 131.1, 129.5, 129.4, 129.3, 129.1, 128.3, 126.4, 125.6, 116.4 (d, J= 285 Hz), 69.4, 37.3, 36.8, 32.3, 30.0, 26.5, 26.5, 25.8, 19.0, -4.2, -4.4.
Step 2. The title compound was prepared from 1-(2-(2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)oxazol-5-y1)phenyl)-2,2,2-trifluoroethanone (43 mg, 0.079 mmol) following General Procedure C. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (26 mg, 76%):
'H NMR (CDC13, 600 MHz) 8 7.80-7.79 (m, 2H), 7.72 (t, 1 H, J = 7.2 Hz), 7.60 (t, 1 H, J= 7.2 Hz), 7.47 (s, 1 H), 7.28-7.25 (m, 2H), 7.18-7.15 (m, 3H), 3.05 (t, 2H, J= 7.8 Hz), 2.60 (t, 2H, J= 7.8 Hz), 1.78-1.73 (m, 2H), 1.66-1.61 (m, 2H), 1.42-1.39 (m, 4H); 13C NMR (CDCI3, 150 MHz) S 188.9, 184.6 (d, J= 36 Hz), 158.6, 152.0, 143.6, 134.2, 131.3, 130.8, 130.8, 130.1, 129.3, 129.1, 129.1, 127.9, 127.7, 126.5, 116.5 (d, J= 290 Hz), 40.0, 36.7, 32.2, 29.8, 29.8, 24.6; MALDI-FTMS m/z 430.1626 (M + H+, ~'i24H23F3NO3, requires 430.1624).
Example 5; 7-Phenyl-l-(5-(3-(2,2,2-trifluoroacetyl)phenyl)oxazol-2-yl)heptan-1-one Step 1: 1-(3-(2-(1-(tert-Butyld imethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenyl)-2,2,2-trifluoroethanone. The title compound was prepared from 2-(1-(tert-butyldimethylsiiyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (37 mg, 0.056 mmol) and 1-(3-chlorophenyl)-2,2,2-trifluoroethanone following General Procedure B. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a clear oil (26 mg, 87%): 'H NMR (CDC13i 600 MHz) S 8.31 (s, IH), 8.01-7.94 (m, 2H), 7.61 (t, 1 H, J= 7.2 Hz), 7.38 (s, 1 H), 7.27-7.24 (m, 2H), 7.16-7.14 (m, 3H), 4.84 (t, 1 H, J = 6.0 Hz), 2.58 (t, 2H, J= 7.5 Hz), 1.95-1.88 (m, 2H), 1.64-1.55 (m, 2H), 1.37-1.34 (m, 6H), 0.90.(s, 9H), 0.10 (s, 3H), 0.00 (s, 3H); 13C
NMR (CDCI3, 150 MHz) S 181.0 (d, J = 35 Hz), 166.7, 150.2, 143.6, 131.5, 130.7, 130.4, 130.2, 129.2, 129.1, 129.0, 126.4, 126.2, 124.0, 117.7 (d, J = 289 Hz), 69.5, 37.2, 36.8, 32.3, 30.0, 26.6, 26.6, 26.0, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 1-(3-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenyl)-2,2,2-trifluoroethanone (36 mg, 0.066 mmol) following General Procedure C. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (17 mg, 61%):
' H NMR (CDCI3, 600 MHz) S 8.41 (s, 1 H), 8.12-8.08 (m, 2H), 7.69-7.63 (m, 2H), 7.28-7.26 (m, 2H), 7.17-7.16 (m, 3H), 3.09 (t, 2H, J= 7.8 Hz), 2.61 (t, 2H, J
= 7.8 Hz), 1.79-1.76 (m, 2H), 1.66-1.61 (m, 2H), 1.44-1.39 (m, 4H); 13C NMR (CDC13, 150 MHz) 8 189.2, 180.7 (d, ,! = 35 Hz), 158.4, 153.0, 143.5, 132.5, 131.8, 131.6, 130.9, 129.3, 129.1, 127.3, 126.5, 125.9, 117.7 (d, J= 289 Hz), 40.0, 36.7, 32.2, 29.9, 29.9, 24.8; MALDI-FTMS mfz 428.1475 (M - H', C24H21F3N03, requires 428.1479).
~ ~ / N
F3COC ~ O O
Example 6; 7-Phenyl-l-(5-(4-(2,2,2-trifluoroacetyl)phenyl)oxazol-2-yl)heptan-1-one Step 1: 1-(4-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)ghenyl)-2,2,2-trifluoroethanone. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributyistannyl)oxazole (55 mg, 0.083 mmol) and 1-(4-bromophenyl)-2,2,2-trifluoroethanone following General Procedure A. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (31 mg, 69%):'H NMR (CDCI3, 600 MHz) 8 8.13-8.12 (d, 2H, J = 7.8 Hz), 7.80-7.79 (d, 2H, J = 7.8 Hz), 7.49 (s, 1 H), 7.27-7.24 (m, 2H), 7.16-7.15 (m, 3H), 4.86 (t, 1 H, J= 6.0 Hz), 2.59 (t, 2H, J= 7.5 Hz), 1.95-1.91 (m, 2H), 1.61-1.59 (m, 2H), 1.37-1.34 (m, 6H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H); 13C NMR (CDC13, 150 MHz) 8 180.4 (d, J= 35 Hz), 167.5, 150.3, 143.6, 135.1, 131.8, 129.9, 129.2, 129.1, 126.5, 126.1, 125.1, 117.6 (d, J= 290 Hz), 69.6, 37.3, 36.8, 32.3, 30.0, 36.6, 26.6, 26.0, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 1-(4-(2-(1-(te-t-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenyl)-2,2, 2-trifluoroethanone (29 mg, 0.053 mmol) following General Procedure C. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (14 mg, 62%):
'H NMR (CDCI3, 600 MHz) S 8.16 (d, 2H, J = 7.8 Hz), 7.94 (d, 2H, J = 7.8 Hz), 7.69 (s, 1 H), 7.28-7.25 (m, 2H), 7.17-7.16 (m, 3H), 3.10 (t, 2H, J = 7.8 Hz), 2.61 (t, 2H, J= 7.8 Hz), 1.79-1.76 (m, 2H), 1.66-1.62 (m, 2H), 1.44-1.39 (m, 4H);
NMR (CDC13, 150 MHz) 8 189.2, 180.6 (d, J= 35 Hz), 152.9, 143.5, 133.7, 131.9, 131.8, 131.2, 129.3, 129.1, 127.4, 126.5, 126.4, 117.7 (d, J= 290 Hz), 40.0, 36.7, 32.1, 29.9, 29.9, 24.8; MALDI-FTMS m/z 428.1474 (M - H", C24H2lF3NO3, requires 428.1479).
N
Example 7; 2-(2-(7-Phenylheptanoy!)oxazol-5-yl)benzamide Step 1: 2-(2-(1-(tert-Butvidimethylsilyloxy)-7-phenylheptyi)oxazol-5-yl)benzamide. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (52 mg, 0.083 mmol) and 2-bromobenzamide following General Procedure A. Flash chromatography (20-40% EtOAc/hexanes) yielded the title compound as a white solid (39 mg, 100%): 'H NMR (CDC13, 600 MHz) 57.70 (d, 1H, J= 7.8 Hz), 7.60 (s, 1 H), 7.51-7.48 (m, 2H), 7.39-7.36 (m, 1 H), 7.25-7.23 (m, 2H), 7.16-7.13 (m, 3H), 6.48 (br s, 1 H), 6.19 (br s, 1 H), 4.88 (t, 1 H, J = 6.0 Hz), 2.57 (t, 2H, J = 7.5 Hz), 1.93-1.87 (m, 2H), 1.59-1.56 (m, 2H), 1.44-1.30 (m, 6H), 0.87 (s, 9H), 0.09 (s, 3H), -0.02 (s, 3H); 13C NMR (CDC13, 150 MHz) 5 170.4, 143.6, 137.6, 134.4, 132.5, 131.3, 130.7, 129.7, 129.2, 129.1, 128.6, 128.5, 126.4, 120.1, 69.3, 37.3, 36.8, 32.2, 30.0, 26.6, 26.6, 25.9, 19.0, -4.0, -4.3.
Step 2. The title compound was prepared from 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzamide (39 mg, 0.079 mmol) following General Procedure C. Flash chromatography (20-70% EtOAc/hexanes) yielded the title compound as a white solid (9 mg, 30%):'H NMR (CDCI3, 500 MHz) 5 7.89 (d, 1 H, J = 7.5 Hz), 7.68 (s, 1 H), 7.63-7.61 (m, 2H), 7.56-7.53 (m, 1 H), 7.36-7.34 (m, 2H), 7.26-7.25 (m, 3H), 6.16 (br s, 1 H), 5.99 (br s, 1 H), 3.15 (t, 2H, J = 7.8 Hz), 2.69 (t, 2H, J= 7.8 Hz), 1.87-1.81 (m, 2H), 1.75-1.69 (m,-2H), 1.54-1.47 (m, 4H); 13C NMR (CDC13, 125 MHz) S 188.8, 171.5, 157.7, 152.0, 143.1, 134.9, 131.0, 130.2, 128.9, 128.8, 128.7, 128.1, 127.5, 126.0, 124.7, 39.5, 36.3, 31.7, 29.4, 29.4, 24.3; MALDI-FTMS m/z 377.1858 (M + H+, C23H25N203, requires 377.1860).
HZNOC N
Q
Example 8; 3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzamide Step 1; 3-(2-(1-(tert-Butyidimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzamide. The title compound was prepared from 2-(1-(tert butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (72 mg, 0.109 mmol) and 3-bromobenzamide following General Procedure A. Flash chromatography (10-40% EtOAc/hexanes) yielded the title compound as a white solid (52 mg, 96%): 'H. NMR (CD30D, 600 MHz) b 8.23 (s, 1 H), 8.03 (s, 1 H), 7.83 (m, 1 H), 7.53 (m, 1 H), 7.35 (m, 1 H), 7.18-7.09 (m, 5H), 3.30 (t, 1 H, J=
6.0 Hz), 2.53 (t, 2H, J = 7.5 Hz), 1.92-1.86 (m, 2H), 1.65-1.55 (m, 2H), 1.34-1.29 (m, 6H), 0.87 (s, 9H), 0.09 (s, 3H), -0.03 (s, 3H); 13C NMR (CD3QD, 150 MHz) 5 166.2, 151.6, 143.3, 136.6, 135.4, 131.3, 130.8, 128.8, 128.7, 126.9, 126.1, 124.0, 122.9, 122.6, 69.2, 36.8, 36.3, 32.0, 29.6, 29.5, 25.7, 25.6, 18.5, -5.3, -5.4.
Step 2. The title compound was prepared from 3-(2-(1-(tert butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-y!)benzamide (48 mg, 0.097 mmol) following General Procedure C. Flash chromatography (10-70% EtOAc/hexanes) yielded the title compound as a white solid (15 mg, 41 %): "H NMR (THF-d8, 600 MHz) 8 8.31 (s, 1 H), 7.94-7.92 (m, I H), 7.76 (s, 1 H), 7.54-7.52 (m, 2H), 7.22-7.19 (m, 2H), 7.16-7.14 (m, 2H), 7.11-7.08 (m, 1 H), 6.77 (br s, 1 H), 3.05 (t, 2H, J = 7.8 Hz), 2.60 (t, 2H, J = 7.8 Hz), 1.74-1.71 (m, 2H), 1.66-1.61 (m, 2H), 1.44-1.39 (m, 4H); 13C NMR (THF-d8, 150 MHz) 6 187.7, 167.6, 158.4, 154.2, 143.3, 136.8, 129.7, 129.6, 129.0, 128.8, 128.0, 128.0, 126.2, 125.1, 124.7, 39.3, 36.6, 32.3, 29.9, 29.8, 24.6; MALDI-FTMS m/z 377.1864 (M + H+, C23H25N203, requires 377.1860). -Ip,N ~ I -O
Example 9; 4-(2-(7-Phenylheptanoyl)oxazot-5-yl)laenzamide Step 1; 4-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylhepty1)oxazol-5-yi)benzamide. The title compound was prepared from 2-(1-(tert butyldimethylsiiyioxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (47 mg, 0.071 mmol) and 4-bromobenzamide following General Procedure A. Flash chromatography (30-50% EtOAc/hexanes) yielded the title compound as a white solid (29 mg, 83%): 'H NMR (CDCI3, 600 MHz) S 7.67 (d, 2H, J = 7.8 Hz), 7.57 (d, 2H, J= 7.8 Hz), 7.38 (s, 1 H), 7.25-7.24 (m, 2H), 7.15-7.14 (m, 3H), 6.16 (br s, 2H), 4.84 (t, 1 H, J = 6.0 Hz), 2.58 (t, 2H, J = 7.5 Hz), 1.93-1.87 (m, 2H), 1.58-1.56 (m, 2H), 1.46-1.34 (m, 6H), 0.88 (s, 9H), 0.09 (s, 3H), -0.01 (s, 3H);
NMR (CDC13i 150 MHz) 6 169.5, 143.6, 132.8, 129.9, 129.5, 129.2, 129.1, 129.0, 128.3, 127.7, 126.4, 125.0, 69.4, 37.3, 36.8, 32.2, 30.0, 26.6, 26.0, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 4-(2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)oxazol-5-y!)benzamide (29 mg, 0.059 mmol) following General Procedure C. Flash chromatography (40-80% EtOAc/hexanes) yielded the title compound as a white solid (7 mg, 32%): 'H NMR (CD3OD, 500 MHz) 8 8.08 (d, 2H, J = 8.5 Hz), 8.02 (d, 2H, J = 8.5 Hz), 7.93 (s, 1 H), 7.32-7.29 (m, 2H), 7.25-7.20 (m, 3H), 3.17 (t, 2H, J = 7.8 Hz), 2.69 (t, 2H, J= 7.8 Hz), 1.85-1.80 (m, 2H), 1.75-1.70 (m, 2H), 1.55-1.45 (m, 4H); 13C NMR (CD3OD, 125 MHz) 8 188.6, 168.8, 160.8, 158.0, 153.5, 142.9, 128.6, 128.4, 128.2, 127.7, 125.6, 125.4, 125.2, 38.8, 35:8, 31.5, 29.0, 29.0, 23.9; MALDI-FTMS m/z 377.1864 (M +
H+, C23H25N203i requires 377.1860).
Example 10; 1-(5-(2-Fluorophenyl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 2-(1-(tert Butyldimethylsilyloxy)-7-phenylhep It )-L 5-(2-fluorouhenvl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (75 mg, 0.113 mmol) and 1-fluoro-2-iodobenzene following General Procedure A. Flash chromatography (2% EtOAc/hexanes) yielded the title compound as a clear oil (52 mg, 98%): 1 H NMR (CDCI3, 400 MHz) 7.77 (dt, 1 H, J = 9.6, 5.6 Hz), 7.42 (d, 1 H, J= 4.0 Hz), 7.31-7.21 (m, 4H), 7.18-7.13 (m, 4H), 4.85 (t, 1 H, J = 6.0 Hz), 2.59 (t, 2H, J= 7.2 Hz), 1.90-1.93 (m, 2H), 1.62-1.60 (m, 2H), 1.33-1.36 (m, 6H), 0.90 (s, 9H), 0.11 (s, 3H), 0.00 (s, 3H); 13C NMR (CDCI3, 100 MHz) S 169.7, 163.4 (d, J = 250 Hz), 150.6, 157.9, 134.4 (d, J 8.3 Hz), 133.5, 133.3, 131.2 (d, J
=
12.6 Hz), 131.1, 131.1, 130.7, 129.6 (d, J= 3.2 Hz), 121.7 (d, J= 13.0 Hz), 120.1 (d, J = 20.9 Hz), 73.8, 41.6, 41.0, 36.5, 34.3, 34.3, 30.9, 30.3, 23.3, 0.2, 0Ø
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(2-fluorophenyl)oxazole (40 mg, 0.086 mmol) following General Procedure C. Flash chromatography (10-20%
EtOAc/hexanes) yielded the title compound as a clear oil (20 mg, 67%): 'H NMR
(CDCI3, 500 MHz) S 8.02 (dt, 1 H, J = 9.2, 5.9 Hz), 7.73 (d, 1 H, J = 4.0 Hz), 7.49-7.46 (m, 1 H), 7.37-7.34 (m, 3H), 7.27-7.23 (m, 4H), 3.18 (t, 1 H, J = 7.4 Hz), 2.69 (t, 2H, J = 7.7 Hz), 1.89-1.85 (m, 2H), 1.73-1.71 (m, 2H), 1.52-1.47 (m, 4H);
NMR (CDCI3, 125 MHz) S 188.8, 159.5 (d, J= 251 Hz), 157.1, 149.0, 143.1, 131.6 (d, J = 8.3 Hz), 128.8, 128.7, 128.2 (d, J= 13.4 Hz), 127.6, 127.6, 126.0, 125.3 (d, J= 3.4 Hz), 116.5 (d, J= 20.6 Hz), 115.8 (d, J= 12.7 Hz), 39.5, 36.3, 31.7, 29.4, 29.4, 24.4; MALDI-FTMS m/z 352.1704 (M + H+, C22H23FN02, requires 352.1707).
F / \ ~ N \ !
`- O
Example 11; 1-(5-(3-Fluorophenyt)oxazol-2-yl)-7-phenytheptan-l-one Step 1 : 2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(3-fluorophenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyioxy)-7-phenylheptyl)-5-(tributylstannyl)oxazoie (75 mg, 0.113 mmol) and 1-fluoro-3-iodobenzene following General Procedure A. Flash chromatography (2% EtOAc/hexanes) yielded the title compound as a clear oil (53 mg, 98 Ao):'H NMR (CDCI3, 400 MHz) 7.43-7.33 (m, 3H), 7.29-7.25 (m, 3H), 7.18-7.15 (m, 3H), 7.04-7.00 (m, 1 H), 4.83 (t, 1 H, J= 6.0 Hz), 2.59 (t, 2H, J= 7.6 Hz), 1.96-1.88 (m, 2H), 1.63-1.59 (m, 2H), 1.47-1.35 (m, 6H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H); 13 C NMR (CDCI3, 100 MHz) 8 170.4, 167.3 (d, J = 245 Hz), 155.1, 147.9, 135.6 (d, J= 8.4 Hz), 135.2 (d, J= 8.5 Hz), 133.5, 133.3, 130.7, 127.7, 124.9 (d, J= 3.0 Hz), 120.2 (d, J= 21.1), 116.2 (d, J= 23.5), 73.8, 41.5, 41.0, 36.5, 34.3, 34.3, 30.8, 30.2, 23.3, 0.2, 0Ø
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(3-fluorophenyl)oxazole (50 mg, 0.106 mmol) following General Procedure C. Flash chromatography (2-10%
EtOAc/hexanes) yielded the title compound as a white solid (26 mg, 68%): 'H
NMR (CDCI3, 500 MHz) 8 7.65-7.60 (m, 2H), 7.56-7.49 (m, 2H), 7.37-7.34 (m, 2H), 7.27-7.25 (m, 3H), 7.21-7.18 (m, 1 H), 3.16 (t, 2H, J= 7.5 Hz), 2.69 (t, 2H, J= 7.5 Hz), 1.88-1.85 (m, 2H), 1..74-1.71 (m, 2H), 1.52-1.48 (m, 4H); 13C NMR
(CDCI3, 125 MHz) 8 188.7, 163.4 (d, J = 245 Hz), 157.7, 153.3, 143.1, 131.3 (d, J= 8.4 Hz), 129.1 (d, J= 8.5 Hz), 128.8, 128.7, 126.0, 124.9, 121.4 (d, J= 3.0 Hz), 117.3 (d, J= 21.1), 112.7 (d, J= 23.8), 39.5, 36.3, 31.7, 29.4, 29.4, 24.4;
MALDI-FTMS m/z 352.1706 (M + H+, C22H23FN02, requires 352.1707).
N
O
Example 12; 1-(5-(4-Fluorophenyl)oxazol-2-yi)-7-phenylheptan-l-one Step 1; 2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-fluorophenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (81 mg, 0.122 mmol) and 1-fluoro-4-iodobenzene following General Procedure A. Flash chromatography (2% EtOAc/hexanes) yielded the title compound as a clear oil (40 mg, 61 %): ' H NMR (CDCI3, 600 MHz) S 7.63-7.61 (m, 2H), 7.27-7.24 (m, 4H), 7.17-7.11 (m, 4H), 4.88 (t, 1 H, J= 6.0 Hz), 2.58 (t, 2H, J= 7.5 Hz), 1.95-1.90 (m, 2H), 1.62-1.59 (m, 2H), 1.46-1.35 (m, 6H), 0.89 (s, 9H), 0.10 (s, 3H), -0.01 (s, 3H); 13C NMR (CDCI3, 150 MHz) 8 165.9, 163.5 (d, J= 258 Hz), 151.5, 143.6, 129.2, 129.1, 127.1 (d, J= 8.3 Hz), 126.4, 124.8, 1 2 1 . 1 , 117.0 (d, J= 22 Hz), 69.4, 37.3, 36.8, 32.3, 30.0, 26.6, 26.6, 25.9, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)-5-(4-fluorophenyl)oxazole (60 mg, 0.110 mmol) following General Procedure C. Flash chromatography (2-10%
EtOAc/hexanes) yielded the title compound as a white solid (24 mg, 62%): ' H
NMR (CDC13, 600 MHz) 5 7.77-7.74 (m, 2H), 7.44 (s, I H), 7.28-7.25 (m, 2H), 7.17-7.14 (m, 3H), 3.07 (t, 2H, J= 7.8 Hz), 2.60 (t, 2H, J = 7.8 Hz), 1.78-1.76 (m, 2H), 1.65-1.62 (m, 2H), 1.45-1.38 (m, 4H); 13C NMR (CDCI3, 150 MHz) S 189.2, 164.6 (d, J= 250 Hz), 158.0, 154.2, 143.5, 129.3, 129.1, 128.3 (d, J= 8.6 Hz), 126.5, 124.2, 123.9, 117.2 (d, J= 22 Hz), 39.8, 36.7, 32.2, 29.9, 29.9, 24.9;
MALDI-FTMS m/z 352.1701 (M + H+, C22H23FN02, requires 352.1707).
N
Example 13; 1-(5-(2-Methoxyphenyl)oxazol-2-yl)-7-phenylheptan-l-one Step 1: 2-(1-(tert-Butyldimethyisilyloxy)-7-phenylheptyl)-5-(2-methoxvphenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (140 mg, 0.211 mmol) and 1-iodo-2-methoxybenzene following General Procedure A. Flash chromatography (2% EtOAc/hexanes) yielded the title compound as a white solid (78 mg, 77%): ' H NMR (CDCI3, 400 MHz) 8 7.81 (dd, 1 H, J = 9.2, 6.0 Hz), 7.49 (s, 1 H), 7.30-7.27 (m, 3H), 7.19-7.16 (m, 3H), 7.07-7.05 (m, 1 H), 6.99 (d, 1 H, J=
8.4 Hz), 4.85 (t, 1 H, J= 6.8 Hz), 3.98 (s, 3H), 2.58 (t, 2H, J= 8.0 Hz), 1.95-1.91 (m, 2H), 1.63-1.60 (m, 2H), 1.38-1.34 (m, 6H), 0.91 (s, 9H), 0.11 (s, 3H), 0.00 (s, 3H); *13C NMR (CDCI3: 100 MHz) S 168.8, 160.7, 152.7, 148.0, 134.0, 133.5, 133.3, 131.0, 130.9, 130.7, 125.9, 122.4, 115.9, 73.8, 60.5, 41.6, 41.1, 36.6, 34.3, 34.3, 30.9, 30.3, 23.3, 0.2, 0Ø
Step 2. The title compound was prepared from 2-(1-(tert butyldimethylsilyloxy)-7-phenylheptyl)-5-(2-methoxyphenyl)oxazole (78 mg, 0.163 mmol) following General Procedure C. Flash chromatography (10% 1 -EtOAc/hexanes) yielded the title compound as a white solid (42 mg, 71 %): ' H
NMR (CDCI3, 400 MHz) 8 7.92 (dd, 1 H, J = 9.2, 6.0 Hz), 7.68 (s, 1 H), 7.37-7.33 (m, 1 H), 7.26-7.22 (m, 2H), 7.16-7.14 (m, 3H), 7.04 (t, 1 H, J= 7.2 Hz), 6.97 (d, 1 H, J = 8.4 Hz), 3.95 (s, 3H), 3.06 (t, 2H, J = 7.2 Hz), 2.58 (t, 2H, J = 7.6 Hz), 1.77-1.73 (m, 2H), 1.63-1.59 (m, 2H), 1.42-1.37 (m, 4H); 13C NMR (CDCI3, 100 MHz) S 188.6, 156.7, 156.2, 151.1, 142.9, 131.0, 128.6, 128.4, 128.0, 127.4, 125.8, 121.2, 116.1, 111.1, 55.7, 39.2, 36.1, 31.5, 29.2, 29.2, 24.3; MALDI-FTMS
m/z 364.1904 (M + H+, C23H26NO3, requires 364.1907).
H3CQ \ ~ ~ \ I
Example 14; 1-(5-(3-Methoxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 2-(1-(tert-Butvidimethylsilyloxv)-7-phenylheptyl)-5-(3-methoxyphenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (190 mg, 0.287 mmol) and 1-iodo-3-methoxybenzene following General Procedure A. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (107 mg, 78%): 'H NMR (CDCI3, 500 MHz) S 8.40 (m, 1 H), 8.07 (d, 1 H, J= 8.0 Hz), 7.90 (d, 1 H, J = 8.0 Hz), 7.58 (t, 1 H, J= 7.6 Hz), 7.44 (s, 1 H), 7.35-7.32 (m, 2H), 7.25-7.23 (m, 3H), 4.93 (t, 1 H, J = 6.0 Hz), 4.03 (s, 3H), 2.67 (t, 2H, J = 7.4 Hz), 2.04-1.99 (m, 2H), 1.75-1.68 (m, 2H), 1.45-1.37 (m, 6H), 1.00 (s, 9H), 0.20 (s, 3H), 0.10 (s, 3H); 13C NMR (CDCI3, 125 MHz) 8 166.9, 165.7, 150.6, 143.1, 131.4, 129.7, 129.5, 128.9, 128.8, 128.6, 128.6, 126.1, 125.8, 123.5, 69.1, 52.7, 36.8, 36.4, 31.8, 29.6, 29.6, 26.2, 25.6, 14.1, -4.5, -4.6.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(3-methoxyphenyl)oxazole (105 mg, 0.219 mmol) following General Procedure C. Flash chromatography (5-20%
EtOAc/hexanes) yielded the title compound as a white solid (53 mg, 66%): 'H
NMR (CDCl3, 500 MHz) 5 8.48 (m, 1 H), 8.15 (d, 1 H, J = 7.5 Hz), 8.03 (d, 1 H, J
8.5 Hz), 7.66 (s, 1 H), 7.62 (t, 1 H, J = 8.0 Hz), 7.34 (t, 2H, J = 8.5 Hz), 7.26-7.24 (m, 3H), 4.04 (s, 3H), 3.17 (t, 2H, J = 7.6 Hz), 2.69 (t, 2H, J== 7.6 Hz), 1.87-1.83 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.46 (m, 4H); 13C NMR (CDC13, 125 MHz) S
188.7, 166.6, 157.7, 153.5, 143.1, 131.6, 131.2, 129.8, 129.7, 128.8, 128.7, 127.5, 126.7, 126.0, 124.9, 52.9, 39.5, 36.3, 31.7, 29.4, 29.4, 24.4; MALDI-FTMS
m/z 364.1908 (M + H+, C23H26N03, requires 364.1907).
/ ~ ~ N
H3CO ~
Example 15; 1-(5-(4-Methoxyphenyl)oxazol-2-yl)-7-phenylheptan-l-one Step 1; .2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-methoxyphenyl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributykstannyl)oxazole (67 mg, 0.101 mmol) and 1-bromo-4-methoxybenzene following General Procedure B. Flash chromatography (5% EtOAc/hexanes) yielded the title compound as a clear oil (41 mg, 84%): 1 H NMR (CDCI3i 500 MHz) 6 7.66 (d, 2H, J = 9.0 Hz), 7.37-7.34 (m, 3H), 7.27-7.23 (m, 3H), 7.03 (d, 2H, J = 9.0 Hz), 4.91 (t, 1 H, J = 5.5 Hz), 3.93 (s, 3H), 2.68 (t, 2H, J = 7.5 Hz), 2.06-1.96 (m, 2H), 1.71-1.68 (m, 2H), 1.46-1.42 (m, 6H), 0.98 (s, 9H), 0.19 (s, 3H), 0.08 (s, 3H); 13C NMR (CDCI3, 125 MHz) 8 164.6, 160.2, 151.6, 143.2, 128.8, 128.7, 126.1, 126.0, 121.3, 120.3, 114.8, 69.1, 55.8, 36.8, 36.3, 31.9, 29.6, 26.2, 26.2, 25.6, 18.7, -4.5, -4.7.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-methoxyphenyl)oxazole (39 mg, 0.081 mmol) following General Procedure C. Flash chromatography (5-10%
EtOAc/hexanes) yielded the title compound as a white solid (18 mg, 60%): iH
NMR (CDCI3, 600 MHz) 87.70 (d, 2H, J= 9.0 Hz), 7.38 (s, 1 H), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 6.96 (d, 2H, J= 9.0 Hz), 3.85 (s, 3H), 3.06 (t, 2H, J=
7.2 Hz), 2.60 (t, 2H, J= 7.2 Hz), 1.79-1.75 (m, 2H), 1.65-1.61 (m, 2H), 1.44-1.37 (m, 4H); 13C NMR (CDCI3, 150 MHz) S 189.1, 161.8, 157.6, 155.3, 143.6, 129.3, 129.1, 127.8, 126.4, 123.2, 120.2, 115.4, 56.3, 39.7, 36.8, 32.2, 29.9, 29.9, 25.0;
MALDI-FTMS m/z 364.1908 (M + H+, C23H26NO3, requires 364.1907).
N
CO
GN Example 16; 2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzonitrile Step 1; 2-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzonitrile. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (60 mg, 0.091 mmol) and 2-bromobenzonitrile following General Procedure A. Flash chromatography (2-5% EtOAc/hexanes) yielded the title compound as a clear oil (35 mg, 81 %): 'H NMR (CDCI3i 600 MHz) 8 7.90 (s, 1 H), 7.85 (d, 1 H, J= 7.8 Hz), 7.74 (d, 1 H, J = 7.8 Hz), 7.66 (t, 1 H, J = 7.8 Hz), 7.40 (t, 1 H, J = 7.8 Hz), 7.27-7.25 (m, 2H), 7.16-7.15 (m, 3H), 4.87 (t, 1 H, J = 6.0 Hz), 2.59 (t, 2H, J =
7.8 Hz), 1.96-1.90 (m, 2H), 1.62-1.60 (m, 2H), 1.38-1.36 (m, 6H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H);13C NMR (CDCI3, 150 MHz) 8 166.7, 148.06, 143.6, 135.0, 134.1, 131.7, 129.2, 129.1, 129.0, 127.3, 126.9, 126.4, 124.2, 119.2, 108.3, 69.5, 37.3, 36.8, 32.3, 30.0, 26.6, 26.6, 26.0, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzonitrile (33 mg, 0.070 mmol) following General Procedure C. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (16 mg, 64%): 'H NMR (CDCI3, 600 MHz) S 8.12 (s, 1 H), 8.03 (d, 1 H, J = 8.4 Hz), 7.79 (d, 1 H, J = 7.8 Hz), 7.72 (t, 1 H, J = 7.8 Hz), 7.51 (t, 1 H, J = 7.8 Hz), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 3.11 (t, 2H, J = 7.2 Hz), 2.61 (t, 2H, J = 7.2 Hz), 1.79-1.77 (m, 2H), 1.65-1.62 (m, 2H), 1.44-1.41 (m, 4H); 13C NMR (CDCI3, 150 MHz) 5 189.3, 158.1, 150.7, 143.5, 135.1, 134.3, 130.5, 130.4, 129.3, 129.1, 128.8, 128.2, 126.5, 118.9, 109.4, 40.1, 36.7, 32.2, 29.8, 29.8, 24.7; MALDI-FTMS m/z 359.1750 (M + Ht, C23H23N202, requires 359.1754).
NC / N
Example 17; 3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzonitrile Step 1; 3-(2-(1-(tert-Butyfdimethylsilyloxy)-7-phenylheptyl)oxazol-5-yi)benzonitrile. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributyfstannyl)oxazofe (60 mg, 0.091 mmol) and 3-bromobenzonitrile following General Procedure A. Flash chromatography (2-5% EtOAc/hexanes) yielded the title compound as a clear oi1 (31 mg, 72%): 'H NMR (CDC13, 600 MHz) 8 7.91 (s, 1 H), 7.84 (d, 1 H, J = 7.8 Hz), 7.59 (d, 1 H, J = 7.8 Hz), 7.53 (t, 1 H, J = 7.8 Hz), 7.36 (s, 1 H), 7.27-7.24 (m, 2H), 7.16-7.15 (m, 3H), 4.83 (t, 1 H, J= 6.0 Hz), 2.58 (t, 2H, J= 7.8 Hz), 1.95-1.88 (m, 2H), 1.65-1.59 (m, 2H), 1.36-1.33 (m, 6H), 0.89 (s, 9H), 0.10 (s, 3H), -0.01 (s, 3H); 13C NMR (CDC13, 150 MHz) S 166.8, 149.8, 143.6, 132.3, 130.7, 130.2, 129.2, 129.1, 128.9, 128.3, 126.5, 124.2, 119.1, 114.2, 69.5, 37.3, 36.8, 32.3, 30.0, 26.6, 26.6, 26.0, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 3-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzonitrile (29 mg, 0.061 mmol) following General Procedure C. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (14 mg, 64%):'H NMR (CDCI3, 600 MHz) 5 8.05 (s, 1 H), 8.00 (d, 1 H, J = 7.8 Hz), 7.68 (d, 1 H, J= 7.8 Hz), 7.59-7.58 (m, 2H), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 3.08 (t, 2H, J = 7.2 Hz), 2.60 (t, 2H, J= 7.2 Hz), 1.78-1.76 (m, 2H), 1.64-1.62 (m, 2H), 1.43-1.39 (m, 4H); 13C
NMR (CDCl3i 150 MHz) 6 189.1, 158.4, 152.5, 143.5, 133.8, 133.8, 131.0, 130.0, 129.4, 129.3, 129.1, 128.9, 126.5, 125.9, 118.7, 114.6, 40.0, 36.7, 32.1, 29.9, 29:9, 24.8; MALDI-FTMS msz 359.1767 (M + H+, C23H23N202, requires 359.1754).
/ N
NC r-- O
O
Example 18; 4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzonitrile Step 1: 4-(2-(1-(tert-Butyldimethylsilyioxy)-7-phenylheptvl)oxazol-5-yI)benzonitrile.' The title compound was prepared from 2-(1-(terf-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (53 mg, 0.080 mmol) and 4-bromobenzonitrile following General Procedure A. Flash chromatography (5-10% EtOAc/hexanes) yielded the title compound as a clear oil (30 mg, 79%): 1H NMR (CDC13, 500 MHz) S 7.82-7.78 (m, 4H), 7.50 (s, 1 H), 7.36-7.33 (m, 2H), 7.26-7.23 (m, 3H), 4.93 (t, 1 H, J = 5.5 Hz), 2.67 (t, 2H, J = 7.5 Hz), 2.06-1.95 (m, 2H), 1.75-1.67 (m, 2H), 1.47-1.40 (m, 6H), 0.98 (s, 9H), 0.19 (s, 3H), 0.08 (s, 3H); 13C NMR (CDCI3, 125 MHz) 8 166.7, 149.7, 143.2, 133.2, 132.4, 128.8, 128.7, 126.0, 124.8, 124.8, 119.0, 112.0, 69.1, 36.8, 36.3, 31.8, 29.6, 28.3, 26.1, 25.5, 18.6, -4.5, -4.7.
Step 2. The title compound was prepared from 4-(2-('I -(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzonitrile (51 mg, 0.107 mmol) following General Procedure C. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a white solid (13 mg, 33%): 'H NMR (CDCI3, 600 MHz) S 7.87 (d, 2H, J = 8.4 Hz), 7.75 (d, 2H; J = 8.4 Hz), 7.63 (s, I H), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 3.08 (t, 2H, J = 7.2 Hz), 2.60 (t, 2H, J = 7.2 Hz), 1.79-1.75 (m, 2H), 1.65-1.61 (m, 2H), 1.44-1.37 (m, 4H); 13C NMR (CDCI3, 150 MHz) 6 189.2, 158.6, 152.8, 143.5, 133.8, 131.5, 129.3, 129.1, 126.8, 126.5, 126.5, 40.0, 36.7, 32.1, 29.9, 29.9, 24.8; MALDI-FTMS m/z 359.1755 (M + H+, C23H23N202, requires 359.1754).
N
Example 19; 2-(2-(7-Phenylheptanoyl)oxazol-5-y1)benzenesulfonamide Step 1; 2-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yI)benzenesulfonamide. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (71 mg, 0.107 mmol) and 2-iodobenzenesulfonamide following General Procedure A. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (25 mg, 44%): 'H NMR (CDCI3, 400 MHz) 5 8.18 (d, 1 H, J= 7.6 Hz), 7.62-7.59 (m, 2H), 7.54-7.51 (m, 1 H), 7.42-7.39 (m, 1 H), 7.36 (s, 1 H), 7.24-7.22 (m, 2H), 7.16-7.12 (m, 2H), 5.29 (ex s, 2H), 4.88 (t, 1 H, J = 6.7 Hz), 2.56 (t, 2H, J
= 7.6 Hz), 1.86-1.84 (m, 2H), 1.62-1.59 (m, 2H), 1.31-1.29 (m, 6H). 0.86 (s, 9H), 0.09 (s, 3H), 0.00 (s, 3H);13C NMR (CDCI3, 100 MHz) 8 170.7, 153.6, 148.0, 144.9, 137.9, 135.7, 134.6, 134.3, 133.6, 133.4, 133.3, 131.0, 130.8, 42.3, 41.1, 36.3, 34.9, 34.3, 34.3, 31.0, 30.0, 23.5, 0.4, 0Ø
Step 2. The title compound was prepared from 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzenesulfonamide (23 mg, 0.043 mmol) following General Procedure C. Flash chromatography (10-30 10 EtOAc/hexanes) yielded the title compound as a white solid (12 mg, 67%):'H
NMR (CDC13, 400 MHz) 8 8.19-8.17 (m, 1 H), 7.61-7.53 (m, 3H), 7.48 (s, 1 H), 7.20-7.19 (m, 2H), 7.12-7.10 (m, 3H), 5.50 (ex s, 2H), 3.04 (t, 2H, J= 7.2 Hz), 2.54 (t, 2H, J = 7.2 Hz), 1.70-1.69 (m, 2H), 1.58-1.56 (m, 2H), 1.37-1.33 (m, 4H);
13C NMR (CDCI3, 100 MHz) 8 189.2, 157.8, 152.1, 143.1, 141.2, 133.1, 131.1, 131.1, 130.0, 128.8, 128.7, 128.3, 127.4, 126.0, 39.0, 36.3, 31.7, 29.4, 29.4, 24.1;
MALDI-FTMS m/z 413.1537 (M + H+, C22H25N204S, requires 413.1529).
H2NO2S \ ~ N \ I
~ p ~ r Example 20; 3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzenesulfonamide Step 1: 3-(2-(1-(tert-Butvldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzenesulfonamide. The title compound was prepared from 2-(1-(tert butyldimethy(silyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (75 mg, 0.113 mmol) and 3-bromobenzenesulfonamide following General Procedure A. Flash chromatography (10-30% EtOAc/hexanes) yielded the title compound as a white solid (55 mg, 91%):'H NMR (CD3OD, 500 MHz) 8 8.24 (m, 1 H), 7.92 (d, 1 H, J=
8.0 Hz), 7.74 (d, 1 H, J = 8.0 Hz), 7.64 (t, 1 H, J = 7.6 Hz), 7.58 (s, 1 H), 7.24-7.20 (m, 2H), 7.14-7.13 (m, 3H), 4.88 (ex s, 2H), 3.32-3.31 (m, 1 H), 2.58 (t, 2H, J=
7.6 Hz), 1.98-1.86 (m, 2H), 1.69-1.60 (m, 2H), 1.38-1.34 (m, 6H), 0.90 (s, 9H), 0.12 (s, 3H), 0.00 (s, 3H); 13C NMR (CDCI3, 100 MHz) 8 165.9, 150.3, 142.7, 130.7, 128.9, 128.8, 128.6, 128.2, 128.2, 128.0, 125.4, 124.7, 122.3, 36.1, 35.6, 31.4, 28.9, 28.8, 28.0, 25.0, 24.9, 17.8, -6.0, -6.1.
Step 2. The title compound was prepared from 3-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzenesulfonamide (55 mg, 0.104 mmol) following General Procedure C. Flash chromatography (20-60%
EtOAc/hexanes) yielded the title compound as a white solid (27 mg, 65%): IH
NMR (CD3OD, 500 MHz) 8 8.41-8.40 (m, 1 H), 8.10-8.09 (m, 1 H), 8.03-8.01 (m, 1 H), 7.90 (s, 1 H), 7.74 (t, 1 H, J= 8.0 Hz),'7.31-7.28 (m, 2H), 7.23-7.17 (m, 3H), 3.17-3.14 (t, 2H, J = 7.5 Hz) 2.69-2.66 (t, 2H, J = 7.6 Hz), 1.85-1.79 (m, 2H), 1.74-1.68 (m, 2H), 1.54-1.44 (m, 4H); 13C NMR (CD3OD, 125 MHz) S 188.5, 157.9, 152.9, 145.4, 142.9, 130.2, 128.5, 128.4, 128.3, 128.1 127.2, 125.6, 125.2, 122.7, 38.8, 35.8, 31.5, 29.0, 29.0, 23.8; MALDI-FTMS m/z 413.1540 (M + H+, C22H25N204S, requires 413.1529).
/ ~ ~ N
HZN02S ~
O
Example 21; 4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzenesulfonamide Step 1; 4-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptYl)oxazol-5-yl)benzenesulfonamide. The title compound was prepared from 2-(1-(tert-' butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (63 mg, 0.095 mmol) and 4-bromobenzenesulfonamide following General Procedure A. Flash chromatography (2-20% EtOAc/hexanes) yielded the title compound as a white solid (41 mg, 82%): 1H NMR (CDC13, 500 MHz) S 8.05 (d, 2H, J = 8.5 Hz), 7.83 (d, 2H, J= 8.5 Hz), 7.49 (s,,1 H), 7.36-7.32 (m, 2H), 7.25-7.22 (m, 3H), 5.39 (s, 2H), 4.92 (t, 1 H, J = 6.0 Hz), 2.67 (t, 2H, J = 7.5 Hz), 2.03-1.96 (m, 2H), 1.74-1.67 (m, 2H), 1.46-1.38 (m, 6H), 0.97 (s, 9H), 0.18 (s, 3H), 0.07 (s, 3H); 13C NMR
(CDCI3, 125 M Hz) S 166.6, 149.9, 141.7, 132.8, 129.6, 128.8, 128.7, 128.4, 127.6, 126.0, 124.9, 124.5, 69.1, 36.8, 36.3, 31.8, 29.6, 26.1, 26.1, 25.5, 18.6, -4.5, -4.6.
Step 2. The title compound was prepared from 4-(2-(1-(tert butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-y!)benzenesulfonamide (39 mg, 0.074 mmol) following General Procedure C. Flash chromatography (40%
EtOAc/hexanes) yielded the title compound as a white solid (17 mg, 54%): 'H
NMR (CD3OD, 500 MHz) S 8.08-8.07 (m, 4H), 7.96 (s, 1H), 7.32-7.38 (m, 5H), 3.17 (t, 2H, J = 7.0 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.84-1.81 (m, 2H), 1.73-1.69 (m, 2H), 1.51-1.43 (m, 4H); 13C NMR (CD3OD, 125 MHz) 8 188.6, 158.1, 152.9, 142.9, 132.4, 130.5, 130.4, 128.4, 128.3, 127.1, 125.9, 125.6, 38.8, 35.8, 31.5, 29.0, 29.0, 23.8; MALDI-FTMS m/z 413.1539 (M + H+, Ca4H25NO4r requires 413.1529).
N
Co2CH3 0 Example 22; Methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate Step 1; Methyl 2-(2-(1-(tert-butyldimethVlsilyloxV)-7-phenylheptyl)oxazol-5-yl)benzoate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (166 mg, 0.251 mmol) and methyl 2-iodobenzoate following General Procedure A. Flash chromatography (2-20% EtOAc/hexanes) yielded the title compound as a clear oil (125 mg, 99%): 'H NMR (CDCI3, 400 MHz) 5 7.75 (d, 1 H, J= 7.6 Hz), 7.62 (d, 1 H, J = 8.0 Hz), 7.53 (t, 1 H, J = 7.6 Hz), 7.41 (t, 1 H, J = 7.6 Hz), 7.28-7.24 (m, 3H), 7.17-7.15 (m, 3H), 4.83 (t, 1 H, J= 6.8 Hz), 3.85 (s, 3H), 2.60 (t, 2H, J= 7.4 Hz), 1.92-1.90 (m, 2H), 1.64-1.60 (m, 2H), 1.38-1.33 (m, 6H), 0.90 (s, 9H), 0.11 (s, 3H), 0.00 (s, 3H); 13C NMR (CDCIa, 100 MHz) 8 173.5, 170.3, 154.6, 147.9, 136.5, 135.1, 135.0, 134.9, 133.7, 133.5, 133.4, 132.3, 130.7, 129.8, 73.8, 57.6, 41.6, 41.1, 36.6, 34.3, 34.3, 30.9, 30.1, 23.4, 0.2, 0Ø
Step 2. The title compound was prepared from methyl 2-(2-(1-(tert butyfdimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzoate (125 mg, 0.246 mmol) following General Procedure C. Flash chromatography (10-20% EtOAc/hexanes) yielded the title compound as a white solid (77 mg, 79%): 'H NMR (CDCI3: 400 MHz) 5 7.81 (dd, 1 H, J = 9.2, 6.4 Hz), 7.66 (dd, 1 H, J = 9.2, 6.4 Hz), 7.57-7.44 (m, 3H), 7.26-7.22 (m, 2H), 7.15-7.13 (m, 3H), 3.85 (s, 3H), 3.05 (t, 2H, J =
7.6 Hz), 2.58 (t, 2H, J= 7.6 Hz), 1.76-1.71 (m, 2H), 1.63-1.59 (m, 2H), 1.40-1.37 (m, 4H); 13C NMR (CDCI3, 100 MHz) S 188.4, 167.9, 157.5, 152.7, 142.9, 131.8, 130.6, 130.4, 130.1, 129.7, 128.6, 128.4, 126.9, 126.4, 125.8, 52.8, 39.2, 36.1, 31.5, 29.2, 29.2, 24.1; MALDI-FTMS m/z 392.1854 (M + H4*, C24H26NO4, requires 392.1856).
H3COZC \ ~ N \ I
Example 23; Methyl 3-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate Step 1; Methyl 3-(2-(1-(tert-butyldimethylsityloxy)-7-phenvlheptyl)oxazol-5-y)benzoate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstanny{)oxazole (188 mg, 0.284 mmol) and methyl 3-bromobenzoate following General Procedure A. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (110 mg, 76%): ' H NMR (CDCI3i 500 MHz) S 8.40 (m, 1 H), 8.07 (d, 1H, J= 8.0 Hz), 7.90 (d, 1 H, J = 8.0 Hz), 7.58 (t, '! H, J = 7.6 Hz), 7.44 (s, 1 H), 7.35-7.32 (m, 2H), 7.25-7.23 (m, 3H), 4.93 (t, 1 H, J = 6.0 Hz), 4.03 (s, 3H), 2.67 (t, 2H, J= 7.4 Hz), 2.04-1.99 (m, 2H), 1.75-1.68 (m, 2H), 1.45-1.37 (m, 6H), 1.00 (s, 9H), 0.20 (s, 3H), 0.10 (s, 3H); 13C NMR (CDCI3, 125 MHz) 5 166.9, 165.7, 150.6, 143.1, 131.4, 129.7, 129.5, 128.9, 128.8, 128.6, 128.6, 126.1, 125.8, 123.5, 69.1, 52.7, 36.8, 36.4, 31.8, 29.6, 29.6, 26.2, 25.6, 14.1, -4.5, -4.6.
Step 2. The title compound was prepared from methyl 3-(2-(1-(tert-butyldirnethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzoate (106 mg, 0.209 mmol) following General Procedure C. Flash chromatography (10-20% EtOAc/hexanes) yielded the title compound as a white solid (64 mg, 77%):'H NMR (CDCI3, 500 MHz) 8 8.48 (m, 1 H), 8.15 (d, 1 H, J = 7.5 Hz), 8.03 (d, 1H, J = 8.5 Hz), 7.66 (s, 1 H), 7.62 (t, 1 H, J= 8.0 Hz), 7.34 (t, 2H, J = 8.5 Hz), 7.26-7.24 (m, 3H), 4.04 (s, 3H), 3.17 (t, 2H, J= 7.6 Hz), 2.69 (t, 2H, J= 7.6 Hz), 1.87-1.83 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.46 (m, 4H);13C NMR (CDCI,, 125 MHz) 8 188.7, 166.6, 157.7, 153.5, 143.1, 131.6, 131.2, 129.8, 129.7, 128.8, 128.7, 127.5, 126.7, 126.0, 124.9, 52.9, 39.5, 36.3, 31.7, 29.4, 29.4, 24.4; MALDI-FTMS mfz 392.1860 (M + H+, C24H26N04, requires 392.1856).
N
r'igcOZC /:>
Example 24; Methyl 4-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate Step 1; Methyl 4-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzoate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (85 mg, 0.128 mmol) and methyl 4-bromobenzoate following General Procedure A. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (44 mg, 68%):'H NMR (CDCI3, 500 MHz) S 8.17 (d, 2H, J= 8.5 Hz), 7.77 (d, 2H, J = 8.5 Hz), 7.47 (s, 1 H), 7.36-7.33 (m, 2H), 7.26-7.23 (m, 3H), 4.93 (t, 1 H, J =
6.0 Hz), 4.02 (s, 3H), 2.67 (t, 2H, J= 7.5 Hz), 2.05-1.97 (m, 2H), 1.75-1.68 (m, 2H), 1.47-1.40 (m, 6H), 0.99 (s, 9H), 0.19 (s, 3H), 0.09 (s, 3H); 13C NMR
(CDCI3, 125 MHz) S 166.9, 166.2, 150.6, 143.2, 132.5, 130.7, 130.0, 128.8, 128.6, 126.0, 124.3, 124.1, 69.1, 52.6, 36.8, 36.3, 31.8, 29.6, 26.2, 26.2, 25.5, 18.6, -4.5, -4.7.
Step 2. The title compound was prepared from methyl 4-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)benzoate (42 mg, 0.083 mmol) following General Procedure C. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a white solid (24 mg, 75%): 'H NMR (CDC13, 500 MHz) 5 8.20 (d, 2H, J = 8.5 Hz), 7.92 (d, 2H, J = 8.5 Hz), 7.69 (s, I H), 7.36-7.33 (m, 2H), 7.26-7.25 (m, 3H), 3.17 (t, 2H, J = 7.5 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.89-1.83 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.46 (m, 4H); 13C NMR (CDCI3, 125 MHz) 5 188.7, 166.6, 158.0, 153.4, 143.1, 131.5, 131.0, 130. 8, 128.8, 128.7, 126.0, 125.7, 125.5, 52.8, 39.4, 36.3, 31.7, 29.4, 29.4, 24.4; MALDI-FTMS m/z 392.1855 (M + H+, C24H26NO4, requires 392.1856).
N
O
O
COZH
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzoic acid The title compound was prepared from methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate (10 mg, 0.026 mmol) following General Procedure E. Preparative thin layer chromatography (EtOAc) yielded the title compound as a white solid (8 mg, 80%): 'H NMR (CD3OD, 600 MHz) 8 7.62 (s, 1 H), 7.22-7.19 (m, 2H), 7.14-7.09 (m, 3H), 3.04 (t, 2H, J= 7.5 Hz), 2.58 (t, 2H, J=
7.5 Hz), 1.71-1.68 (m, 2H), 1.62-1.59 (m, 2H), 1.41-1.32 (m, 4H);13C NMR
(CD3OD, 150 MHz) S 189.0, 159.4, 159.4, 143.3, 143.3, 134.6, 128.9, 128.7, 126.1, 39.6, 36.3, 32.0, 29.5, 29.4, 23.9; MALDI-FTMS m/z 378.1705 (M + H+, C23H24NO4, requires 378.1700).
O
Example 25; 3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzoic acid The title compound was prepared from methyl 3-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate (29 mg, 0.074 mmol) following General Procedure E. Preparative thin layer chromatography (EtOAc) yielded the title compound as a white= solid (22 mg, 79%): 'H NMR (THF-d8i 500 MHz) S 8.55 (s, 1 H), 8.16 (d, 1 H, J= 7.5 Hz), 8.09 (d, 1 H, J = 8.0 Hz), 7.88 (s, 1 H), 7.66 (t, I H, J= 8.0 Hz), 7.32-7.29 (m, 2H), 7.25-7.24 (m, 2H), 7.20-7.18 (m, 1 H), 3.15 (t, 2H, J= 7.0 Hz), 2.70 (t, 2H, J = 7.5 Hz), 1.84-1.81 (m, 2H), 1.77-1.71 (m, 2H), 1.54-1.49 (m, 4H); '3C NMR (THF-d8, 125 MHz) S 187.2, 166.9, 158.0, 153.4, 142.9, 133.1, 130.9, 129.4, 128.9, 128.5, 128.4, 127.8, 126.4,.125.7, 124.8, 38.9, 36.1, 31.8, 29.4, 29.4, 24.2; MALDI-FTMS m/z 378.1699 (M + H+, C23H24NO4, requires 378.1700).
/ ~ / N
HO2C ~ O
O
Example 26; 4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzoic acid The title compound was prepared from methyl 4-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate (10 mg, 0.026 mmol) following General Procedure E. Preparative thin layer chromatography (EtOAc) yielded the title compound as a white solid (8 mg, 83%):'H NMR (THF-ds, 500 MHz) S 8.21 (d, 2H, J = 8.5 Hz), 8.00 (d, 2H, J 8.5 Hz),. 7.90 (s, 1 H), 7.32-7.18 (m, 5H), 3.15 (t, 2H, J = 7.5 Hz), 2.70 (t, 2H, J 7.5 Hz), 1.80-1.71 (m, 2H), 1.52-1.50 (m, 2H), 1_44-1.38 (m, 4H); '3C NMR (THF-d8, 500 MHz) S 187.3, 165.4, 158.2, 153.2, 142.9, 132.2, 131.1, 130.7, 128.5, 128.4, 126.9, 125.7, 125.1, 38.9, 36.1, 31.6, 31.6, 29.4, 24.1; MALDI-FTMS m/z 378.1697 (M + H+, C23H24NO4, requires 378.1700).
N .
NH2 Exampl e 27; 1-(5-(2-Aminophenyl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 2-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-I aniline. The title compound was prepared from 2-(1-(tert-butyldimethylsilyfoxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (188 mg, 0.284 mmol) and 2-iodoaniline following General Procedure A. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a clear oil (122 mg, 90%): 'H NMR (CDCI3r 400 MHz) S 7.48 (dd, 1 H, J = 6.4, 9.3 Hz), 7.29-7.25 (m, 2H), 7.21 (s, 1 H), 7.18-7.13 (m, 4H), 6.84-6.80 (m, 1 H), 6.77-6.75 (m, 1 H), 4.85 (t, 1 H, J = 6.0 Hz), 3.81 (br s, 2H), 2.60 (t, 2H, J = 7.5 Hz), 1.97-1.89 (m, 2H), 1.68-1.59 (m,- 2H), 1.40-1.29 (m, 6H), 0.91 (s, 9H), 0.11 (s, 3H), 0.00 (s, 3H);13C NMR (CDCI3, 100 MHz) 8 169.1, 155_2, 148.5, 147.9, 134.8, 133.5, 133.4, 132.5, 130.7, 127.8, 123.8, 121.9, 118.4, 73.8, 41.6, 41.1, 36.5, 34.3, 34.3, 30.9, 30.3, 23.3, 0.2, 0Ø
Step 2. The title compound was prepared from 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)aniline (74 mg, 0.159 mmol) following General Procedure D. Flash chromatography (10-20% EtOAc/hexanes) yielded the title compound as a yellow oil (3 mg, 5%): 'H NMR (CDCI3, 500 MHz) S 7.65 (dd, 1 H, J = 6.2, 9.0 Hz), 7.57 (s, 1 H), 7.37-7.31 (m, 6H), 7.25 (m, 2H), 6.99-6.95 (m, 2H), 3.14 (t, 2H, J = 7.5 Hz), 2.69 (t, 2H, J= 7.5 Hz), 1.84=1.81 (m, 2H), 1.74-1.69 (m, 2H), 1.51-1.46 (m, 4H); 13C NMR (CDCI3, 125 MHz) S 188.5, 161.9, 156.9, 145.9, 143.1, 135.8, 131.6, 128.8, 128.7, 128.5, 126.0, 125.0, 120.1, 118.6, 39.3, 36.3, 31.7, 30.1, 29.4, 24.4; MALDI-FTMS m1z 349.1916 (M +
H C22H25N202, requires 349.1910).
H2N u f N \ I
O
r Example 28; 1-(S-(3-Aminophenyl)oxazol-2-yl)-7-phenylheptan-1-one The title compound was prepared from 1-(5-(3-nitrophenyl)oxazol-2-yl)-7-phenylheptan-l-one (22 mg, 0.159 mmol) following General Procedure F. Flash chromatography (10-30% EtOAc/hexanes) yielded the title compound as a yellow oil (10 mg, 40%): 'H NMR (CDC13r 500 MHz) S 7.52 (s, 1H), 7.37-7.31 (m, 3H), 7.26-7.20 (m, 5H), 6.82 (d, I H, J = 6.5 Hz), 3.56 (br s, 2H), 3.15 (t, 2H, J
= 7.5 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.88-1.82 (m, 2H), 1.75-1.69 (m, 2H), 1.55-1.46 (m, 4H); 13C NMR (CDC13, 125 MHz) 6 188.8, 157.4, 154.8, 147.1, 143.1, 130.5, 128.8, 128.7, 128.0, 126.0, 124.1, 117.2, 116.2, 111.9, 39.4, 36.3, 31.7, 29.5, 29.5, 24.5; MALDI-FTMS m/z 349.1915 (M + H+, C22H25N202, requires 349.1910)_ H2N/,~~ON
~
Q
Example 29; 1-(5-(4-Aminophenyl)oxazof-2-yl)-7-phenylheptan-l-one The title compound was prepared from 1-(5-(4-nitrophenyl)oxazol-2-yl)-7-phenylheptan-l-one (9 mg, 0.024 mmol) following General Procedure F.
Preparative thin layer chromatography (40% EtOAc/hexanes) yielded the title compound as a yellow oil (3 mg, 36%): 'H NMR (CD3OD, 500 MHz) S 8.07 (d, 2H, J = 8.5 Hz), 7.90 (s, 1 H), 7.56 (d, 2H, J = 8.4 Hz), 7.32-7.29 (m, 2H), 7.25-7.20 (m, 3H), 3_16 (t, 2H, J= 7.5 Hz), 2.69 (t, 2H, J= 7.5 Hz), 1.84-1.81 (m, 2H), 1.75-1.70 (m, 2H), 1.53-1.47 (m, 4H); '3C NMR (CD3OD, 125 MHz) S 188.6; 157.8, 153.0, 142.9, 128.4, 128.3, 127.0, 126.1, 125.6, 124.9, 123.5, 118.8, 38.8, 35.8, 31.6, 29.0, 29.0, 23.9; MALDI-FTMS m/z 349.1898 (M + H+, C22H25N202, requires 349.1910).
N
OH O
Exa m ple 30; 1 -(5-(2-Hydroxyphenyl)oxazol-2-yl)-7-phenyi hepta n-1-one Step 1; 2-(211-(tert-Buty,IdimethylsilYloxyZ 7-phenylhept rLI)oxazol-5-I henol. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazo(e (88 mg, 0.134 mmol) and 2-lodophenol following General Procedure A. Flash chromatography (10-30% EtOAc/hexanes) yielded the title compound as a clear oil (21 mg, 34%):'H NMR (CDCI3, 500 MHz) S 7.80-7.76 (m, 1 H), 7.62 (s, 1 H), 7.56 (br s, 1 H), 7.36-7.20 (m, 6H), 7.09-7.04 (m, 2H), 4.94 (t, 1 H, J = 6.0 Hz), 2.62 (t, 2H, J = 7.5 Hz), 2.05-1.93 (m, 2H), 1.68-1.65 (m, 2H), 1.47-1.32 (m, 6H), 0.97 (s, 9H), 0.17 (s, 3H), 0.07 (s, 3H);13C
NMR
(CDC13, 125 MHz) 8 166.3, 154.3, 148.8, 143.2, 130.0, 128.8, 128.6, 126.5, 126.0, 124.9, 119.2, 116.8, 115.6, 70.1, 37.0, 35.3, 31.8, 29.6, 26.2, 26.2, 25.5, 18.6, -4.4, -4.6.
Step 2. The title compound was prepared from 2-(2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenol (44 mg, 0.094 mmol) following General Procedure D. Preparative thin layer chromatography (30%
EtOAc) yielded the title compound as a white solid (3.4 mg, 12%):'H NMR
(CDC13, 500 MHz) 6 7.94-7.93 (m, 1 H), 7.82 (br s, 1 H), 7.38-7.34 (m, 4H), 7.26-7.25 (m, 3H), 7.12 (t, 1 H, J = 15.0 Hz), 7.00 (d, 1 H, J = 8.0 Hz), 3.18 (t, 2H, J =
7.5 Hz), 2.69 (t, 2H, J= 7.5 Hz), 1.89-1.83 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.46 (m, 4H);13C NMR (CDCIJ, 125 MHz) 8 188.8, 153.4, 151.7, 143.1, 131.3, 128.8, 128.7, 127.7, 127.5, 126.0, 121.7, 116.9, 114.5, 39.4, 36.3, 31.7, 29.5, 29.4, 24.5;
MALDI-FTMS m/z 350.1751 (M + H+, C22H24NO3, requires,350.1751).
HO / \ ~ N \ I
O
~
Example 31; 1-(5-(3-Hydroxyphenyl)oxazol-2-yl)-7-phenylheptan-l-one Step 1; 3-(2-(1-(tert-Butyldimethylsilvioxy)-7-phenylheptyl)oxazol-5-yl)phenol. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (99 mg, 0.149 mmol) and 3-iodophenol following General Procedure A. Flash chromatography (10-30% EtOAc/hexanes) yielded the title compound as a clear oil (29 mg, 41 %): 'H NMR (CDCI3, 500 MHz) & 7.79-7.77 (m, 1 H), 7.62 (s, 1 H), 7.56 (br s, 1 H), 7.39-7.35 (m, 2H), 7.29-7.24 (m, 4 H), 7.09-7.04 (m, 2H), 4.95 (t, 1 H, J= 6.0 Hz), 2.65 (t, 2H, J= 7.5 Hz), 2.05-1.95 (m, 2H), 1.67-1.64 (m, 2H), 1.47-1.34 (m, 6H), 0.97 (s, 9H), 0.17 (s, 3H), 0.07 (s, 3H);13C NMR (CDC13, 125 MHz) S 164.3, 153.1, 148.8, 143.2, 129.7, 128.8, 128.6, 126.5, 126.0, 124.8, 121.0, 116.8, 115.6, 69.0, 37.0, 36.3, 31.8, 30.1, 26.2, 26.2, 25.5, 18.6, -4.5, -4.7.
Step 2. The title compound was prepared from 3-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenol (29 mg, 0.062 mmol) following General Procedure D. Preparative thin layer chromatography (30%
EtOAc) yielded the title compound as a white solid (5.2 mg, 27%): 'H NMR
(CD3OD, 500 MHz) 8 7.74 (s, I H), 7.38-7.37 (m, 2H), 7.32-7.29 (m, 3H), 7.24-7.23 (m, 2H), 7.21-7.20 (m, 1 H), 6.95-6.94 (m, 1 H), 3.14 (t, 2H, J= 7.0 Hz), 2.69 (t, 2H, J= 7.5 Hz), 1.85-1.79 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.42 (m, 4H);
NMR (CD3OD, 125 MHz) S 188.5, 158.4, 157.4, 154.7, 142.9, 130.5, 128.4, 128.2, 128.2, 125.6, 123.9, 117.2, 116.5, 111.7, 38.7, 35.8, 31.5, 29.0, 29.0, 23.9;
MALDI-FTMS mAz 350.1752 (M + H+, C22H24NO3, requires 350.1751).
N
/ ~ /
H ~
O
Example 32; 1-(5-(4-Hydroxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 4-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenyiheptyl)oxazol-5-yi)phenyl acetate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylhepty!)-5-(tributylstannyl)oxazole (74 mg, 0.112 mmol) and 4-iodophenyl acetate following General Procedure A. Flash chromatography (5-20% EtOAc/hexanes) yielded the title compound as a clear oil (31 mg, 54%): 1 H NMR (CDCI3, 600 MHz) S 7.65 (d, 2H, J = 7.8 Hz), 7.27-7.24 (m, 3H), 7.16-7.14 (m, 5H), 4.82 (t, I H, J = 6.0 Hz), 2.58 (t, 2H, J = 7.5 Hz), 2.32 (s, 3H), 1.97-1.87 (m, 2H), 1.65-1.60 (m, 2H), 1.45-1.34 (m, 6H), 0.89 (s, 9H), 0.09 (s, 3H), -0.02 (s, 3H); 13C NMR (CDC13, 150 MHz) S 170.2, 165.8, 151.4, 151.3, 143.7, 129.2, 129.1, 126.7, 126.4, 126.2, 123.1, 122.4, 69.5, 37.3, 36.8, 32.3, 30.0, 26.6, 26.6, 26.0, 22.1, 19.1, -4.1, -4.2.
Step 2. The title compound was prepared from 4-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)phenyl acetate (30 mg, 0.059 mmol) following General Procedure D except the reaction with Bu4NF stirred for h. Preparative thin layer chromatography (40% EtOAc) yielded the title compound as a white solid (2.4 mg, 10%):'H NMR (CDC13, 600 MHz) S 7.66 (d, 2H, J= 8.4 Hz), 7.37 (s, 1 H), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 6.91 (d, 2H, J= 8.4 Hz), 3.06 (t, 2H, J= 7.5 Hz), 2.60 (t, 2H, J = 7.5 Hz), 1.79-1.75 (m, 2H), 1.65-1.61 (m, 2H), 1.43-1.38 (m, 4t-I);13C NMR (CD3OD, 125 MHz) 8188.7, 161.1, 159.2, 157.7, 143.1, 128.8, 128.7, 127.6, 126.0, 122.7, 120.0, 116.6, 39.3, 36.3, 31.7, 29.5, 29.4, 24.5; MALDI-FTMS m/z 350.1748 (M + H+, C22HP-4NO3, requires 350.1751).
~ ) 0~ \
~
Example 33; Methyl 6-(2-(7-phenytheptanoyl)oxazol-5-yl)picolinate Step 1; Methyl 6-(2-(1-(terf-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)picolinate. The title compound was prepared from 2-(1-(tert-butyldimethylsityloxy)-7-phenylheptyl)-5-(tributylstannyi)oxazole (94 mg, 0.142 mmol) and methyl 6-chloropicolinate following General Procedure A. Flash chromatography (5-10% EtOAc/hexanes) yielded the title compound as a clear oil (72 mg, 100%): 'H NMR (CDC13, 500 MHz) 8 8.12-8.10 (m, 1 H), 7.99 (t, 1H, J=
7.8 Hz), 7.90-7.89 (m, 1 H), 7.86 (s, 1 H), 7.35-7.32 (m, 2H), 7.25-7.22 (m, 3H), 4.94 (t, 1 H, J= 7.0 Hz), 4.10 (s, 3H), 2.67 (t, 2H, J= 7.5 Hz), 2.04-1.96 (m, 2H), 1.74-1.67 (m, 2H), 1.55-1.39 (m, 6H), 0.97 (s, 9H), 0.17 (s, 3H), 0.07 (s, 1 H);13C
NMR (CDC13, 125 MHz) S 166.5, 165.8, 150.3, 148.7, 148.2, 143.3, 138.4, 128.8, 128.6, 126.8, 126.0, 124.3, 122_5, 69.2, 53.4, 36.8, 36.3, 31.8, 29.6, 26.1, 26.1, 25.5, 14.0, -4.5, -4.7.
Step 2. The title compound was prepared from methyl 6-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)picolinate (70 mg, 0.138 mmol) following General Procedure C. Flash chromatography (10-30% EtOAc) yielded the title compound as a white solid (19 mg, 35%):'H NMR (CDCI3, 500 MHz) S
8.19 (d, 1 H, J= 7.0 Hz ), 8.12-8.09 (m, 2H), 8.06-8.03 (m, 1 H), 7.36-7.33 (m, 2H), 7.26-7.24 (m, 3H), 4.11 (s, 3H), 3.19 (t, 2H, J= 7.0 Hz), 2.69 (t, 2H, J=
7.5 Hz), 1.89-1.83 (m, 2H), 1.75-1.69 (m, 2H), 1.55-1.47 (m, 4H); 13C NMR (CDC13i 125 MHz) S 188.9, 165.5, 158.0, 152.7, 149.0, 147.0, 143.1, 138.7, 128.8, 128.7, 128.4, 126.0, 125.6, 123.7, 53.5, 39.6, 36.3, 31.7, 29.4, 29.4, 24.3; MALDI-FTMS
m/z 393.=1796 (M + H+, C23H25N204, requires 393.1809).
N /~
O
Example 34; Methyl 6-(2-(7-phenylheptanoyl)oxazol-5-yl'nicotinate Step 1: Methyl 6-(2-(1-(tert butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)nicotinate. The title compound was prepared from 2-(1-(tert-butyldimethylsi(yloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (83 mg, 0.125 mmol) and methyl 6-chloronicotinate following General Procedure A. Flash chromatography (5-10% EtOAc/hexanes) yielded the title compound as a clear oil (46 mg, 72%): ' H NMR (CDCI3, 500 MHz) 6 9.28 (d, 1 H, J= 2.0 Hz), 8.43 (dd, 1 H, J= 10.0, 6.0 Hz), 7.84 (s, 1 H), 7.78 (d, 1 H, J= 8.5 Hz), 7.35-7.32 (m, 2H), 7.25-7.22 (m, 3H), 4.95 (t, 1 H, J = 7.0 Hz), 4.04 (s, 3H), 2.67 (t, 2H, J = 7.5 Hz), 2.05-1.98 (m, 2H), 1.74-1.67 (m, 2H), 1.48-1.40 (m, 6H), 0.98 (s, 9H), 0.18 (s, 3H), 0.08 (s, 3H); 13C NMR (CDC13r 125 MHz) S 167.1, 165.8, 151.6, 151.0, 150.5, 143.2, 138.5, 128.8, 128.6, 127.9, 126.0, 125.0, 118.7, 69.2, 52.9, 36.9, 36.3, 31.8, 29.6, 26.1, 26.1, 25.5, 18.6, -4.5, -4.7.
Step 2. The title compound was prepared from methyl 6-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)nicotinate (44 mg, 0.086 mmol) following General Procedure C. Flash chromatography (10-20% EtOAc) yielded the title compound as a white solid (19 mg, 56%):'H NMR (CDCI3, 500 MHz) S
9.32 (d, 1 H, J= 2.0 Hz ), 8.48 (dd, 1 H, J= 8.5, 2.0 Hz), 8.06 (s, 1 H), 8.00 (d, 1 H, J = 8.5 Hz), 7.36-7.33 (m, 2H), 7.26-7.24 (m, 3H), 4.07 (s, 3H), 3.19 (t, 2H, J =
7.0 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.89-1.84 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.47 (m, 4H); 13C NMR (CDCI3, 125 MHz) 5 188.9, 165.5, 158.2, 152.8, 151.7, 149.8, 143.1, 138.7, 129.1, 128.8, 128.7, 126.3, 126.0, 120.1, 53.0, 39.6, 36.3, 31.7, 29.4, 29.4, 24.3; MALDI-FTMS m/z 393.1811 (M + H+, C23H25N204, requires 393.1809).
~ ~ / N
O
"~ O
Example 35; Methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)isonicotinate Step 1; Methyl 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-YI? isonicotinate. The title compound was prepared from 2-(1-(te+t-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (130 mg, 0.196 mmol) and methyl 2-chloroisonicotinate following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (72 mg, 71%): ' H NM R(C DCI3, 400 MHz) 8 8.77 (d, IH, J= 5.0 Hz), 8.20 (s, 1 H), 7.77 (dd, 1 H, J = 5.0, 1.5 Hz), 7.70 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 4.88 (dd, 1 H, J = 7.0, 5.9 Hz), 4.00 (s, 3H), 2.60 (t, 2H, J= 7.8 Hz), 1.95 (m, 2H), 1.61 (m, 2H), 1.36 (m, 4H), 0.92 (s, 9H), 0.11 (s, 3H)~, 0.02 (s, 3H); 13C NMR
(CDC13, 100 MHz) 8 166.2, 165.2, 150.7, 150.1, 148.4, 142.7, 138.3, 128.3, 128.2, 126.0, 125.5, 121.8, 118.3, 68.7, 52.8, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 18.2, -5.0, -5.1.
Step 2. The title compound was prepared from methyl 2-(2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)isonicotinate (36 mg, 0.071 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (15 mg, 56%): 1H
NMR (CDC13, 400 MHz) 5 8.82 (dd, 1 H, J = 5.0, 0.9 Hz), 8.39 (d, 1 H, J = 0.9 Hz), 7.93 (s, 1 H), 7.87 (dd, 1 H, J= 5.0, 1.4 Hz), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 4.02 (s, 3H), 3.13 (t, 2H, J = 7.5 Hz), 2.60 (t, 2H, J = 7.8 Hz), 1.80 (quint, 2H, J
7.3 Hz), 1.65 (quint, 2H, J = 7.4 Hz), 1.48-1.40 (m, 4H); '3C NMR (CDC13, 100 MHz) S 188.5, 164.9, 157.6, 152.6, 151.0, 147.3, 142.7, 138.7, 128.4, 128.2, 127.6, 125.6, 123.2, 119.5, 53.0, 39.2, 35.8, 31.3, 29.0, 29.0, 23.9; MALDI-FTMS
mlz 393.1811 (M + H+, C23H25N204, requires 393.1809).
QN / N O
Example 36; Methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)nicotinate Step 1; Methyl 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)nicotinate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (83 mg, 0.125 mmol) and methyl 2-chloronicotinate following General Procedure A. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a white solid (60 mg, 94%): 'H NMR (CDCI3i 500 MHz) 6 8.80 (dd, 1 H, J = 6.4, 3.0 Hz), 8.02 (dd, 1 H, J= 10.0, 6.0 Hz), 7.72 (s, 1 H), 7.39-7.32 (m, 3H), 7.25-7.23 (m, 3H), 4.91 (t, I H, J = 7.0 Hz), 4.01 (s, 3H), 2.66 (t, 2H, J = 7.5 Hz), 2.03-1.91 (m, 2H), 1.74-1.68 (m, 2H), 1.46-1.35 (m, 6H), 0.96 (s, 9H), 0.17 (s, 3H), 0.05 (s, 3H);13C NMR (CDCI3, 125 MHz) S 168.0, 166.5, 151.5, 149.9, 145.2, 143.2, 137.5, 128.8, 128.6, 128.0, 126.4, 126.0, 122.7, 69.1, 53.3, 37.0, 36.3, 31.8, 29.6, 26.2, 26.2, 25.5, 18.6, -4.5, -4.8.
Step 2. The title compound was prepared from methyl 2-(2-(1-(tert=
butyidimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)nicotinate (30 mg, 0.059 mmol) following General Procedure C. Flash chromatography (10-30 fo EtOAc) yielded the title compound as a white solid (17 mg, 73%):'H NMR (CDCI3, 500 MHz) S
8.85-8.84 (m, 1 H), 8.10 (dd, 1 H, J= 8.0, 1.5 Hz), 7.94 (s, 1 H), 7.49-7.47 (m, 1 H), 7.36-7.33 (m, 2H), 7.26-7.25 (m, 3H), 4.07 (s, 3H), 3.17 (t, 2H, J= 7.0 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.88-1.82 (m, 2H), 1.75-1.69 (m, 2H), 1.53-1.47 (m, 4H);
NMR (CDCI3, 125 MHz) 8 188.5, 167.6, 152.3, 151.8, 144.3, 143.1, 137.7, 129.5, 128.8, 128.7, 127.5, 126.0, 123.9, 53.7, 39.5, 36.3, 31.7, 29.4, 29.4, 24.2;
MALDI-FTMS m/z 393.1799 (M + H+, C23H25N204, requires 393.1809).
FiO2C N 7 N
Z
Exarnple 37; 6-(2-(7-Phenylheptanoyl)oxazol-5-yl)picolinic acid The title compound was prepared from methyl 6-(2-(7-phenylheptanoyl)oxazol-5-yl)picolinate (9 mg, 0.059 mmol) following General Procedure E. Preparative thin layer chromatography (2% AcOH/EtOAc) yielded the title compound as a white solid (5 mg, 57%): 'H NMR (THF-d8, 500 MHz) S
8.11-8.04 (m, 4H), 7.22-7.08 (m, 5H), 3.08 (t, 2H, J = 7.5 Hz), 2.61 (t, 2H, J
= 7.5 Hz), 1.76-1.68 (m, 2H), 1.68-1.62 (m, 2H), 1.45-1.41 (m, 4H); 13C NMR (THF-d8, 125 MHz) 8 185.6, 163.1, 156.4, 151.4, 147.6, 144.7, 141.0, 137.1, 126.7, 126.5, 126.1, 123.9, 122.8, 121.1, 37.1, 34.3, 30.0, 27.6, 27.5, 22.2; MALDI-FTMS m/z 379.1645 (M + H+, C22H23N204, requires 379.1652).
N / N
HOzC O
Example 38; 6-(2-(7-Phenylheptanoyl)oxazol-5-yl)nicotinic acid The title compound was prepared from methyl 6-(2-(7-phenylheptanoyl)oxazol-5-yl)nicotinate (10 mg, 0.025 mmol) following General Procedure E. Preparative thin layer chromatography (2% AcOH/EtOAc) yielded the title compound as a white solid (4 mg, 40%): 'H NMR (THF-d8, 500 MHz) S
9.18 (s, 1 H), 8.41 (d, 1 H, J = 8.0 Hz), 7.97-7.94 (m, 2H), 7.22-7.09 (m, 5H), 3.08 (t, 2H, J = 7.5 Hz), 2.61 (t, 2H, J = 7.5 Hz), 1.74-1.69 (m, 2H), 1.67-1.61 (m, 2H), 1.47-1.40 (m, 4H); 13C NMR (THF-d8, 125 MHz) S 185.6, 163.6, 156.7, 151.1, 149.8, 147.9, 141.0, 136.7, 126.7, 126.5, 125.0, 123.9, 117.7, 37.2, 34.3, 29.9, 27.6, 27.5, 22.2; MALDI-FTMS m/z 379.1645 (M + H+, C22H23N204, requires 379.1652).
Example 39; 2-(2-(7-Phenylheptanoyl)oxazol-5-yl)isonicotinic acid The title compound was prepared from methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)isonicotinate (12 mg, 0.025 mmol) following General Procedure E. Preparative thin layer chromatography (2% AcOH/EtOAc) yielded the title compound as a white solid (2 mg, 17%):'H NMR (CDCI3, 600 MHz) 8.85 (d, 1 H, J= 4.2 Hz), 8.42 (s, 1 H), 7.93-7.90 (m, 2H), 7.26-7.30 (m, 2H), 7.17-7.16 (m, 3H), 3.12 (t, 2H, J = 7.5 Hz), 2.61 (t, 2H, J = 7.6 Hz), 1.79 (quint, 2H, J = 7.4 Hz), 1.65 (quint, 2H, J= 7.5 Hz), 1.44-1.40 (m, 4H); MALDI-FTMS m/z 377.1523 (M - H-, C22H21N204i requires 377.1507).
(N N
O
Example 40; 2-(2-(7-Phenylheptanoyl)oxazol-5-yl)nicotinic acid The title compound was prepared from methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)nicotinate (8 mg, 0.020 mmol) following General Procedure E. Preparative thin layer chromatography (2% AcOH/EtOAc) yielded the title compound as a white solid (3 mg, 38%): 'H NMR (THF-dB, 600 MHz) S
8.71 (d, 1 H, J= 4.8 Hz), 8.09 (d, 1 H, J= 7.8 Hz), 7.79 (s, 1 H), 7.45-7.44 (m, 2H), 7.22-7.19 (m, 2H), 7.16-7.14 (m, 2H), 7.11-7.08 (m, 1 H), 3.05 (t, 2H, J = 7.8 Hz), 2.60 (t, 2H, J = 7.2 Hz), 1.73-1.69 (m, 2H), 1.66-1.61 (m, 2H), 1.43-1.39 (m, 4H);
13C NMR (THF-de, 150 MHz) S 185.5, 165.6, 156.4, 150.9, 149.5, 142.7, 141.1, 135.7, 127.0, 126.7, 126.5, 125.9, 123.9, 121.9, 37.1, 24.3, 30.0, 27.6, 27.5, 22.2;
MALDI-FTMS mOz 379.1646 (M + H+, C22H23N204, requires 379.1652).
N
O
~ O
Example 41; 1-(5-(6-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-l-one Step 1: 2-(1-(tert-Butyldimethvlsilyloxv)-7-phenylheotyl)-5-(6-methylpyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (70 mg, 0.106 mmol) and 2-br6mo-6-methylpyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a white solid (26 mg, 57%): 'H NMR (CDCIa, 400 MHz) 8 7.64 (s, 1 H), 7.64 (t, 1 H, J =
7.6 Hz), 7.47 (d, 1 H, J= 7.6 Hz), 7.30-7.26 (m, 2H), 7.19-7.16 (m, 3H), 7.08 (d, 1 H, J
= 7.6 Hz), 4.85 (dd, 1 H, J = 7.3, 5.8 Hz), 2.60 (t, 2H, J = 7.6 Hz), 2.59 (s, 3H), 1.93 (m, 2H), 1.65 (m, 2H), 1.36 (m, 4H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H);
13C NMR (CDC13, 100 MHz) S 165.4, 158.8, 150.9, 146.8, 142.8, 137.0, 128.4, 128.2, 125.5, 124.8, 122.5, 116.1, 68.7, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 24.5, 13.6, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(6-methylpyridin-2-yi)oxazole (20 mg, 0.043 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (12 mg, 80%):1 H
NMR (CDCI3, 400 MHz) 7.87 (s, 1 H), 7.69 (m, 2H), 7.30-7.26 (m, 2H), 7.19-7.16 (m, 4H), 3.11 (t, 2H, J = 7.5 Hz), 2.62 (t, 2H, J = 7.8 Hz), 2.61 (s, 3H), 1.78 (quint, 2H, J= 7.4 Hz), 1.64 (quint, 2H, J= 7.4 Hz), 1.51-1.34 (m, 4H); 13C NMR
(CDC13, 100 MHz) 5 188.5, 159.2, 157.2, 153.6, 145.6, 142.7, 137.1, 128.4, 128.2, 126.6, 125.6, 123.9, 117.5, 39.0, 35.8, 31.3, 29.0, 29.0, 24.5, 23.9; MALDI-FTMS m/z 349.1917 (M + H+, C21H23N202, requires 349.191).
N / N
O
Example 42; 1-(5-(5-Methylpyridin-2-yl)oxazol-2-yl)-7-phenytheptan-1-one Step 1: 2-(1-(tert-Butyldimethvlsilyloxy)-7-phenylheptyl)-5-{5-methylpyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyidimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (100 mg, 0.106 mmol) and 2-bromo-5-methylpyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (42 mg, 61 %): ' H NMR (CDC13, 400 MHz) 8 7.64 (s, 1 H), 7.64 (t, 1 H, J= 7.6 Hz), 7.47 (d, 1 H, J= 7.6 Hz), 7.30-7.26 (m, 2H), 7.19-7.16 (m, 3H), 7.08 (d, 1 H, J=
7.6 Hz), 4.85 (dd, 1 H, J= 7.3, 5.8 Hz), 2.60 (t, 2H, J= 7.6 Hz), 2.59 (s, 3H), 1.93 (m, 2H), 1.65 (m, 2H), 1.36 (m, 4H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H);
NMR (CDC13i 100 MHz) 5 165.4, 158.8, 150.9, 146.8, 142.8, 137.0, 128.4, 128.2, 125.5, 124.8, 122.5, 116.1, 68.7, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 24.5, 13.6, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(1-(fert-butyldimethyisiiyloxy)-7-phenylheptyl)-5-(5-methylpyridin-2-yl)oxazole (20 mg, 0.043 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (8 mg, 89%):'H NMR
(CDCI3, 400 MHz) 8.5 (s, 1 H), 7.83 (s, 1 H), 7.78 (d, 1 H, J= 7.9 Hz), 7.63 (dd, 1 H, J = 7.9, 2.0 Hz), 7.30-7.26 (m, 2H), 7.19-7.17 (m, 3H), 3.11 (t, 2H, J= 7.5 Hz), 2.62 (t, 2H, J = 7.6 Hz), 2.41 (s, 3H), 1.78 (m, 2H), 1.65 (m, 2H), 1.47 (m, 4H); 13C
NMR (CDC13, 100 MHz) 6 188.6, 157.1, 153.5, 150.6, 143.7, 142.7, 137.5, 134.3, 128.4, 128.2, 126.2, 125.6, 120.0, 39.0, 35.9, 31.3, 29.0, 29.0, 24.0, 18.6;
MALDI-FTMS m/z 349.1903 (M + H+, C21H23N202i requires 349.191).
N N
70~
O
Example 43; 1-(5-(4-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-l-one Step 1: 2-(1-(tert Butyldimethylsilyloxy)-7-phenylheptYl)-5-(4-methylQyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyidimethylsiiyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (130 mg, 0.196 mmol) and 2-bromo-4-methylpyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (41 mg, 59%): iH NMR (CDCI3, 400 MHz) 5 8.48 (d, 1 H, J = 5 Hz), 7.63 (s, 1 H), 7.50 (d, 1 H, J= 0.6 Hz), 7.29-7.25 (m, 2H), 7.18-7.15 (m, 3H), 7.05 (ddd, 1 H, J=
5.0, 1.5, 0.6 Hz), 4.86 (dd, 1 H, J = 7.3, 5.8 Hz), 2.59 (t, 2H, J = 7.8 Hz), 2.41 (s, 3H), 1.93 (m, 2H), 1.61 (m, 2H), 1.36 (m, 4H), 0.91 (s, 9H), 0.11 (s, 3H), 0.01 (s, 3H); 13C NMR (CDCI3, 100 MHz) 5 165.5, 150.7, 149.6, 148.1, 147.2, 142.7, 128.2; 125.5, 125.0, 123.8, 119.9, 68.7, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 21.1, 18.2, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-methylpyridin-2-yl)oxazole (27 mg, 0.058 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (16 mg, 84%):1 H
NMR (CDCI3, 400 MHz) 8.52 (d, 1 H, J= 5.0 Hz), 7.87 (s, 1 H), 7.72 (d, 1 H, J
= 0.9 Hz), 7.30-7.26 (m, 2H), 7.19-7.16 (m, 4H), 7.14 (dd, IH, J = 5.0, 0.6 Hz), 3.11 (t, 2H, J = 7.5 Hz), 2.62 (t, 2H, J = 7.6 Hz), 2.44 (s, 3H), 1.79 (quint, 2H, J =
7.4 Hz), 1.65 (quint, 2H, J = 7.5 Hz), 1.51-1.34 (m, 4H); 13C NMR (CDCI3, 100 MHz) S
188.6, 157.2, 153.4, 149.8, 148.6, 146.0, 142.7, 128.4, 128.2, 126.7, 125.6, 125.1, 121:3, 39.0, 35.8, 31.3, 29.0, 29.0, 23.9, 21.1; MALDI-FTMS m/z 349.1904 (M + H+, C21H23N2 Z,requires 349.191).
N /ON
' O
Example 44; 1-(5-(3-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(3-methylpyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (130 mg, 0.196 mmol) and 2-bromo-3-methylpyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (28 mg, 40%): 1 H NMR (CDC13, 400 MHz) S 8.52 (dd, 1 H, J= 4.7, 1.5 Hz), 7.57 (ddd, 1 H, J = 7.6, 1.4, 0.6 Hz), 7.55 (s, 1 H), 7.29-7.24 (m, 2H), 7.18-7.15 (m, 4H), 4.89 (dd, 1 H, J = 7.6, 5.9 Hz), 2.59 (t, 2H, J = 7.8 Hz), 2.55 (s, 3H), 1.93 (m, 2H), 1.61 (m, 2H), 1.36 (m, 4H), 0.89 (s, 9H), 0.10 (s, 3H), -0.02 (s, 3H);13C
NMR
(CDC13, 100 MHz) S 165.6, 150.9, 147.1, 146.0, 142.8, 139.3, 130.3, 128.3, 128.2, 127.1, 125.5, 122.6, 68.6, 36.5, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 20.4, 18.2, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(3-methylpyridin-2-yl)oxazole (25 mg, 0.097 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (13 mg, 70%): 'H
NMR (CDCI3, 500 MHz) S 8.55 (dd, 1 H, J = 4.4, 1.1 Hz), 7.82 (s, 1 H), 7.62 (dd, .20 1 H, J = 7.7, 1.1 Hz), 7.29-7.23 (m, 3H), 7.19-7.16 (m, 3H), 3.12 (t, 2H, J = 7.5 Hz), 2.64 (s, 3H), 2.62 (t, 2H, J= 7.9 Hz), 1.79 (quint, 2H, J= 7.6 Hz), 1.65 (quint, 2H, J= 7.5 Hz), 1.51-1.34 (m, 4H);13C NMR (CDCI3, 125 MHz) 8 188.3, 157.4, 153.9, 147.4, 144.9, 142.7, 139.6, 131.7, 128.7, 128.4, 128.2, 125.6, 123.8, 39.1, 35.8, 31.2, 29.0, 29.0, 23.9, 20.1; MALDI-FTMS mfz 349.1913 (M + H+, C21H23N2 2, requires 349.191).
N
o Example 45; 1-(5-(4-Methoxypyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 2-(1-(tert-Butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-methoxypyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(terf-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (144 mg, 0.302 mmol) and 2-chioro-4-methoxypyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (88 mg, 61 H NMR (CDCI3, 400 MHz) 8 8.43 (d, 1 H, J = 5.6 Hz), 7.63 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.75 (dd, 1 H, J= 5.8, 2.6 Hz), 4.85 (dd, 1 H, J = 7.3, 5.8 Hz), 3.9 (s, 3H), 2.59 (t, 2H, J = 7.6 Hz), 1.93 (m, 2H), 1.61 (m, 2H), 1.36 (m, 4H), 0.90 (s, 9H), 0.10 (s, 3H), 0.01 (s, 3H); '3C NMR (CDCI3i MHz) S 166.3, 165.5, 151.1, 150.6, 148.9, 142.7, 128.3, 128.2, 125.5, 125.3, 109.0, 105.1, 68.7, 55.3, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 18.2, -5.0, -5.1.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-methoxypyridin-2-yl)oxazole (70 mg, 0.146 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (51 mg, 96%): ' H
NMR (CDCI3, 400 MHz) S 8.49 (d, 1 H, J = 5.3 Hz), 7.88 (s, I H), 7.39 (d, I H, J
2.3 Hz), 7.29-7.26 (m, 2H), 7.19-7.16 (m, 3H), 6.84 (dd, 1 H, J= 5.9, 2.6 Hz), 3.94 (s, 3H), 3.12 (t, 2H, J Y 7.5 Hz), 2.62 (t, 2H, J = 7.8 Hz), 1.79 (quint, 2H, J
7.3 Hz), 1.65 (quint, 2H, J= 7.9 Hz), 1.47-1.39 (m, 4H);13C NMR (CDC13, 100 MHz) 6188.6,175.3,166.6,157.2,153.1,151.3,147.6,142.7,128,4,128.2, 127.1, 125.6, 110.5, 106.4, 55.6, 39.1, 35.9, 31.3, 29.0, 23.9, 20.6; MALDI-FTMS
m/z 365.1863 (M + H+, C22H25N203, requires 365.186).
/ N /ON
..--NC
Example 46; 2-(2-(7-Phenylheptanoyl)oxazol-5-yl)isonicotinonitrile Step 1; 2-(2-(1-(tert-Butyldimethylsilyloxy)-7-phenyiheptyl)oxazol-5-yl)isonicotinonitrile. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (110 mg, 0.166 mmol) and 2-chloro-4-cyanopyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (72 mg, 75%): ' H NMR (CDCI3, 400 MHz) 58.79 (dd, 1H, J= 5.0, 0.9 Hz), 7.84 (s, 1 H), 7.74 (s, 1 H), 7.43 (dd, 1 H, J= 5.0, 1.4 Hz), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 4.88 (dd, 1 H, J = 7.3, 6.6 Hz), 2.60 (t, 2H, J = 7.8 Hz), 1.93 (m, 2H), 1.61 (m, 2H), 1.36 (rri, 4H), 0.91 (s, 9H), 0.12 (s, 3H), 0.01 (s, 3H);13C NMR (CDCI3i M Hz) 8 166.7, 150.8, 149.0, 148.6, 142.7, 128.3, 128.2, 127.1, 125.5, 123.7, 121.4, 120.2, 116.1, 68.6, 36.4, 35.8, 31.3, 29.0, 25.6, 25.6, 25.0, 18.1, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(2-(1-(tert-butyldimethylsi{yloxy)-7-phenylheptyl)oxazol-5-yl)isonicotinonitrile (46 mg, 0.097 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (24 mg, 69%): 'H
NMR (CDCI3, 400 MHz) 8 8.84 (d, 1 H, J= 5.0 Hz), 8.07 (s, 1 H), 7.96 (s, 1 H), 7.53 (d, 1 H, J= 5.0, 1.5 Hz), 7.29-7.26 (m, 2H), 7.19-7.16 (m, 3H), 6.84 (dd, 1 H, J=
5.9, 2.6 Hz), 3.12 (t, 2H, J= 7.5 Hz), 2.62 (t, 2H, J= 7.6 Hz), 1.80 (quint, 2H, J=
7.2 Hz), 1.65 (quint, 2H, J= 7.3 Hz), 1.42 (m, 4H); 13C NMR (CDCI3, 100 MHz) 6 188.3, 157.8, 151.3, 151.1, 147.6, 142.6, 128.5, 128.4, 128.2, 125.6, 125.2, 121.8, 121.5, 115.7, 39.2, 35.8, 31.2, 28.9, 23.8; MALDI-FTMS m/z 360.1717 (M
+ H+, C22H22N302, requires 360.1706).
l N /
O
~
Example 47; 7-Phenyl-l-(5-(4-(trifluoromethyl)pyridin-2-yl)oxazol-2-yi)heptan-1-one Step 1; 2-(1-(tert-Butyldimethylsilyioxy)-7-phenylheptyl)-5-(4-(trifluoromethyl)pYridin-2-Lrl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (130 mg, 0.196 mmol) and 2-chloro-4-(trifiuoromethyl)pyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (80 mg, 77%): 'H NMR (CDCI3, 400 MHz) 8 8.79 (d, 1 H, J= 5.0 Hz), 7.84 (s, 1 H), 7.73 (s, 1 H), 7.43 (dd, 1 H,. J= 5.0, 0.9 Hz), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 4.88 (dd, 1 H, J = 7.3, 5.9 Hz), 2.60 (t, 2H, J = 7.8 Hz), 1.93 (m, 2H), 1.61 (m, 2H), 1.36 (m, 4H), 0.91 (s, 9H), 0.11 (s, 3H), 0.01 (s, 3H); 13C NMR
(CDCI3, 100 MHz) 8 166.5, 150.9, 149.6, 148.6, 142.8, 139.3 (q, J = 33.9 Hz), 128.4, 128.2, 126.6, 125.6, 118.1 (q, J = 3.5 Hz), 114.6 (q, J = 3.0 Hz), 68.7, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 18.2, -5.0, -5.1.
Step 2. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(4-(trifluoromethyl)pyridin-2-yl)oxazole (51 mg, 0.098 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (32 mg, 80%):'H
NMR (CDCI3, 400 MHz) S 8.85 (d, 1 H, J = 5.0 Hz), 8.06 (s, 1 H), 7.96 (s, 1 H), 7.54 (d, 1 H, J = 5.0 Hz), 7.29-7.26 (m, 2H), 7.19-7.16 (m, 3H), 3.13 (t, 2H, J=
7.5 Hz), 2.62 (t, 2H, J = 7.8 Hz), 1.80 (quint, 2H, J = 7.4 Hz), 1.65 (quint, 2H, J =
7.8 Hz), 1.47-1.40 (m, 4H); 13C NMR (CDCI3, 100 MHz) S 188.5, 157.7, 152.0, 151.1, 147.5, 142.6, 139.6 (q, J= 34.9 Hz), 128.4, 128.2, 128.0, 125.6, 123.7, 121.0, 119.4 (q, J= 3.0 Hz), 115.9 (q, J= 4.6 Hz), 39.2, 35.8, 31.2, 29.0, 29.0, 23.9;
MALDI-FTMS rrr/z 403.1628 (M + Ht, C22H22F3N202, requires 403.1628).
~ N
Example 48; 1-(5-(4-Nitropyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one Step 1; 2-(1-(tert-Butyldirnethylsilyloxy)-7-phenylheptyl)-5-(4-nitropyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (190 mg, 0.287 mmol) and 2-chloro-4-nitropyridine following General Procedure A. Flash chromatography (10%o EtOAc/hexanes) yielded the title compound as a thick oil (98 mg, 66%): 'H NMR (CDCI3, 400 MHz) S 8.91 (dd, 1 H, J = 5.3, 0.6 Hz), 8.33 (d, 1 H, J= 2.1), 7.93 (dd, 1 H, J = 5.3, 2.1 Hz), 7.78 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 4.90 (dd, 1 H, J= 7.3, 5.8 Hz), 2.60 (t, 2H, J= 7.8 Hz), 1.96 (m, 2H), 1.62 (m, 2H), 1.36 (m, 4H), 0.92 (s, 9H), 0.12 (s, 3H), 0.03 (s, 3H); 13C NMR
(CDCI3, 100 MHz) S 166.9, 154.6, 152.2, 150.1, 149.1, 142.7, 128.3, 128.2, 127.5, 125.5, 114.8, 111.4, 68.7, 36.4, 35.9, 31.3, 29.1, 25.7, 25.7, 25.0, 18.2, -5.0,-5.1.
Step 2. The title compound was prepared from 2-(1-(tert-butyldirnethylsilyloxy)-7-phenylheptyl)-5-(4-nitropyridin-2-yl)oxazole (88 mg, 0.178 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yieided the title compound as a white solid (40 mg, 63%): ' H
NMR (CDCI3, 400 MHz) 8 8.96 (dd, 1 H, J = 5.8, 0.6 Hz), 8.53 (d, 1 H, J = 2.0 Hz), 8.03 (dd, 1 H, J= 5.3, 2.1 Hz), 8.00 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 3.14 (t, 2H, J = 7.5 Hz), 2.62 (t, 2H, J = 7.8 Hz), 1.81 (quint, 2H, J = 7.3 Hz), 1.65 (quint, 2H, J= 7.4 Hz), 1.48-1.40 (m, 4H); 13C NMR (CDCI3, 100 MHz) S 188.3, 157.8, 154.6, 152.4, 151.3, 149.0, 128.7, 128.3, 128.2, 125.6, 116.1, 112.7, 39.2, 35.8, 31.2, 28.9, 28.9, 23.8; MALDI-FTMS m/z 380.1609 (M + Ht, C2lH22N304, requires 380.1605).
I N I N
O
O
Exam ple 49; 1-(5-(4-Aminopyriidin-2-yl)oxazol-2-yl)-7-phenyiheptan-1-one The title compound was prepared from 1-(5-(4-nitropyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one (8 mg, 0.021 mmol) following General Procedure F.
Flash chromatography (50% EtOAc/hexanes) yielded the title compound as a white solid (6 mg, 80%): 'H NMR (CDCl3 /CD3OD, 400 MHz) S 8.26 (d, 1 H, J= 5.6 Hz), 7.82 (s, 1 H), 7.35 (d, 1 H, J= 2.1 Hz), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.78 (dd, 1 H, J= 5.9, 2.4 Hz), 3.07 (t, 2H, J = 7.3 Hz), 2.58 (t, 2H, J = 7.8 Hz), 1.74 (quint, 2H, J = 7.3 Hz), 1.60 (quint, 2H, J = 7.3 Hz), 1.48-1.40 (m, 4H);
'3C
NMR (CDCI3/CD3OD, 100 MHz) S 189.0, 158.0, 157.0, 153.3, 149.8, 128.3, 128.1, 126.7, 125.5, 107.6, 104.3, 38.9, 35.7, 31.2, 28.9, 28.9, 23.8; MALDI--FTMS mlz 350.1862 (M + H+, C21H22N304, requires 350.1863).
/ N N
O
F
Example 50; 1-(5-(4-Nitropyridin-2-yl)oxazol-2-yl)-7-phenylheptan-l-one Step 1; 2-(1-(tert-ButyldimethylsilVloxy)-7-phenylheptyl)-5-(4-fluoropyridin-2-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (130 mg, 0.196 mmol) and 2-chloro-4-fluoropyridine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (48 mg, 51 %): ' H NMR (CDCI3, 400 MHz) 6 8.59 (dd, 1 H, J = 8.5, 5.6 Hz), 7.69 (s, 1 H), 7.38 (dd, 1 H, J= 9.4, 2.3 Hz), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.96 (ddd, 1 H, J= 8.2, 5.6, 2.4 Hz), 4.87 (dd, 1 H, J = 7.0, 6.2 Hz), 2.60 (t, 2H, J = 7.6 Hz), 1.96 (m, 2H), 1.62 (m, 2H), 1.36 (m, 4H), 0.91 (s, 9H), 0.11 (s, 3H), 0.01 (s, 3H); 13C NMR (CDCI3i 100 MHz) S 170.4, 167.8, 166.1, 152.4 (d, J = 7.6 Hz), 150.2, (d, J 7.6 Hz), 149.8 (d, J 4.6 Hz), 142.7, 128.3, 128.2, 126.2, 125.5, 110.5 (d, J 15.2 Hz), 106.9 (d, J 18.2 Hz), 68.7, 36.4, 35.9, 31.4, 29.1, 25.7, 25.7, 25.1, 18.2, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(1-(terf-butyfdimethyfsilyloxy)-7-phenylheptyl)-5-(4-fluoropyridin-2-yl)oxazole (44 mg, 0.094 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (23 mg, 70%): 'H
NMR (CDCI3, 400 MHz) 5 8.63 (dd, 1 H, J= 7.9, 5.6 Hz), 7.90 (d, 1 H, J = 0.9 Hz), 7.60 (dd, 1 H, J= 9.4, 2.4 Hz), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.96 (dddd, 1 H, J= 7.4, 5.6, 2.4, 0.6 Hz), 3.11 (t, 2H, J= 7.3 Hz), 2.62 (t, 2H, J= 7.6 Hz), 1.79 (quint, 2H, J = 7.3 Hz), 1.67 (quint, 2H, J = 7.3 Hz), 1.48-1.40 (m, 4H);
NMR (CDCI3, 100 MHz) 6 188.4, 170.4, 167.8, 157.5, 152.6 (d, J = 6.1 Hz), 152.2, (d, J= 4.6 Hz), 149.0 (d, J= 7.6 Hz), 142.6, 128.4, 128.2, 127.7, 125.6, 111.8 (d, J= 16.7 Hz), 108.4 (d, J= 19.7 Hz), 39.1, 35.8, 31.2, 28.9, 28.9, 23.8; MALDI-FTMS m/z 353.1681 (M + H+, C21H22FN202, requires 353.1665).
H3C0 N / N ~ I
NrJ
O
Example 51; 1-(5-(2,6-Dimethoxypyrimidin-4-yl)oxazol-2-yl)-7-phenylheptan-1-one Step 1: 2-(1-(tert-Butvldimethylsilyloxy)-7-phenylheptyl)-5-(2,6-dimethoxypyrimidin-4-yl)oxazole. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (200 mg, 0.302 mmol) and 6-chloro-2,4-dimethoxypyrimidine following General Procedure A. Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a thick oil (138 mg, 90%): 'H NMR (CDCI3, 400 MHz) S 7.73 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.67 (s, 1 H), 4.85 (dd, 1 H, J = 7.3, 5.9 Hz), 4.03 (s, 3H), 4.00 (s, 3H), 2.59 (t, 2H, J= 7.6 Hz), 1.96 (m, 2H), 1.62 (m, 2H), 1.36 (m, 4H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H); 13C NMR (CDCI3r 100 MHz) 5 172.3, 166.6, 165.4, 155.2, 149.0, 142.6, 128.3, =128.1, 128.0, 125.5, 95.8, 68.6, 54.8, 53.9, 36.2, 35.8, 31.3, 29.0, 25.6, 25.6, 24.9, 18.1, -5.1, -5.2.
Step 2. The title compound was prepared from 2-(1 -(tert-butyld im ethylsilyloxy)-7-phenylheptyl)-5-(2,6-dimethoxypyri mid in-4-yl)oxazole (130 mg, 0.254 mmol) following General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (88 mg, 88%): ' H
NMR (CDCI3, 400 MHz) S 7.94 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.88 (s, 1 H), 4.07 (s, 3H), 4.04 (s, 3H), 3.11 (t, 2H, J= 7.3 Hz), 2.63 (t, 2H, J= 7.7 Hz), 1.80 (quint, 2H, J = 7.7 Hz), 1.66 (quint, 2H, J = 7.5 Hz), 1.48-1.40 (m, 4H);
13C NMR (CDCI3, 100 MHz) 5 188.3, 172.5, 165.5, 157.7, 154.1, 142.5, 129.1, 128.3, 128.3, 128.1, 125.5, 97.4, 54.9, 54.2, 39.1, 35.7, 31.1, 28.9, 28.9, 23.7;
MALDI-FTMS mlz 396.1913 (M + H+, C22H26N304, requires 396.1918).
ON / N
HN O
O
Example 52; 6-(2-(7-Phenylheptanoyl)oxazol-5-yl)pyrimidine-2,4(1 H,3H)-dione The title compound was prepared from 1-(5-(2,6-dimethoxypyrimidin-4-yl)oxazol-2-yi)-7-phenylheptan-l-one (20 mg, 0.051 mmol) following General Procedure H. Flash chromatography (EtOAc) yielded the title compound as a white solid (16 mg, 90%): 'H NMR (CDCI3/CD3OD, 500 MHz) 5 7.92 (s, 1H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 6.19 (s, 1 H), 3.06 (t, 2H, J= 7.4 Hz), 2.58 (t, 2H, J= 7.7 Hz), 1.73 (quintet, 2H, J = 7.3 Hz), 1.61 (quintet, 2H, J = 7.4 Hz), 1.38-1.36 (m, 4H); 13C NMR (CDC13r 125 MHz) S 188.3, 163.8, 158.0, 151.7, 144.9, 142.5, 139.1, 129.8, 128.3, 128.1, 125.5, 98.8, 39.2, 35.7, 31.1, 28.81, 28.78, 23.5;
MALDI-FTMS m/z 368.1595 (M + H+, C20H22N304i requires 368.1605).
N
N
H3CON p Example 53; 1-(5-(2,4-Dimethoxypyrimidin-5-yl)oxazol-2-y1)-7-phenylheptan-1-one Step 1; 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(2 4-dimethoxypyrimidin-5-yl)oxazofe. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (130 mg, 0.196 mmol) and 5-iodo-2:,6-dimethoxypyrimidine following General Procedure A.
Flash chromatography (10% EtOAc/hexanes) yielded the title compound as a 'thick oil (85 mg, 83%): 'H NMR (CDCI3, 400 MHz) 8 8.67 (s, 1 H), 7.34 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.14 (m, 3H), 4.85 (dd, 1 H, J= 7.4, 5.9 Hz), 4.13 (s, 3H), 4.05 (s, 3H), 2.59 (t, 2H, J= 7.8 Hz), 1.93 (m, 2H), 1.60 (m, 2H), 1.41 (m, 4H), 0.89 (s, 9H), 0.09 (s, 3H), 0.01 (s, 3H);13C NMR (CDCI3, 100 MHz) S 166.4, 164.3, 154.1, 143.9, 142.7, 128.3, 128.1, 125.5, 125.2, 104.9, 68.5, 55.0, 54.4, 36.3, 35.8, 31.3, 29.1, 25.6, 25.6, 25.0, 18.1, -5.0, -5.2.
Step 2. The title compound was prepared from 2-(1-(tett-butyldimethylsilyloxy)-7-phenylheptyl)-5-(2,4-dimethoxypyrimidin-5-y1)oxazole (85 mg, 0.166 mmof) foflowing General Procedure C. Flash chromatography (30%
EtOAc/hexanes) yielded the title compound as a white solid (43 mg, 66%): 'H
NMR (CDCI3, 400 MHz) 5 8.82 (s, 1 H), 7.57 (s, 1 H), 7.28-7.24 (m, 2H), 7.14-7.18 (m, 3H), 4.17 (s, 3H), 4.07 (s, 3H), 3.08 (t, J = 7.5 Hz), 2.61 (t, 2H, J =
7.6 Hz), 1.77 (quint, 2H, J = 7.3 Hz), 1.64 (quint, 2H, J = 7.4 Hz), 1.45-1.38 (m, 4H);
NMR (CDCI3, 100 MHz) 8 188.2, 166.9, 165.1, 156.4, 156.0, 147.4, 142.6, 128.3, 128.2, 126.9, 125.5, 103.6, 55.3, 54.6, 38.9, 35.8, 31.2, 28.9, 28.9, 23.9;
MALDi-FTMS m/z 396.1920 (M + H+, C22H26N3O4, requires 396.1918).
O
O N
H
Example 54; 5-(2-(7-Phenylheptanoyl)oxazol-5-yl)pyrimidine-2,4(1H,3H)-dione The title compound was prepared from 1-(5-(2,4-dimethoxypyrimidin-5-yl)oxazol-2-yl)-7-phenylheptan-l-one (15 mg, 0.038 mmol) following General Procedure H. Flash chromatography (EtOAc) yielded the title compound as a white solid (10 mg, 71 %): 'H NMR (CDCI3, 400 MHz) S 7.90 (s, 1 H), 7.71 (s, 1 H), 7.28-7.24 (m, 2H), 7.18-7.14 (m, 3H), 2.99 (t, J = 7.5 Hz), 2.52 (t, 2H, J=
7.8 Hz), 1.67 (quint, 2H, J= 7.3 Hz), 1.55 (quint, 2H, J = 7.4 Hz), 1.33-1.31 (m, 4H);
13C NMR (CDCI3, 100 MHz) S 188.8, 160.9, 155.4, 150.6, 147.4, 142.5, 139.0, 128,2, 128.0, 126.0, 125.4, 102.6, 38.6, 35.6, 31.1, 28.8, 28.8, 23.8; MALDI-FTMS m/z 368.1613 (M + H+, C20H2jN304, requires 368.1610).
N
/o H3CO2C ' Example 55; Methyl 5-(2-(7-phenylheptanoyl)oxazol-5-yl)furan-2-carboxylate Step 1: Methyl 5-(2-(1-(tert-butyldimethyisil)tloxy)-7-phenylheptyl)oxazol-5-yl)furan-2-carboxylate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (82 mg, 0.125 mmol) and methyl 5-bromofuran-2-carboxylate following,General Procedure A.
Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (62 mg, 99%):'H NMR (CDCI3, 400 MHz) 5 7.42 (s, 1 H), 7.29-7.25 (m, 3H), 7.19-7.16 (m, 3H), 6.70 (d, 1 H, J = 3.6 Hz), 4.83 (t, 1 H, J= 6.0 Hz), 3.92 (s, 3H), 2.60 (t, 2H, J= 7.6 Hz), 1.96-1.85 (m, 2H), 1.71-1.57 (m, 2H), 1.40-1.33 (m, 6H), 0.90 (s, 9H), 0.10 (s, 3H), 0.00 (s, 3H); 33C NMR (CDCI3, 100 MHz) S
163.8, 151.9, 149.1, 147.8, 147.5, 133.4, 133.2, 130.6, 129.3, 124.6, 113.6, 113.5, 73.6, 57.1, 41.3, 40.9, 36.4, 34.1, 30.7, 30.7, 30.1, 23.2, 0.0, -0.1.
Step 2. The title compound was prepared from methyl 5-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)furan-2-carboxylate (60 mg, 0.121 mmol) following General Procedure C. Flash chromatography (10-20 fo EtOAc/hexanes) yielded the title compound as a white solid (29 mg, 63%): 'H
NMR (CDCI3i 500 MHz) S 7.72 (s, 1 H), 7.36-7.33 (m, 4H), 7.25-7.23 (m, 2H), 7.04-7.03 (d, J = 3.5 Hz, 1 H), 4.02 (s, 3H), 3.16 (t, 2H, J = 7.5 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.88-1.82 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.44 (m, 4H); 13C NMR
(CDC{3, 125 MHz) 8 188.5, 162.3, 159.0, 145.9, 145.8, 143.1, 128.8, 128.7, 128.7, 126.1, 126.0, 119.9, 111.7, 52.7, 39.6, 36.3, 31.7, 29.4, 29.4, 24.3;
MALDI-FTMS m/z 382.1640 (M + H+, C2ZHZ4NO5, requires 382.1649).
N
O O
Ho2c Example 56; 5-(2-(7-Phenylheptanoyl)oxazol-5-yl)furan-2-carboxylic acid The title compound was prepared from methyl 5-(2-(7-phenylheptanoyl)oxazol-5-yl)furan-2-carboxylate (7 mg, 0.018 mmol) following General Procedure E. Preparative thin layer chromatography (10%
MeOH/CH2CI2) yielded the title compound as a white solid (6 mg, 85%): ~ H NMR
(THF-de, 500 MHz) S 7.68 (s, 1 H), 7.27 (d, 1 H, J = 3.5 Hz), 7.22-7.07 (m, 5H), 7.04 (d, 1 H, J= 4.0 Hz), 3.05 (t, 2H, J = 7.0 Hz), 2.60 (t, 2H, J = 7.5 Hz), 1.73-1.71 (m, 2H), 1.65-1.61 (m, 2H), 1.42-1.40 (m, 4H); 13C NMR NMR (THF-d8, 125 MHz) 5 187.6, 164.6, 158.3, 146.2, 145.8, 143.5, 129.1, 128.9, 128.9, 126.3, 126.0, 119.7, 111.7, 39.6, 36.7, 32.4, 30.0, 30.0, 24.6; MALDI-FTMS m/z 368.1501 (M + H}, C21 H22NO5, requires 368.1492).
N ,\ I
H3CO2C (Slo O
Example 57; Methyl 5-(2-(7-phenylheptanoyl)oxazol-5-yl)thiophene-2-carboxylate Step 1: Methyl 5-(2-(1-(tert butyldimeth rlsilyloxy)-7-phenylheptyl)oxazol-5-yl)thiophene-2-carboxylate. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (89 mg, 0.134 mmol) and methyl 5-bromothiophene-2-carboxylate following General Procedure A. Flash chromatography (2-10% EtOAc/hexanes) yielded the title compound as a clear oil (65 mg, 94%): ?H NMR (CDCI3, 400 MHz) 8 7.72 (d, 1 H, J = 3.6 Hz), 7.26-7.23 (m, 4H), 7.17-7.14 (m, 3H), 4.80 (t, 1 H, J= 6.0 Hz), 3.89 (s, 3H), 2.58 (t, 2H, J= 7.6 Hz), 1.95-1.87 (m, 2H), 1.68-1.56 (m, 2H), 1.38-1.27 (m, 6H), 0.88 (s, 9H), 0.09 (s, 3H), 0.00 (s, 3H);13C NMR (CDCI3i 100 MHz) S 167.4, 150.8, 147.9, 141.3, 139.2, 137.7, 133.5, 133.3, 130.7, 129.2, 129.2, 128.5, 73.7, 57.5, 41.4, 41.0, 36.5, 34.2, 30.8, 30.9, 30.2, 23.3, 0.2, 0Ø
Step 2. The title compound was prepared from methyl 5-(2-(1-(tert-butyldi-methylsilyloxy)-7-phenylheptyl)oxazol-5-yl)thiophene-2-carboxylate (63 mg, 0.123 mmol) following General Procedure C. Flash chromatography (5-20%
EtOAc/hexanes) yielded the title compound as a white solid (25 mg, 50%): ' H
NMR (CDCI3, 500 MHz) S 7.85 (d, 1 H, J = 4.0 Hz), 7.54-7.53 (m, 2H), 7.36-7.33 (m, 2H), 7.26-7.24 (m, 3H), 4.00 (s, 3H), 3.15 (t, 2H, J = 7.5 Hz), 2.69 (t, 2H, J
7.5 Hz), 1.86-1.82 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.44 (m, 4H); 13C NMR
15(CDCI3i 125 MHz) S 188.4, 162.4, 157.4, 148.9, 143.1, 135.3, 134.7, 134.5, 128.8, 128.7, 127.0, 126.0, 125.4, 53.0, 39.5, 36.3, 31.7, 29.4, 29.4, 24.4;
MALDI-FTMS m/z 398.1407 (M + H+, C22Hz4NO4S, requires 398.1420).
N
Example 58; 5-(2-(7-Phenylheptanoyl)oxazol-5-yl)thiophene-2-carboxylic acid The title compound was prepared from methyl 5-(2-(7-phenylheptanoyl)oxazol-5-yl)thiophene-2-carboxylate (7 mg, 0.018 mmol) following General Procedure E. Preparative thin layer chromatography (10%
MeOH/CH2CI2) yielded the title compound as a white solid (3 mg, 41%): 'H NMR
(THF-d8, 500 MHz) S 7.73 (d, 1 H, J= 3.5 Hz), 7.72 (s, 1 H), 7.55 (d, 1 H, J =
4.0 Hz), 7.22-7.08 (m, 5H), 3.03 (t, 2H, J = 7.0 Hz), 2.60 (t, 2H, J= 7.5 Hz), 1.73-1.71 (m, 2H), 1.65-1.61 (m, 2H), 1.42-1.40 (m, 4H);13C NMR NMR (THF-d8, 125 MHz) S 185.1, 164.0, 155.8, 147.0, 141.0, 134.8, 132.7, 132.1, 126.7, 126.5, ? 24.9, 123.9, 123.3, 37.0, 34.3, 30.0, 27.6, 27.5, 22.2; MALDI-FTMS rn/z 384.1272 (M + H+, CZ1H22N04S, requires 384.1264).
N
H2NO2S o Example 59; 5-(2-(7-Phenylheptanoyl)oxazol-5-yl)thiophene-2-sulfonamide Step 1: 5-(2-(1-(tert-Bu Idimethylsilyloxy)-7_phenylheptyl)oxazol-5-yI)thiophene-2-sulfonamide. The title compound was prepared from 2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)-5-(tributylstannyl)oxazole (54 mg, 0.081 mmol) and 5-bromothiophene-2-sulfonamide following General Procedure A.
Flash chromatography (10-20% EtOAc/hexanes) yielded the title compound as a white solid (33 mg, 75%): 'H NMR (CDCI3, 500 MHz) S 7.68 (d, 1 H, J = 4.0 Hz), 7.36-7.33 (m, 3H), 7.29 (d, 1 H, J= 3.5 Hz), 7.26-7.23 (m, 3H), 5.29 (s, 2H), 4.89 (t, 1 H, J = 6.0 Hz), 2.67 (t, 2H, J= 7.5 Hz), 2.02-1.95 (m, 2H), 1.74-1.59 (m, 2H), 1.40-1.38 (m, 6H), 0.97 (s, 9H), 0.17 (s, 3H), 0.08 (s, 3H); 13C NMR (CDCI3, MHz) S 166.2, 145.2, 143.2, 142.5, 136.4, 132.7, 128.8, 128.7, 126.0, 124.2, 123.8, 68.9, 36.7, 36.3, 31.8, 29.6, 26.1, 26.1, 25.5, 18.6, -4.5,-4.7.
Step 2. The title compound was prepared from 5-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)thiophene-2-suIfonamide (30 mg, 0.056 mmol) following General Procedure C. Flash chromatography (30-60%
EtOAc/hexanes) yielded the title compound as a white solid (11 mg, 46%): ' H
NMR (CDCI3i 500 MHz) 5 7.71 (d,. 1 H, J = 3.5 Hz), 7.55 (s, 1 H), 7.50 (d, 1 H, J
3.5 Hz), 7.90 (s, 1 H), 7.37-7.34 (m, 2H), 7.26-7.24 (m, 3H), 5.36 (s, 2H), 3.15 (t, 2H, J = 7.0 Hz), 2.69 (t, 2H, J = 7.5 Hz), 1.87-1.82 (m, 2H), 1.75-1.69 (m, 2H), 1.54-1.46 (m, 4H);73C NMR (CDCI3, 500 MHz) S 188.5, 144.9, 143.1, 143.5, 133.3, 132.6, 128.8, 128.7, 126.4, 126.1, 125.7, 125.6, 39.6, 36.3, 31.7, 29.4, 29.4, 24.3; MALDI-FTMS m/z 419.1093 (M + H+, C20H22N204S2, requires 419.1094).
c02H
O-cc Example 60; 2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzoic acid The following compounds in Examples 61 and 62 may be prepared using methods analogous to those described in the preceding examples.
~
CN'IN I /
N O
Example 61; 1-[5-(1-Methyl-lH-imidazol-2-yl)-oxazol-2-yl]-7-phenyl-heptan-l-one N,N~N
N_N
Example 62; 1-[5-(1-Methyl-1H-tetrazol-5-yl)-oxazol-2-yl]-7-phenyl-heptan-l-one The title compounds per se of Comparative Examples 1 and 2 are known and are provided for comparative purposes. Compounds in Comparative Examples 1 and 2 were prepared according to the general procedures described above or according to the procedures described in WO 04/033652.
o-cc O
Comparative Example 1; 7-Phenyi-l-(5-pyridin-2-yl-oxazol-2-yl)-heptan-l-one % N
Comparative Example 2; 1-(5-Furan-2-yl-oxazol-2-yl)-7-phenyl-heptan-l-one Biological Testing:
Assay Method 1A
All enzyme assays were performed at 20-23 C using a solubilized liver plasma membrane extract containing FAAH in a reaction buffer of 125 mM Tris, 1 mM EDTA, 0.2% glycerol, 0.02% Triton X-100, 0.4 mM HEPES, pH 9.0 buffer (Patricelli, M.P. et al. Bioorg. Med. Chem. Lett. 1998, 8, 613-618; Patterson, J.E., et al. J. Am Chem. Soc. 1996, 118, 5938-5945). The initial rates of hydrolysis were monitored by following the breakdown of14C-olearnide to oleic acid as described previously (Cravatt, B.F. et al. Science 1995, 268, 1506-1509;
Patricelli, M.P. et al., 1998). The inhibition was reversible, non time-dependent. Linear least squares fits were used for all reaction progress curves and R2 values were consistently >0.97. IC50 values were determined from the inhibition observed at 3-5 different test compound concentrations (from three or more trials at each concentration) using the formula IC50 =[I]/[K&1K;)-1], where Ko is the control reaction rate without inhibitor and K; is the rate with test compound at concentration [I] (Conde-Frieboes, K., et al. J. Am. Chem. Soc. 1996, 118, 5525). K; values were determined by the Dixon Method (x-intercepts of weighted linear fits of [I] versus 1/rate plots at constant substrate concentration, which were converted to K; values using the formula K; =-x;,,t/[1+[S]/{tm]). Results for compounds tested in this assay are presented in presented in Table 1.
Table 1 Ex. Assay 1A Ex. Assay 1A
K, (nM) K, (nM) 10 110 40 >50 14 40 43 . 1 36 >50 60 6000 Assay Method 1 B
A. Transfection of Cells with Human FAAH
A 10-cm tissue culture dish with a confluent monolayer of SK-N-MC cells was split 2 days (d) prior to transfection. Using sterile technique, the media was removed and the cells were detached from the dish by the addition of trypsin.
One fifth of the cells were then placed onto a new 10-cm dish. Cells were grown in a 37 C incubator with 5% CO2 in Minimal Essential Media Eagle with 10%
Fetal Bovine Serum. After 2 d, cells were approximately 80% confluent. These cells were removed from the dish with trypsin and pelleted in a clinical centrifuge.
The pellet was re-suspended in 400 L complete media and transferred to an electroporation cuvette with a 0.4 cm gap between the electrodes. Supercoiled human FAAH cDNA (1 pg) was added to the cells and mixed. The voltage for the electroporation was set at 0.25 kV, and the capacitance was set at 960 F.
After electroporation, the cells were diluted into complete media (10 mL) and plated onto four 10-cm dishes. Because of the variability in the efficiency of electroporation, four different concentrations of cells were plated. The ratios used were 1:20, 1:10, and 1:5, with the remainder of the cells being added to the fourth dish. The cells were allowed to recover for 24 h before adding the selection media (complete media with 600 g/mL G418). After 10 d, dishes were analyzed for surviving colonies of celis. Dishes with well-isolated colonies were used.
Cells from individual colonies were isolated and tested. The clones that showed the most FAAH activity, as measured by anandamide hydrolysis, were used for further study.
B. FAAH Assay T84 frozen cell pellets or transfected SK-N-MC cells (contents of I x 15 cm culture dishes) were homogenized in 50 mL of FAAH assay buffer (125 mM
Tris, 1 mM EDTA, 0.2% Glycerol, 0.02% Triton X-100, 0.4 mM Hepes, pH 9). The assay mixture consisted of 50 L of the cell homogenate, 10 L of the test compound, and 40 L of anandamide [1 3H-ethanolamine] (3H-AEA, Perkin-Elmer, 10.3 Ci/mmol), which was added last, for a final tracer concentration of 80 nM. The reaction mixture was incubated at rt for 1 h. During the incubation, well Multiscreen filter plates (catalog number MAFCNOB50; Millipore, Bedford, MA, USA) were loaded with 25 L of activated charcoal (Multiscreen column loader, catalog number MACL09625, Millipore) and washed once with 100 L of MeOH. Also during the incubation, 96-well DYNEX MicroLite plates (catalog number NL510410) were loaded with 100 pL of MicroScint40 (catalog number 60'! 3641, Packard Bioscience, Meriden, CT, USA). After the I h incubation, 60 pL of the reaction mixture were transferred to the charcoal plates, which were then assembled on top of the DYNEX plates using Centrifuge Alignment Frames (catalog number MACF09604, Millipore). The unbound labeled ethanolamine was centrifuged through to the bottom plate (5 min at 2000 rpm), which was preloaded with the scintillant, as described above. The plates were sealed and left at rt for 1 h before counting on a Hewlett Packard TopCount. Results for compounds tested in this assay are presented in Table 2.
Assay Method 2 A. Transfection of Cells with Rat FAAH
A 10-cm tissue culture dish with a confluent monolayer of SK-N-MC cells was split 2 days (d) prior to transfection. Using sterile technique, the media was removed and the cells were detached from the dish by the addition of trypsin.
One fifth of the cells were then placed onto a new 10-cm dish. Cells were grown in a 37 C incubator with 5% CO2 in Minimal Essential Media Eagle with 10%
Fetal Bovine Serum. After 2 d, cells were approximately 80% confluent. These cells were removed from the dish with trypsin and pelleted in a clinical centrifuge.
The pellet was re-suspended in 400 L complete media and transferred to an electroporation cuvette with a 0.4 cm gap between the electrodes. Supercoiled rat FAAH cDNA (1 pg) was added to the cells and mixed. The voltage for the electroporation was set at 0.25 kV, and the capacitance was set at 960 F.
After electroporation, the cells were diluted into complete media (10 mL) and plated onto four 10-cm dishes. Because of the variability in the efficiency of electroporation, four different concentrations of cells were plated. The ratios used were 1:20, 1:10, and 1:5, with the remainder of the cells being added to the fourth dish. The cells were allowed to recover for 24 h before adding the selection media (complete media with 600 g/mL G418). After 10 d, dishes were analyzed for surviving colonies of cells. Dishes with well-isolated colonies were used.
Cells from individual colonies were isolated and tested. The clones that showed the most FAAH activity, as measured by anandamide hydrolysis, were used for further study.
B. FAAH Assay T84 frozen cell pellets or transfected SK-N-MC cells (contents of 1 x 15 cm culture dishes) were homogenized in 50 mL of FAAH assay buffer (125 mM Tris, 1 mM EDTA, 0.2% Glycerol, 0.02% Triton X-1 00, 0.4 mM Hepes, pH 9). The assay mixture consisted of 50 L of the cell homogenate, 10 L of the test compound, and 40 L of anandamide [1-3H-ethanolamine] (3H-AEA, Perkin-Elmer, 10.3 Ci/mmol), which was added last, for a final tracer concentration of 80 nM. The reaction mixture was incubated at rt for I h. During the incubation, well Multiscreen filter plates (catalog number MAFCNOB50; Millipore, Bedford, MA, USA) were loaded with 25 L of activated charcoal (Multiscreen column loader, catalog number MACL09625, Millipore) and washed once with 100 L of MeOH. Also during the incubation, 96-well DYNEX MicroLite plates (catalog number NL51041 0) were loaded with 100 pL of MicroScint40 (catalog number 6013641, Packard Bioscience, Meriden, CT, USA). After the 1 h incubation, 60 pL of the reaction mixture were transferred to the charcoal plates, which were then assembled on top of the DYNEX plates using Centrifuge Alignment Frames (catalog number MACF09604, Millipore). The unbound labeled ethanolamine was centrifuged through to the bottom plate (5 min at 2000 rpm), which was preloaded with the scintillant, as described above. The plates were sealed and left at rt for 1 h before counting on a Hewlett Packard TopCount. Results for compounds tested in this assay are presented in Table 2.
Table 2 Ex. Assay 1 B Assay 2 Ex. Assay 1 B Assay 2 tC50 (nM) ICro (nM) IC5o (nM) IC50 (nM) 13 1900 10000 37 0.4 11 14 100 4500 38 0.2 2 770 4000 52 0.1 1.5 18 290 220 56 0.8 2 Physical Chemical Properties Solubility determinations were made by mixing the test compound in water at 5 mg/mL, 1 mg/mL, and 0.1 mg/mL concentrations. The pH of the resulting solutions was 7-8.5. Results for compounds tested are presented in Table 3.
Table 3 Ex. Solubility Comp. Ex. 1 < 0.1 mg/mL
Comp. Ex. 2 < 0.1 mg/mL
37 > 5.0 mg/mL
38 > 5.0 mg/mL
56 > 5.0 mg/mL
Pharmacokinetic Testing For each test compound, two male Sprague Dawley Rats (Charles River Laboratories; approx. 300 g body weight) were used. Animals were individually housed, provided food and water ad libitum, and were maintained on a 12 h light and dark cycle. Animals received from the vendor were surgically cannulated by the vendor with right jugular vein and left carotid artery catheters. Animals were acclimatized for at least 5 days after receipt from the vendor prior to investigations.
Animals received a bolus intravenous dose of the test compound at a dose of 1 mg/mL in a volume of 2 mL/kg via the right jugular vein catheter. The intravenous dosing solution was prepared in 55% pharmasolve, 20% cremophor, and 75% physiological saline, or 100% saline adjusted to pH 8Ø
Following intravenous administration, blood was collected (sampled 0.35 mL per time point from the left carotid artery catheter) at 0.083, 0.25, 0.5, 1, 2, 4, and 6 h post-dose. Blood was collected into tubes containing EDTA and stored at 4 C for not more than 2 h. The samples were centrifuged at 10,000 rpm in a micro-centrifuge for 5 min to obtain a plasma fraction. The plasma was stored at between -20 and -80 C until processed for analysis. These samples were analyzed by LC-MS/MS to determine the plasma level of the compound.
Plasma level vs. time plots were created and WinNonlin (Pharsight Corp.) was used to analyze the data. A non-compartmental pharmacokinetic model was used to determine the pharmacokinetic parameters, including clearance, volume of distribution (Vd), and half-life (t112). Data for compounds tested in this assay are presented in Table 4.
Table 4 Ex. Clearance (L/hr/kg) Vd (L/kg) t1,2 (hr) Comp. Ex. 1 5.9 27.3 3.23 Comp. Ex. 2 3.8 22.9 3.49 37 0.46 0.86 1.24 38 6.7 1.4 0.15 While the invention has been illustrated by reference to exemplary and preferred embodiments, it will be understood that the invention is intended not to be limited to the foregoing detailed description, but to be defined by the appended claims as properly construed under principles of patent law.
Claims (17)
1. A compound of Formula (I):
wherein:
Ar is a 5- or 6-membered aryl or heteroaryl ring having a carbon as its point of attachment to the oxazole;
R1 is independently -C1-6alkyl, -C3-6cycloalkyl, -CF3, -CN, -C(O)C1-4alkyl optionally substituted with one, two, or three fluoro substituents, -CO2C1-4alkyl, -CO2H, -C(O)N(R a)R b, -OH, -OC1-6alkyl, halo, -NO2, -NR a R b, -N(R a)COR b, -N(R a)SO2R b, SO2N(R a)R b, or S(O)0-2R a; where R a and R b are each independently -H, -C1-6alkyl, or -C3-6cycloalkyl; and R2 is independently -H, -C1-6alkyl, -C3-6cycloalkyl, -CF3, -CN, -C(O)C1-4alkyl optionally substituted with one, two, or three fluoro substituents, -CO2C1-4alkyl, -CO2H, -C(O)N(R c)R d, -OH, -OC1-6alkyl, halo, -NO2, -NR c R d, -N(R c)COR d, -N(R c)SO2R d, -SO2N(R c)R d, or -S(O)0-2R c;
where R c and R d are each independently -H, -C1-6alkyl, or -C3-6cycloalkyl;
or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite of said compound.
wherein:
Ar is a 5- or 6-membered aryl or heteroaryl ring having a carbon as its point of attachment to the oxazole;
R1 is independently -C1-6alkyl, -C3-6cycloalkyl, -CF3, -CN, -C(O)C1-4alkyl optionally substituted with one, two, or three fluoro substituents, -CO2C1-4alkyl, -CO2H, -C(O)N(R a)R b, -OH, -OC1-6alkyl, halo, -NO2, -NR a R b, -N(R a)COR b, -N(R a)SO2R b, SO2N(R a)R b, or S(O)0-2R a; where R a and R b are each independently -H, -C1-6alkyl, or -C3-6cycloalkyl; and R2 is independently -H, -C1-6alkyl, -C3-6cycloalkyl, -CF3, -CN, -C(O)C1-4alkyl optionally substituted with one, two, or three fluoro substituents, -CO2C1-4alkyl, -CO2H, -C(O)N(R c)R d, -OH, -OC1-6alkyl, halo, -NO2, -NR c R d, -N(R c)COR d, -N(R c)SO2R d, -SO2N(R c)R d, or -S(O)0-2R c;
where R c and R d are each independently -H, -C1-6alkyl, or -C3-6cycloalkyl;
or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite of said compound.
2. A compound as defined in claim 1, wherein Ar is selected from the group consisting of phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrimidine-dione, pyrazinyl, thiophenyl, furanyl, imidazolyl, oxazolyl, and tetrazolyl.
3. A compound as defined in claim 1, wherein Ar is selected from the group consisting of 3-(R1)-phenyl, 3-(R1)-2-pyridyl, 4-(R1)-2-pyridyl, 5-(R1)-2-pyridyl, 6-(R1)-2-pyridyl, 5-(R1)-2-furanyl, 5-(R1)-2-thiophenyl, 1-(R1)-1H-2-imidazolyl, and 1-(R1)-1H-5-tetrazolyl.
4. A compound as defined in claim 1, wherein R1 is selected from the group consisting of -CH3, -CF3, -CN, -C(O)CF3, -CO2CH3, -CO2H, -C(O)NH2, -OH, -OCH3, fluoro, -NO2, -NH2, and -SO2NH2.
5. A compound as defined in claim 1, wherein R2 is -H.
6. A compound as defined in claim 2, wherein R1 is selected from the group consisting of -CH3, -CF3, -CN, -C(O)CF3, -CO2CH3, -CO2H, -C(O)NH2, -OH, -OCH3, fluoro, -NO2, -NH2, and -SO2NH2.
7. A compound as defined in claim 2, wherein R2 is -H.
8. A compound as defined in claim 3, wherein R1 is selected from the group consisting of -CH3, -CF3, -CN, -C(O)CF3, -CO2CH3, -CO2H, -C(O)NH2, -OH, -OCH3, fluoro, -NO2, -NH2, and -SO2NH2.
9. A compound as defined in claim 3, wherein R2 is -H.
10. A compound as defined in claim 8, wherein R2 is -H.
11. A compound selected from the group consisting of:
1-(5-(2-Nitrophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(3-Nitrophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Nitrophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
7-Phenyl-1-(5-(2-(2,2,2-trifluoroacetyl)phenyl)oxazol-2-yl)heptan-1-one;
7-Phenyl-1-(5-(3-(2,2,2-trifluoroacetyl)phenyl)oxazol-2-yl)heptan-1-one;
7-Phenyl-1-(5-(4-(2,2,2-trifluoroacetyl)phenyl)oxazol-2-yl)heptan-1-one;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzamide;
3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzamide;
4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzamide;
1-(5-(2-Fluorophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(3-Fluorophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Fluorophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(2-Methoxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(3-Methoxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Methoxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzonitrile;
3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzonitrile;
4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzonitrile;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzenesulfonamide;
3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzenesulfonamide;
4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzenesulfonamide;
Methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate;
Methyl 3-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate;
Methyl 4-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate;
3-(2-(7-Phenylheptanoyl)oxazot-5-yl)benzoic acid;
4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzoic acid;
1-(5-(2-Aminophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(3-Aminophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Aminophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(2-Hydroxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(3-Hydroxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Hydroxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one;
Methyl 6-(2-(7-phenylheptanoyl)oxazol-5-yl)picolinate;
Methyl 6-(2-(7-phenylheptanoyl)oxazol-5-yl)nicotinate;
Methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)isonicotinate;
Methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)nicotinate;
6-(2-(7-Phenylheptanoyl)oxazol-5-yl)picolinic acid;
6-(2-(7-Phenylheptanoyl)oxazol-5-yl)nicotinic acid;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)isonicotinic acid;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)nicotinic acid;
1-(5-(6-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(5-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(3-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Methoxypyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)isonicotinonitrile;
7-Phenyl-1-(5-(4-(trifluoromethyl)pyridin-2-yl)oxazol-2-yl)heptan-1-one;
1-(5-(4-Nitropyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Aminopyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Nitropyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(2,6-Dimethoxypyrimidin-4-yl)oxazol-2-yl)-7-phenylheptan-1-one;
6-(2-(7-Phenylheptanoyl)oxazol-5-yl)pyrimidine-2,4(1H,3H)-dione;
1-(5-(2,4-Dimethoxypyrimidin-5-yl)oxazol-2-yl)-7-phenylheptan-1-one;
5-(2-(7-Phenylheptanoyl)oxazol-5-yl)pyrimidine-2,4(1H,3H)-dione;
Methyl 5-(2-(7-phenylheptanoyl)oxazol-5-yl)furan-2-carboxylate;
5-(2-(7-Phenylheptanoyl)oxazol-5-yl)furan-2-carboxylic acid;
Methyl 5-(2-(7-phenylheptanoyl)oxazol-5-yl)thiophene-2-carboxylate;
5-(2-(7-Phenylheptanoyl)oxazol-5-yl)thiophene-2-carboxylic acid;
5-(2-(7-Phenylheptanoyl)oxazol-5-yl)thiophene-2-sulfonamide;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzoic acid;
1-[5-(1-Methyl-1H-imidazol-2-yl)-oxazol-2-yl]-7-phenyl-heptan-1-one; and 1-[5-(1-Methyl-1H-tetrazol-5-yl)-oxazol-2-yl]-7-phenyl-heptan-1-one;
or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite of said compound.
1-(5-(2-Nitrophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(3-Nitrophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Nitrophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
7-Phenyl-1-(5-(2-(2,2,2-trifluoroacetyl)phenyl)oxazol-2-yl)heptan-1-one;
7-Phenyl-1-(5-(3-(2,2,2-trifluoroacetyl)phenyl)oxazol-2-yl)heptan-1-one;
7-Phenyl-1-(5-(4-(2,2,2-trifluoroacetyl)phenyl)oxazol-2-yl)heptan-1-one;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzamide;
3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzamide;
4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzamide;
1-(5-(2-Fluorophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(3-Fluorophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Fluorophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(2-Methoxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(3-Methoxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Methoxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzonitrile;
3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzonitrile;
4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzonitrile;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzenesulfonamide;
3-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzenesulfonamide;
4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzenesulfonamide;
Methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate;
Methyl 3-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate;
Methyl 4-(2-(7-phenylheptanoyl)oxazol-5-yl)benzoate;
3-(2-(7-Phenylheptanoyl)oxazot-5-yl)benzoic acid;
4-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzoic acid;
1-(5-(2-Aminophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(3-Aminophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Aminophenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(2-Hydroxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(3-Hydroxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Hydroxyphenyl)oxazol-2-yl)-7-phenylheptan-1-one;
Methyl 6-(2-(7-phenylheptanoyl)oxazol-5-yl)picolinate;
Methyl 6-(2-(7-phenylheptanoyl)oxazol-5-yl)nicotinate;
Methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)isonicotinate;
Methyl 2-(2-(7-phenylheptanoyl)oxazol-5-yl)nicotinate;
6-(2-(7-Phenylheptanoyl)oxazol-5-yl)picolinic acid;
6-(2-(7-Phenylheptanoyl)oxazol-5-yl)nicotinic acid;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)isonicotinic acid;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)nicotinic acid;
1-(5-(6-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(5-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(3-Methylpyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Methoxypyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)isonicotinonitrile;
7-Phenyl-1-(5-(4-(trifluoromethyl)pyridin-2-yl)oxazol-2-yl)heptan-1-one;
1-(5-(4-Nitropyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Aminopyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(4-Nitropyridin-2-yl)oxazol-2-yl)-7-phenylheptan-1-one;
1-(5-(2,6-Dimethoxypyrimidin-4-yl)oxazol-2-yl)-7-phenylheptan-1-one;
6-(2-(7-Phenylheptanoyl)oxazol-5-yl)pyrimidine-2,4(1H,3H)-dione;
1-(5-(2,4-Dimethoxypyrimidin-5-yl)oxazol-2-yl)-7-phenylheptan-1-one;
5-(2-(7-Phenylheptanoyl)oxazol-5-yl)pyrimidine-2,4(1H,3H)-dione;
Methyl 5-(2-(7-phenylheptanoyl)oxazol-5-yl)furan-2-carboxylate;
5-(2-(7-Phenylheptanoyl)oxazol-5-yl)furan-2-carboxylic acid;
Methyl 5-(2-(7-phenylheptanoyl)oxazol-5-yl)thiophene-2-carboxylate;
5-(2-(7-Phenylheptanoyl)oxazol-5-yl)thiophene-2-carboxylic acid;
5-(2-(7-Phenylheptanoyl)oxazol-5-yl)thiophene-2-sulfonamide;
2-(2-(7-Phenylheptanoyl)oxazol-5-yl)benzoic acid;
1-[5-(1-Methyl-1H-imidazol-2-yl)-oxazol-2-yl]-7-phenyl-heptan-1-one; and 1-[5-(1-Methyl-1H-tetrazol-5-yl)-oxazol-2-yl]-7-phenyl-heptan-1-one;
or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite of said compound.
12. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by FAAH activity, comprising administering to the subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite of said compound.
13. A method according to claim 12, wherein the disease, disorder, or medical condition is selected from the group consisting of: anxiety, pain, sleep disorders, eating disorders, inflammation, movement disorders, HIV wasting syndrome, closed head injury, stroke, Alzheimer's disease, epilepsy, Tourette's syndrome, Niemann-Pick disease, Parkinson's disease, Huntington's chorea, optic neuritis, autoimmune uveitis, drug withdrawal, nausea, emesis, sexual dysfunction, post-traumatic stress disorder, cerebral vasospasm, glaucoma, irritable bowel syndrome, inflammatory bowel disease, immunosuppression, gastroesophageal reflux disease, paralytic ileus, secretory diarrhea, gastric ulcer, rheumatoid arthritis, unwanted pregnancy, hypertension, cancer, hepatitis, allergic airway disease, autoimmune diabetes, intractable pruritis, and neuroinflammation.
14. A method according to claim 12, wherein the disease, disorder, or medical condition is selected from the group consisting of: anxiety, pain, inflammation, sleep disorders, eating disorders, and movement disorders.
15. A pharmaceutical composition for treating a disease, disorder, or medical condition mediated by FAAH activity, comprising:
(a) an effective amount of an agent selected from compounds of Formula (I), and pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites thereof; and (b) a pharmaceutically acceptable excipient.
(a) an effective amount of an agent selected from compounds of Formula (I), and pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites thereof; and (b) a pharmaceutically acceptable excipient.
16. A pharmaceutical composition according to claim 15, further comprising:
an analgesic selected from the group consisting of opioids and non-steroidal anti-inflammatory drugs.
an analgesic selected from the group consisting of opioids and non-steroidal anti-inflammatory drugs.
17. A pharmaceutical composition according to claim 15, further comprising:
an analgesic selected from the group consisting of aspirin, acetaminophen, ibuprofen, naproxen, COX-2 inhibitors, gabapentin, pregabalin, and tramadol.
an analgesic selected from the group consisting of aspirin, acetaminophen, ibuprofen, naproxen, COX-2 inhibitors, gabapentin, pregabalin, and tramadol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77432206P | 2006-02-17 | 2006-02-17 | |
US60/774,322 | 2006-02-17 | ||
PCT/US2007/004341 WO2007098142A2 (en) | 2006-02-17 | 2007-02-20 | Oxazole ketones as modulators of fatty acid amide hydrolase |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2642737A1 true CA2642737A1 (en) | 2007-08-30 |
Family
ID=38437944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002642737A Abandoned CA2642737A1 (en) | 2006-02-17 | 2007-02-20 | Oxazole ketones as modulators of fatty acid amide hydrolase |
Country Status (6)
Country | Link |
---|---|
US (1) | US7915270B2 (en) |
EP (1) | EP1983994B1 (en) |
JP (1) | JP2009527483A (en) |
AU (1) | AU2007217813A1 (en) |
CA (1) | CA2642737A1 (en) |
WO (1) | WO2007098142A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0720452A2 (en) * | 2006-12-20 | 2014-01-14 | Novartis Ag | ORGANIC COMPOUNDS |
WO2008150492A1 (en) * | 2007-05-31 | 2008-12-11 | The Scripps Research Institute | Tricyclic inhibitors of fatty acid amide hydrolase |
US8598202B2 (en) * | 2008-02-19 | 2013-12-03 | Janssen Pharmaceutica Nv | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
US20110184026A1 (en) * | 2008-06-19 | 2011-07-28 | Boger Dale L | C4-substituted alpha-keto oxazoles |
US8987312B2 (en) * | 2008-07-09 | 2015-03-24 | The Scripps Research Institute | Alpha-keto heterocycles as FAAH inhibitors |
WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
KR20190082985A (en) | 2009-10-02 | 2019-07-10 | 아벡신 에이에스 | Anti inflammatory 2-oxothiazoles and 2-oxooxazoles |
WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
EP2951164B1 (en) | 2013-01-29 | 2019-06-05 | Avexxin AS | Antiinflammatory and antitumor 2-oxothiazoles compounds |
GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
RU2607630C1 (en) * | 2015-09-11 | 2017-01-10 | Михаил Владимирович Дорогов | Aromatic derivatives of sulfanilamides carbonic anhydrase ii (ca ii) inhibitors, methods for production and use thereof |
GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
CN110804048A (en) * | 2019-11-08 | 2020-02-18 | 暨南大学 | Oxazolone compound and application thereof, and positron medicine of FAAH |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4921963A (en) * | 1987-04-13 | 1990-05-01 | British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
US5464871A (en) * | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
US5612380A (en) | 1994-09-27 | 1997-03-18 | The Scripps Research Institute | Method for sleep induction |
US5856537A (en) | 1996-06-26 | 1999-01-05 | The Scripps Research Institute | Inhibitors of oleamide hydrolase |
EP1039902B1 (en) | 1997-11-24 | 2006-03-08 | The Scripps Research Institute | Inhibitors of gap junction communication |
US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
US6562846B2 (en) | 2001-04-27 | 2003-05-13 | Bristol-Myers Squibb Company | Bisarylimidazolyl fatty acid amide hydrolase inhibitors |
BR0314980A (en) * | 2002-10-08 | 2005-08-09 | Scripps Research Inst | Fatty Acid Amide Hydrolase Inhibitors |
-
2007
- 2007-02-20 CA CA002642737A patent/CA2642737A1/en not_active Abandoned
- 2007-02-20 EP EP07751123.6A patent/EP1983994B1/en not_active Not-in-force
- 2007-02-20 US US11/708,788 patent/US7915270B2/en not_active Expired - Fee Related
- 2007-02-20 JP JP2008555412A patent/JP2009527483A/en not_active Withdrawn
- 2007-02-20 WO PCT/US2007/004341 patent/WO2007098142A2/en active Application Filing
- 2007-02-20 AU AU2007217813A patent/AU2007217813A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1983994B1 (en) | 2015-09-30 |
US7915270B2 (en) | 2011-03-29 |
JP2009527483A (en) | 2009-07-30 |
WO2007098142A3 (en) | 2008-09-04 |
WO2007098142A2 (en) | 2007-08-30 |
EP1983994A2 (en) | 2008-10-29 |
AU2007217813A1 (en) | 2007-08-30 |
US20070203156A1 (en) | 2007-08-30 |
EP1983994A4 (en) | 2011-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1983994B1 (en) | Oxazole ketones as modulators of fatty acid amide hydrolase | |
US7351724B2 (en) | Oxadiazole ketone inhibitors of fatty acid amide hydrolase | |
US7541359B2 (en) | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | |
US20090111778A1 (en) | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase | |
EP2937341B1 (en) | 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions | |
TWI444378B (en) | Sulfur containing heterocyclic derivatives having β secretase inhibitory activities and use thereof | |
US20100292266A1 (en) | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | |
US20090062294A1 (en) | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | |
EP2161997A1 (en) | Tricyclic inhibitors of fatty acid amide hydrolase | |
US20140045800A1 (en) | Tetracyclic inhibitors of fatty acid amide hydrolase | |
US8268817B2 (en) | Substituted oxazole ketone modulators of fatty acid amide hydrolase | |
WO2009154785A2 (en) | C4-substituted alpha-keto oxazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |